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Summary
Summary
Cigarette smoking is the single largest cause of preventable death and disease. 
Each year ~50% of smokers attempt to quit, but less than 5% are successful, 
despite using pharmacotherapy. Immunotherapy is being explored as a new 
approach to smoking cessation; several anti-nicotine vaccines are being 
developed, which reduce nicotine reinforcement. Anti-nicotine antibodies bind 
nicotine, preventing it from entering the brain and acting on nicotinic 
acetylcholine receptors (nAChRs). However, this approach also renders 
nicotine replacement therapy (NRT) ineffective.
Cotinine, the major metabolite of nicotine, is a weak agonist at nAChRs, 
inducing striatal dopamine release; there is also evidence that it antagonises 
nicotine's actions. An anti-cotinine vaccine would reduce such antagonism by 
preventing cotinine from passing the blood-brain-barrier, and sequestering it in 
the bloodstream. This should enhance the efficacy of NRT and assist with a 
reduce-to-quit approach to smoking cessation.
Here we characterise the immune response to anti-cotinine vaccination and 
study the impact of vaccination on measures of nicotine dependence. 
Anti-cotinine vaccination was found to be safe and immunogenic, with regular 
booster injections required to maintain antibody levels. Antibodies raised were 
specific for cotinine, retaining it in the blood. Upregulation of nAChRs by chronic 
nicotine administration was not increased after vaccination, and no effects on 
conditioned taste aversion were observed. However, increases in locomotor 
activity induced by repeated nicotine administration occurred earlier and were 
more pronounced in vaccinated rats. And in a model of nicotine withdrawal, 
abstinence scores were increased in vaccinated rats, due to the removal of 
cotinine-mediated antagonism of nicotine's actions.
Antibody levels measured here were not as high as titres in studies of anti­
nicotine vaccines; however, in view of the effects observed with comparatively 
low titres, vaccination against cotinine could offer a new approach to smoking 
cessation, provided higher titres of cotinine-specific antibodies can be achieved.
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Nicotine is a naturally occurring alkaloid found in plants, such as tobacco 
(Nicotiana tobaccum). It is a tertiary amine consisting of a pyridine and a 
pyrrolidine ring (Benowitz 1996, Schneider et al 2001, Yildiz 2004, Tutka et al 
2005) and was first isolated as the major alkaloid in tobacco in 1828. (S)- 
nicotine is the main stereoisomer present in tobacco, whereas (R)-nicotine is 
found only in small quantities in cigarette smoke. Nicotine is the primary 
psychoactive component of tobacco, and addiction to nicotine is generally 
considered to be the reason why smokers find it so hard to quit (see section 
1.6). Nicotine can have both stimulant and depressant effects, affecting mood, 
performance, cognitive function, as well as producing pleasure, reducing hunger 
and relieving anxiety and depression (Benowitz 1996, Schneider et al 2001, 
Yildiz 2004, Tutka et al 2005). However, whether this is a result of the positive 
actions of nicotine, or due to the relief of withdrawal symptoms, or both is 
unclear (see sections 1.4.2,1.6 & 4.5).
In humans, nicotine is obtained through smoked (mainly cigarettes) or smoke- 
free (snuff, chewing tobacco, snus) tobacco products (see section 1.5), or from 
nicotine replacement therapy (NRT) products (see section 1.6.1.1). Nicotine can 
be absorbed through the oral cavity, skin, lung, urinary bladder and 
gastrointestinal tract. Absorption is pH-dependent: smoke from cigarettes has 
an acidic pH (-5.5), which means that nicotine is mostly ionised and does not 
readily permeate cell membranes (Yildiz 2004, Tutka et al 2005). However, in 
the lungs nicotine is buffered to a physiological pH and is rapidly absorbed, so 
that approximately a third of the nicotine inhaled passes into the bloodstream. In 
smokeless tobacco (snuff, chewing tobacco, etc) users and smokers who do not 
inhale, absorption occurs mainly through the oral mucosa. At an alkaline pH, 
such as in smoke from tobacco in pipes, nicotine is mostly non-ionised and 
easily crosses the oral mucosa (Yildiz 2004, Tutka et al 2005).
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Nicotine has a half-life of approximately 1-2 hours and, once absorbed, is 
extensively metabolised by the liver to a number of major and minor 
metabolites, as discussed in section 1.2 of this thesis (Benowitz 1996, 
Schneider et al 2001, Yildiz 2004, Tutka et al 2005).
1.1.1 Nicotine administration in animal models of nicotine
dependence
One of the main issues associated with preclinical models of nicotine addiction, 
is the question of how to give animals nicotine in a meaningful way. Smokers 
achieve a high dose of nicotine very quickly after each cigarette (see section 
1.5.1), with levels declining gradually between cigarettes. Despite these 
repeated peaks and troughs, smokers maintain a relatively constant plasma 
nicotine level throughout their waking hours, leading to prolonged 
desensitisation of nAChRs (see section 1.3.2). During overnight abstinence 
plasma levels decrease, allowing the receptors to re-sensitise.
- Intravenous administration via implanted cannulae most closely mimics the 
pharmacokinetics of nicotine observed in smokers: repeated sudden peaks, 
followed by a gradual reduction in plasma nicotine levels in between cigarettes. 
This route of administration is used in self-administration experiments (see 
Chapter 4), however it is not suitable for a lot of other experimental setups, as it 
is quite invasive because of the surgery required to implant the intravenous 
cannula.
- Subcutaneous or intraperitoneal injections are probably one of the easiest and 
least stressful ways of administering nicotine to animals. Injections are usually 
given once or twice a day, which does not very accurately reflect the repeated 
administration seen in patients smoking cigarettes throughout the day. Usually 
the doses of nicotine given with each injection are also relatively large 
compared to intravenous administration, in order to be able to achieve the 
desired longer-term minimum plasma levels.
- Chronic administration of nicotine via subcutaneous osmotic minipumps is not 
a very accurate reflection of smoking behaviour, as nicotine is delivered at a 
steady rate and continuously for several days/weeks, rather than in frequent 
bursts. However, it does reproduce the steady state nicotine levels achieved by 
smokers (Sanderson et al 1993, Rowell & Li 1997), albeit without the overnight
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abstinence, and mimics the situation of a patient using transdermal nicotine 
patches during a quit attempt quite well. There are differences in the route of 
administration (subcutaneous versus transdermal), though, as well as in the 
dosing pattern, with nicotine being delivered continuously with no overnight 
abstinence, as would be the case for a patient using NRT.
- Transdermal nicotine patches are not very practical for use on animals, as 
they can be removed/chewed by the individual or a cage mate, and fur usually 
has to be shaved prior to application in order to achieve a reasonable adhesion 
of the patch.
- A further alternative is the administration of nicotine in drinking water, which is 
often flavoured to disguise the aversive taste of nicotine. It has the advantage of 
being self-administered by the animal and, as surgical implantation of osmotic 
pumps is not very convenient due to their size, it is frequently used with mice 
(Brunzell et al 2006). The disadvantage here is that the experimenter has no 
direct control over the amount consumed or the dosing pattern, and at higher 
concentrations animals appear to dislike the taste of nicotine-containing 
solutions.
1.2 Nicotine metabolism
1.2.1 Enzymes & metabolic pathways involved in nicotine
metabolism
The pathways involved in the metabolism of nicotine (and cotinine) are 
summarised in Figure 1.1. In humans, approximately 70-80% of nicotine is 
metabolised to cotinine by C-oxidation involving members of the cytochrome P- 
450 (CYP) enzyme family (Siu & Tyndale 2007, Yildiz 2004, Benowitz 1996). 
CYPs are mixed function oxidases, which are predominantly expressed in the 
liver and biotransform drugs, endogenous compounds, dietary constituents, and 
environmental toxins (Howard et al 2001).
High levels of CYPs have been observed in the liver, but they have also been 
located in other tissues, including lung, kidney and brain, indicating that some 
local metabolism of nicotine might also occur (Howard et al 2003). Exposure to 
low doses of nicotine for 7 days or more leads to an induction of CYPs in rat 
liver, lung, kidney and brain, which persists for up to 18 hrs in the liver
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(Anandatheerthavarada et al 1993, Iba et al 1999, Miksys et al 2000, Howard et 
al 2001 & 2003). CYP levels also appear to be elevated in the brains and lungs 
of smokers compared to non-smokers (Iba et al 1999, Howard et al 2003). 
Chronic administration of cotinine, on the other hand, does not appear to 
increase CYP levels in rats (Micu et al 2003).
Figure 1.1: Pathways of nicotine and cotinine metabolism
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Summary of nicotine and cotinine metabolism in man (from Hukkanen et al 2005)
In humans the CYP2A6 isoform, found primarily in the liver, mediates 
approximately 90% of the conversion of nicotine to cotinine (Yildiz 2004, Siu et 
al 2007). This conversion is a two-step process, involving the initial formation of
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nicotine-A-1 (5 ^ iminium ions, which are then converted into cotinine by the 
cytosolic enzyme aldehyde oxidase. Cotinine is then extensively metabolised, 
again by CYP2A6, to trans-3'-hydroxycotinine, which is the most abundant 
metabolite found in urine (Benowitz 1996, Siu & Tyndale 2007). The remaining 
nicotine is either transformed to other minor metabolites, such as nicotine-N'- 
oxide (~4%), or excreted unchanged. Nicotine and cotinine also undergo N- 
glucuronidation, while 3-hydroxycotinine is subject to O-glucuronidation 
(Benowitz 1996).
Genetic polymorphism of CYP isoforms is observed in humans, and it has been 
suggested that the efficiency of the conversion of nicotine to cotinine and 
resulting variations in nicotine metabolism are at least partly due to such 
polymorphisms (Yildiz 2004, Tutka et al 2005). Metabolism of cotinine appears 
to be slower in black than in white smokers, for example, because of both 
slower oxidative metabolism of nicotine to cotinine via CYP2A6, and slower N- 
glucuronidation (Perez-Stable et al 1998, Pianezza et al 1998, Benowitz et al 
1999). As this is the primary route for nicotine metabolism, alterations in the 
amount or function of CYP2A6 significantly affect plasma nicotine levels during 
smoking and nicotine replacement therapy (NRT), and may lead to a change in 
smoking behaviour and variations in the efficacy of NRT (Nakajima et al 2000, 
Yildiz et al 2004, Siu & Tyndale 2007).
While CYP2A6 is found in large amounts in the liver, it has not been identified in 
the human brain. However, in the CNS (especially following induction by 
exposure to nicotine) human CYP2B6 may play a role in nicotine metabolism, at 
least in some brain regions. This could be a factor in the development of central 
tolerance to nicotine observed both in animal models and in human smokers 
(Miksys et al 2000).
Compared to humans, the metabolism of nicotine to cotinine is less extensive in 
rats and nicotine-1'-N-oxide is the major nicotine metabolite in this species 
(Micu et al 2003, Tutka et al 2005). Nicotine is metabolised to cotinine primarily 
by hepatic CYP2B1, the rat homologue of CYP2B6, which has overlapping 
substrate specificity and is also found in other organs such as lung and brain 
(Miksys et al 2000, Micu et al 2003). Both CYP2E1 and 2B1/2 are expressed in 
various brain regions, including dopaminergic neurons in the substantia nigra 
where they may play a role in dopamine regulation. CYP2E1 expression has
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also been detected in human brain regions, including hippocampus, medulla 
and substantia nigra (Howard et al 2003). Compared with the liver, however, the 
brain is generally a poor metabolising organ for nicotine biotransformation 
(Ghosheh et al 2001).
Members of the CYP2A and CYP2B families, along with CYP2E1, also 
bioactivate several procarcinogens, including tobacco-specific nitrosamines 
such as N-nitrosodimethylamine (NDMA) and 4-(methylnitrosamino)-1-(3- 
pyridyl)-1-butanone (NNK), to their reactive intermediates. These are implicated 
in the development of tobacco-related cancers, which could be exacerbated if 
the production of such carcinogens is increased by the upregulation of CYPs 
due to chronic nicotine exposure (Miksys et al 2000, Howard et al 2001 & 2003, 
Iba et al 1999).
1.2.2 Metabolites of nicotine
Figure 1.2: Quantitative scheme of nicotine metabolism
Nicotine

























Estimated average (urinary) excretion of nicotine metabolites as percent of total 
nicotine dose in man (from Hukkanen et al 2005)
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In both rats and humans, the primary urinary metabolites are cotinine and 
secondary cotinine metabolites, together with variable but small amounts of 
nicotine-N-oxide, norcotinine, and nornicotine (Crooks & Dwoskin 1997). Figure
1.2 summarises the relative amount various metabolites contribute to the 
breakdown of the total nicotine dose administered.
1.2.2.1 Cotinine
In man, 70-80% of administered nicotine is converted to cotinine (Benowitz & 
Jacob 1994), making cotinine the major metabolite of nicotine. It has a much 
longer half-life (15-19 h) than the parent compound (2-3 h), which means that 
nicotine administration results in much higher blood concentrations of cotinine 
than nicotine (Benowitz et al 1983, Schneider et al 2001, Buccafusco & Terry
2003).
Cotinine has been reported to possess weak activity at nAChRs in vitro. Both 
cotinine and nicotine dose-dependently increase intracellular Ca2+ levels in 
bovine adrenal chromaffin cells, indicative of agonist activity, but pre-treatment 
with a low concentration of nicotine or cotinine was shown to inhibit the Ca2+ 
increase in response to the other compound (Vainio et al 1998a & 2000). Pre­
treatment of these cells with cotinine for 10 min also dose-dependently 
decreased nicotine-evoked [3H]noradrenaline release, but did not reduce 
potassium-evoked release (Vainio et al 1998b). Audesirk and Cabell have 
reported opposing effects of nicotine and cotinine in terms of cell survival and 
axon or dendrite branching in cultured hippocampal cells (Audesirk & Cabell 
1999). On the other hand, cotinine has been observed to have cytoprotective 
effects similar to nicotine in PC12 cells (Buccafusco & Terry 2003).
Furthermore, nicotine appears to inhibit immune responses, whereas cotinine 
had no such effect (Geng et al 1995).
Cotinine can evoke DA release in brain slices in a concentration-dependent 
manner (EC50 30 pM), although it is less potent than nicotine (EC50 0.1-4.0 pM), 
and nornicotine (EC5 0 1 pM) (Teng et al 1997, Dwoskin et al 1993 & 1999a). 
Nicotine-induced DA release in conscious rats also appears to be inhibited by 
prior intravenous administration of cotinine, although the dose used (500 pg/kg) 
was quite large (Sziraki et al 1999).
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Evaluation of cotinine on aspects of human memory processing and on animal 
behaviour, such as operant food-motivated responding, has shown biphasic 
effects, with doses in the 0.1-0.5 mg/kg range providing a positive effect, and 
higher doses (1-30 mg/kg) resulting in reduced performance levels (Crooks et al 
1997, Herzig et al 1998, Risner et al 1985).
1.2.2.2 Trans-3'-hydroxycotinine
In humans, (S)-Cotinine is metabolised primarily to (3'R,5'S)-fra/7s-3'- 
hydroxycotinine (3-HC), with only very little conversion to the stereoisomer, 
(S'R.S'SJ-c/s-S'-hydroxycotinine, although the percentage appears to be higher 
in some animal species. Approximately 60-75% of 3-HC is excreted unchanged 
in the urine, with ~30% metabolised further and excreted as 3-HC glucuronide. 
The ratio of plasma 3-HC/cotinine appears to be inversely correlated with the 
plasma nicotine concentration during ad libitum cigarette smoking, suggesting 
this might be useful as a marker of CYP2A6 activity (Benowitz & Jacob 2001).
1.2.2.3 Norcotinine
Norcotinine has been shown to occur as a urinary metabolite of cotinine in 
dogs, mice, rats and humans, and is formed in vitro from cotinine in hepatic, 
pulmonary, and renal tissues (Ghosheh et al 1999 & 2001). Following nicotine 
administration, it can be detected in the urine of rats and humans, accounting 
for ~2% of the systemic nicotine dose in the latter, but was not observed after 
administration of cotinine to humans (Wada et al 1961, Bowman et al 1959, 
Tutka et al 2005). Norcotinine is also found in brain after peripheral nicotine 
administration, and has a half-life of approximately 4 hours. Brain norcotinine 
appears to originate from 5-C-oxidation of brain nornicotine, rather than from N- 
demethylation of cotinine, as occurs peripherally (Ghosheh et al 2001). In their 
paper, Crooks et al (1997) refer to some unpublished data indicating that 
norcotinine neither evokes the release of [3H]dopamine from rat striatal slices, 
nor inhibits [3H]dopamine uptake into rat striatal synaptosomes, and there is no 
evidence to suggest that norcotinine is pharmacologically active, however, very 
little research on the actions of this nicotine metabolite has been conducted 
(Ghosheh et al 2001).
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1.2.2.4 Nornicotine
Nornicotine is a major tobacco alkaloid, constituting 15-20% of total alkaloid 
content in tobacco (Dwoskin et al 2001). In addition, nornicotine is a very minor 
N-demethylated peripheral metabolite of nicotine in various animal species, with 
only ~8% (in rats) or ~1% (in humans) of peripherally administered nicotine 
converted to nornicotine in the periphery (Ghosheh et al 1999 & 2001, Crooks & 
Dwoskin 1997, Dwoskin et al 2001). The majority of nornicotine excreted by 
cigarette smokers is derived from metabolised nicotine, while up to 40% may be 
absorbed directly from tobacco (Tutka et al 2005). Although only a minor 
metabolite in the periphery, nornicotine is a major nicotine metabolite in the 
CNS and has a significantly longer half-life (7-8 h) than nicotine (1-2 h)
(Dwoskin et al 1999b & 2001). Nicotine appears to be transformed to 
nornicotine locally in the brain, and the metabolite has been shown to 
accumulate in rat CNS to pharmacologically relevant concentrations following 
repeated peripheral nicotine administration. It seems likely that nornicotine may 
also reach pharmacologically relevant concentrations in smokers’ brains as a 
result of direct exposure to nornicotine in tobacco, indirect exposure from 
nicotine metabolism, and due to the comparatively longer brain residence time 
of nornicotine, which results in CNS accumulation (Dwoskin et al 2001). 
Nornicotine has been shown to evoke the release of [3H]dopamine from rat 
striatal and nucleus accumbens slices in a concentration- and calcium- 
dependent manner (Dwoskin et al 1993, Green et al 2001), which is both 
mecamylamine- and dihydro-p-erythroidine-sensitive (Teng et al 1997), 
suggesting a nAChR-mediated mechanism of action. It competes with 
[3H]nicotine for high affinity binding sites in rat brain membranes, and is 
reported to have a 10-fold lower affinity for nicotinic receptors than nicotine. 
However, in DA release studies, nornicotine and nicotine were found to have 
similar potency (Crooks & Dwoskin 1997).
Nornicotine has been reported to produce stimulant-like locomotor sensitisation 
effects (Dwoskin et al 1999b), which appear to be dependent upon activation of 
D2 DA receptors in the mesolimbic system (Green et al 2002), as well as 
discriminative stimulus effects (Dwoskin et al 2001). This metabolite has also 
been observed to maintain self-administration behaviour (Bardo et al 1999) and 
decrease nicotine self-administration in rats (Dwoskin et al 2001), suggesting
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that it may desensitise nAChRs. It is possible that nicotine self-administration 
behaviour in both animal models and smokers is maintained, at least in part, by 
prolonged nAChR stimulation by nornicotine even after nicotine concentrations 
have diminished below the pharmacologically active range.
1.3 Sites of action -  nicotinic acetylcholine receptors (nAChRs)
In order to understand nicotine addiction it is essential to have some knowledge 
of the structure and function of the nicotinic acetylcholine receptors, through 
which nicotine mediates its effects. nAChRs are found in the brain, autonomic 
ganglia, and the neuromuscular junction. Most relevant to nicotine addiction are 
the neuronal nAChRs, which are found throughout the brain, with the greatest 
number of binding sites in the cortex, thalamus, and interpeduncular nucleus, 
and further substantial binding in the amygdala, septum, brain stem motor 
nuclei and locus coeruleus (Gotti & Clementi 2004).
1.3.1 Structure of nAChRs
Langley's description of a "nicotinic receptive substance" at the neuromuscular 
junction (Langley 1907) lead to the formulation of the receptor concept and kick- 
started research into the structure and function of nAChRs. Along with GABAa, 
glycine and 5 HT3 receptors, nAChRs belong to the superfamily of ligand-gated 
ion channels. Each nAChR subunit has 4 transmembrane domains, and 
subunits assemble to form pentameric structures arranged around a central ion- 
conducting channel, which opens upon binding of acetylcholine (ACh; Karlin 
2002, Gotti & Clementi 2004). Distinct nAChR subtypes are found at the 
neuromuscular endplate, the sympathetic and parasympathetic ganglia, and in 
the central nervous system (CNS) of vertebrate species, where they regulate 
cholinergic transmission, cell excitability, and muscle contraction, as well as 
modulating the release of other neurotransmitters such as dopamine (DA), 
noradrenalin (NA), y-aminobutyric acid (GABA) and glutamate. As a result, they 
play an important role in physiological functions such as arousal, sleep, fatigue, 
anxiety, the central processing of pain, food intake, and a variety of cognitive 
functions (Karlin 2002, Laviolette & van der Kooy 2004, Nicke et al 2004, Gotti 
& Clementi 2004).
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Twelve neuronal nAChR subunits (a2-a10, P2-P4) have been identified in 
vertebrates, although a mammalian homologue of the avian a8 subunit has not 
yet been found. Embryonic vertebrate muscle and Torpedo nAChR (see Figure 
1.4) on the other hand are composed of a1 and p1, as well as y and 5 subunits, 
with £ replacing the y subunit in adult muscle (Karlin 2002, Laviolette & van der 
Kooy 2004, Gotti & Clementi 2004).
The a7-a9 subunits can form homomeric nAChRs, whereas the remaining 
subunits form different combinations of a- and p-subunits, with a4p2* nAChRs 
being the most predominant subtype (Gotti & Clementi 2004). The a2, a3, a4 
and a6 subunits require co-expression of at least one p subunit (p2 or p4) to 
form functional channels (Nicke et al 2004).
Figure 1.3: Subtypes of nAChR found in the VTA and striatum





Striatum (a4)2(P2)3, (a4)2a5(p2)2, (a6)2(P2)2p3, a4a6(p2)2p3 Dopaminergic
Summary of somatodendritic nAChR subtypes proposed to reside on dopaminergic 
and GABAergic neurones in the VTA and presynaptic nAChRs on dopaminergic 
boutons in the terminal field (from Wonnacott et al 2005)
The mesocorticolimbic dopamine system is central to reward and reinforcement 
of both natural rewards and addictive drugs, such as nicotine (see section 1.4). 
Neurons involved in this "reward circuitry" express nAChRs consisting of a 
variety of subunit combinations (see Figure 1.3). These subtypes are thought to 
have a stoichiometry of (a)2(p)3 or (a)3(P)2 (Gotti & Clementi 2004, Wonnacott et 
al 2005). The areas of distribution for various subunits, and thus also subunit 
combinations, appear to overlap, resulting in a great diversity of nAChRs, with 
distinct pharmacological, physiological and electrical properties, depending on 
the subunit composition of the channel (Gotti & Clementi 2004, Wonnacott et al 
2005).
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Figure 1.4: Structure of nicotinic acetylcholine receptors
A B
Electron microscopic images (a & b; averaged structure) and ribbon diagrams (c & d) o f 
nAChR derived from tubular crystals o f Torpedo postsynaptic membranes (a & b from 
Miyazawa et al 1999, c & d from Unwin 2005)
a) Cross-section along the central axis o f the receptor, illustrating the position o f the ion 
channel within the membrane (hatched lines). The asterisk in the extracellular portion 
o f the receptor indicates the proposed acetylcholine (ACh) binding site, with the dotted 
line highlighting the narrow tunnel connecting the ACh binding pocket to the vestibule
of the ion channel
b) Cross-section parallel to the membrane plane, showing the pentameric arrangement
o f receptor subunits, with the putative ACh binding pockets indicated by arrows 
c) Ribbon diagram of the nAChR seen from the synaptic cleft 
d) Ribbon diagram of the nAChR as viewed parallel with the membrane plane (the front 
2 subunits are highlighted for clarity; E  =  extracellular, I =  intracellular)
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Most of the work on structural characterisation of nAChRs has been done using 
the electric organs of the electric ray (Torpedo) and eel (Electrophorus), which 
provide a rich source of nAChRs. High-resolution images (4 A), obtained using 
electron microscopy techniques (Unwin 2005), have provided valuable 
information about the channel architecture and dimensions (see Figure 1.4), 
with crystallisation studies of nAChRs and acetylcholine binding protein 
(AChBP) giving a deeper insight into the molecular structure (Brejc et al 2001, 
Miyazawa et al 2003).
AChBP is a homopentameric, soluble protein secreted by snail glial cells into 
cholinergic synapses where it modulates synaptic transmission by binding 
acetylcholine (ACh). It is a structural and functional homologue of the 
extracellular portion of nAChRs (especially a7 homomeric receptors), which 
contains the amino-terminal ligand-binding domain (Brejc et al 2001, Miyazawa 
et al 2003, Unwin 2005).
The receptor channel is funnel-shaped, with a narrow section towards the 
cytoplasmic end of the membrane-spanning pore, which selects for ion charge 
and size, and determines conductance. The pore is composed of an inner ring 
of 5 a-helices, curving radially to create a tapering path for the ions, and an 
outer ring of 15 a-helices, which coil around each other and shield the inner 
ring. This region also contains the "gate", a constricting hydrophobic girdle near 
the middle of the lipid bilayer formed by weak interactions between 
neighbouring inner helices (Karlin 2002, Sine 2002, Miyazawa et al 2003, Unwin 
2005).
The ACh and nicotine binding sites are located at the interface between the a 
subunit and either an adjacent p subunit (heteromeric neuronal nAChR), 
another a subunit (homomeric nAChR), or, in the case of muscle nAChRs, a 6, 
y or e subunit. The a5, p1 and P3 subunits appear to play a more structural role, 
possibly also modulating channel function and influencing membrane transport 
and targeting of nAChRs, while the remaining subunits can contribute to the 
ACh binding site (Karlin 2002, Nicke et al 2004, Gotti & Clementi 2004).
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1.3.2 Function of nAChRs
nAChRs contain multiple agonist- and non-competitive-antagonist binding sites, 
as well as a gate, all of which interact at a distance through changes in the 
quaternary structure of the receptor to modulate its function (Karlin 2002, Sine 
2002). When an agonist, such as acetylcholine or nicotine, enters the ligand- 
binding domain, it triggers rotations of the protein chains on opposite sides of 
the entrance to the pore (see Figure 1.5). These rotations are communicated 
through the inner helices, allowing the channel gate to open, and permitting the 
passage of cations (Na+, K+, and Ca2+) through the channel pore (Miyazawa et 
al 2003, Laviolette & van der Kooy 2004, Unwin 2005). In neurons, activation of 
nAChRs is involved in calcium homeostasis and signalling, both via an influx of 
Ca2+ through the nAChR channel, but also because nAChR-mediated 
depolarisation of the plasma membrane can activate voltage-operated calcium 
channels (VOCCs), leading to an increase in intracellular Ca2+, which can 
induce further mobilisation of Ca2+ from intracellular stores (Gotti & Clementi
2004).
Figure 1.5: Proposed model for nAChR gating mechanism
ACh binding to the receptor induces rotations in the alpha-subunits, which are 
transmitted to the gate through the M2 helices (coils lining the pore). This destabilises 
the gate and causes the helices to adopt an alternative configuration that is permeable 
to the ions. S-S: disulphide bridge, G: glycine residue (from Miyazawa et al 2003).
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Muscle nAChRs, located at the neuromuscular endplate, transmit the nerve 
stimulus to the muscle, by causing depolarisation via the influx of cations 
through the opening receptor channels. This leads to contraction of the muscle 
fibres (Ganong 1999).
Neuronal nAChRs appear to be located at the cell body, as well as on neuronal 
processes, both pre- and postsynaptically (Laviolette & van der Kooy 2004). 
Postsynaptic nAChRs are involved in the generation of action potentials by 
enabling the depolarisation of the postsynaptic neuron, again via cation influx 
through the open ion channels. Presynaptic nAChRs directly enhance the Ca2+- 
dependent release of many neurotransmitters, as well as modulating dopamine 
release indirectly by regulating glutamate and y-aminobutyric acid (GABA) 
release. nAChRs located presynaptically can also influence synaptic efficacy 
and long-term potentiation or long-term depression (Mansvelder & McGehee 
2000, Wonnacott et al 2005).
The nAChR receptor complex can exist in several conformational states (see 
Figure 1.6), which are dynamically regulated by exposure to the agonist: closed, 
open and desensitised (Karlin 2002, Sine 2002, Laviolette & van der Kooy 
2004, Unwin 2005). When nAChRs are exposed to an agonist repeatedly or for 
prolonged periods, they enter an inactive, desensitised state, from which they 
can recover upon agonist removal. The recovery time appears to depend on the 
duration of agonist exposure, and the agonist used, as well as the receptor 
subtype (Grady et al 1994, Reitstetter et al 1999). A reasonable explanation 
might be that during longer exposure to an agonist nAChRs can enter deeper 
levels of desensitisation (Pidoplichko et al 1997, Reitstetter et al 1999). 
Homomeric a7 receptors appear to have more rapid activation and 
desensitisation kinetics than a4p2 high-affinity nAChRs, which take much 
longer to recover from the desensitised state (Wooltorton et al 2003).
Nicotine addiction is characterised by repeated nicotine intake, resulting in 
sustained levels of nicotine in the blood. As a consequence of such prolonged 
exposure to nicotine, nAChRs in the brain are likely to be desensitised for long 
periods of time (most of the day in a smoker). Chronic exposure to nicotine, or 
other nAChR agonists, via subcutaneous infusion or repeated injections, has 
been observed to elicit an increase in the number of nicotine binding sites in the 
brains of rodents (Wonnacott 1990, Flores et al 1992, Parker et al 2004). The
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a4p2* nAChR displays the highest level of upregulation, with relatively little 
effect on other receptor subtypes (Nguyen et al 2003). Numbers of [3H]nicotine 
binding sites in the post-mortem brains of smokers are also higher than in non- 
smokers (Benwell et al 1988). This observed increase in binding appears to be 
due to an increase in receptor density, rather than affinity (Marks et al 1985 & 
1987, Schwartz & Kellar 1985).
Figure 1.6: Conformational states of nAChRs
Upon agonist binding, nAChRs undergo an ailosteric 
transition from the closed, resting conformation to an 
open state that conducts cations (sodium, potassium, 
calcium). In the active/open conformation, the nAChR 
binds agonists with low affinity. The continued presence 
of agonist leads to ion channel closure and receptor 
I desensitisation. Prolonged agonist exposure may produce
an inactivation state, from which recovery is very slow.
R = low-affinity resting state; A = active/open receptor state; D & I desensitised states, 
(adapted from Changeux & Edelstein 1998)
Because nAChRs are subject to profound and prolonged desensitisation upon 
exposure to agonists, it was initially suggested that this might underlie the 
mechanism of agonist-induced upregulation (Marks et al 1985, Schwartz & 
Kellar 1985). However, desensitisation alone is not sufficient to induce 
measurable upregulation of binding sites. Treatment with nicotine 
concentrations sufficient to achieve complete desensitisation of receptors does 
not appear to result in upregulation (Rowell & Li 1997, Marks et al 1994). A 
single injection of nicotine, which should desensitise the receptors, is without 
effect on receptor numbers (Schwartz & Kellar 1985), instead, repeated daily 
injections or chronic infusion appear to be required for upregulation. Increased 
receptor numbers are observed after several days (Schwartz & Kellar 1985, 
Marks et al 1985), compatible with altered protein turnover, which could result 
from increased receptor synthesis or assembly, increased incorporation into the 
membrane from a "reserve” pool of receptors, or decreased degradation. 
However, the absence of an increase in mRNA points to a post-transcriptional
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mechanism. Upon termination of drug treatment, recovery to the original 
receptor density occurs over a similar time-course (Wonnacott 1990). 
Surface-expressed nAChRs are constitutively and rapidly endocytosed from the 
plasma membrane and directed into a lysosomal degradation pathway. Under 
normal conditions, surface nAChRs are constantly replaced by new receptors 
from the secretory pathway. Chronic exposure of surface nAChRs to nicotinic 
agonists is sufficient for induction of surface receptor upregulation but does not 
appear to alter the endocytic trafficking or subunit mRNA levels (Sallette et al
2005). It has been proposed that an internal pool of immature nAChR subunits 
may reside in the endoplasmatic reticulum (ER), where they are thought to 
oligomerise prior to the assembly of mature pentameric receptors. This would 
help explain the observed accumulation of high-affinity binding sites in 
intracellular compartments (Harkness & Millar 2002, Whiteaker et al 1998, 
Sallette et al 2005). The immature receptor components may contain exposed 
ER retention signals, which act to keep unassembled components in the ER 
until packaging is complete (Nashmi et al 2003, Ren et al 2005), as appears to 
be the case with muscle nAChRs (Keller et al 2001). Nicotine could bind to 
these precursors to stabilise a conformation possessing higher affinity for 
nicotine and facilitate progression to further steps of maturation toward high- 
affinity receptors, such as packaging into secretory vesicles and exit from the 
ER (Darsow et al 2005, Sallette et al 2004 & 2005).
1.4 Addiction & reward
Several neural circuits in the brain are thought to mediate the addictive actions 
of drugs of abuse, including nicotine. These brain structures represent reward 
pathways, which are very old from an evolutionary point of view and presumably 
evolved to mediate an individual's response to natural rewards such as food, 
sex and social interaction (Wise 1996, Nestler 2002).
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1.4.1 Reward circuitry
Nicotine induces feelings of pleasure and reward in humans and other species, 
but like many other addictive drugs it also has aversive, unpleasant effects. 
Many people experience noxious effects (nausea, coughing, dizziness) on their 
initial experience with tobacco, although tolerance to these aversive effects 
develops with repeated exposure (Laviolette & van der Kooy 2004). 
Understanding how the neural systems interact may yield important clues about 
how the brain responds to acute nicotine exposure, and how continued 
exposure can lead to dependence.
The mesocorticolimbic dopamine (DA) system (see Figure 1.7) has been 
implicated in the rewarding effects of a variety of addictive drugs, including 
cocaine, alcohol, opiates and nicotine (Wise 1996, Corrigal 1999, Gerrits et al 
2002, Nestler 2002, Wonnacott et al 2005). Cell bodies of this system originate 
in the ventral tegmental area (VTA) and project to the forebrain, mainly the 
nucleus accumbens (NAcc), olfactory tubercle, (pre-) frontal cortex, amygdala 
and septal areas. Functional interactions between DA, GABA and glutamate 
within the VTA appear to play a vital role in mediating the motivational 
properties of nicotine (Koob 1992, Wise 1996, Pidoplichko et al 1997 & 2004, 
Laviolette & van der Kooy 2004, Wonnacott et al 2005).
VTA GABA neurons provide inhibitory input to the mesocorticolimbic DA 
neurons (Koob 1992, Wise 1996, Laviolette & van der Kooy 2004, Wonnacott et 
al 2005), and project to the brainstem mesopontine region, including the 
tegmental pedunculopontine nucleus (TPP). The VTA also receives excitatory 
glutamatergic inputs from several cortical and subcortical structures 
(Pidoplichko et al 1997 & 2004), as well as cholinergic inputs from the TPP and 
adjacent laterodorsal tegmental nucleus (LDT), and inhibitory GABA inputs from 
the TPP (Koob 1992, Wise 1996, Laviolette & van der Kooy 2004, Wonnacott et 
al 2005).
Electrical stimulation of the TPP elicits striatal DA efflux, whereas LDT 
stimulation leads to a similar DA efflux in the NAcc through activation of 
cholinergic and glutamatergic receptors in the VTA (Wise 1996). The 
importance of these brain areas in relation to the effects of nicotine has been 
demonstrated by means of lesion studies. LDT lesioned rats showed no 
differences in responding to nicotine compared to saline, whereas in sham-
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lesioned control rats an initial depression of locomotor activity was observed 
followed by a progressive increase in locomotion upon repeated exposure 
(Alderson et al 2005). The spontaneous locomotor activity of lesioned rats was 
also decreased compared to controls. Intravenous self-administration (see 
Chapter 4) was significantly increased following lesions of the posterior TPP 
compared to sham-lesioned controls, however lesions of the anterior TPP had 
no significant effect (Alderson et al 2006).
Figure 1.7: Simplified schematic of afferent and efferent connections between
the VTA, NAcc, PFC and TPP/LDT
Major pathways using dopamine (DA), GABA, acetylcholine (ACh) and glutamate (Glu), 
and locations of a7- and ($2* nAChRs are illustrated. See text for details and 
abbreviations (adapted from Wonnacott et al 2005).
Nicotine acts through nAChRs, enhancing DA release (Stolerman & Shoaib 
1991, Pidoplichko et al 2004). In vitro (transmitter release assays) and in vivo 
(microdialysis, voltammetry) techniques (discussed in more detail in Chapter 2) 
have shown that administration of nicotine, at concentrations within the 
physiological range of plasma levels obtained by smokers (-0.5 pM), potently 
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DA release in the NAcc (Stolerman & Shoaib 1991, Wise 1996, Corrigall 1999, 
Gerrits et al 2002, Nestler 2002, Wonnacott et al 2005). This activation is 
followed by desensitisation of nAChRs with continued exposure to nicotine 
(Pidoplichko et al 1997 & 2004), suggesting that acute excitatory action of 
nicotine on DA neurons might signal its reinforcing, rewarding effect, whereas 
the long-lasting desensitisation of VTA nAChRs may represent a cellular basis 
of nicotine tolerance. This could explain why smokers tend to enjoy the first 
cigarette of the day most, as overnight abstinence would have allowed nAChRs 
to recover from their state of prolonged desensitisation (Laviolette & van der 
Kooy 2004).
In rat and mouse striatum, two principal nAChR populations have been 
identified using various strains of knockout mice (Zoli et al 1998, Marubio & 
Changeux 2000, Whiteaker et al 2002, Champtiaux et al 2003, Salminen et al 
2004, Gotti & Clementi 2004): one population contains the a4 and (32 subunits 
but not a6 (a4(32*), while the other contains a6 and (32 subunits (a6|32*). These 
populations account for approximately 70 and 20% of striatal nAChRs, 
respectively.
There is evidence to suggest that a7 nAChRs play a role in the regulation of 
glutamate release (Pidoplichko et al 2004). Lesions of the prefrontal cortex 
(PFC), a region providing glutamatergic inputs to the VTA, reduce binding of the 
a7 antagonist a-bungarotoxin in the VTA, and blockade of NMDA (N-methyl-D- 
aspartate) or a7 receptors in the VTA reduces the increase in mesolimbic DA 
release induced by nicotine (Schilstrom et al 1998 & 2000, Laviolette & van der 
Kooy 2004).
In the acute stage of nicotine reward signalling, activation of GABA neurons in 
the VTA by nicotine produces rewarding effects through a GABA-dependent 
system projecting to the TPP (Laviolette et al 2002), as illustrated in Figure 1.8 
a. These effects are thought to involve activation of a7 presynaptic nAChRs, 
however, nicotine may also exert its motivational effects through direct actions 
on (32* nAChRs located on GABA or DA neurons, since pharmacological 
blockade or genetic deletion of this subunit appear to block both aversive and 
rewarding effects of nicotine (Pidoplichko et al 1997 & 2004, Picciotto et al 
1998, Klink et al 2001, Wooltorton et al 2003, Marubio et al 2003).
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a) In the acute stage, activation of dopaminergic neurons by nicotine induces aversive 
effects, whereas GABA neurons and associated inputs to the TPP mediate rewarding
effects.
b) Repeated nicotine exposure leads to desensitisation of the GABA system and 
results in sensitisation of dopaminergic pathways, which signal the incentive salience
(ie how much the drug is craved).
[from Laviolette & van der Kooy 2004; GABA = y-aminobutyric acid; NMDA = N- 
methyl-D-aspartate; TPP = tegmental pedunculopontine nucleus; VTA = ventral
tegmental area]
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It has been proposed that, with repeated nicotine exposure (see Figure 1.8 b), 
the GABA system becomes desensitised (Pidoplichko et al 2004), leading to a 
net shift towards DA neuronal activity due to reduced inhibition by GABA 
neurons (Wise 1996, Laviolette & van der Kooy 2004). The desensitisation of 
inhibitory inputs to the DA system also correlates with enhanced glutamatergic 
input to DA neurons (Pidoplichko et al 2004) through nicotine acting on 
presynaptic 07 nAChRs on VTA glutamatergic terminals (Nomikos et al 2000), 
which show a lesser degree of desensitisation. This shift in the functional 
balance between GABA and DA neuronal populations may lead to a 
dysregulated DA signal in the VTA, resulting in the aversive psychological 
effects of nicotine craving and withdrawal, and/or the potentiation of the 
incentive salience of nicotine and its compulsive use (Laviolette & van der Kooy 
2004).
Nicotine has also been shown to suppress striatal dopamine release during 
non-reward low firing frequencies through nAChR desensitisation, while 
selectively enhancing reward-related dopamine release by relieving short-term 
depression at higher burst-like firing frequencies (Rice & Cragg 2004). This 
mechanism is likely to play an important role in the ability of nicotine to enhance 
the reinforcing efficacy of reward-related stimuli (Caggiula et al 2001), including 
non-nicotine conditioned stimuli (e.g. visual cues), which can support nicotine 
self-administration behaviour (see Chapter 4). This exaggeration of 
dopaminergic reinforcement mechanisms results in a powerful signal for 
nicotine-associated behaviours, habit and addiction at a synaptic level (Schultz 
2002).
1.4.2 Addiction
Addiction can be defined as the loss of control over drug use, or the compulsive 
seeking and taking of drug regardless of the consequences (Nestler 2002). The 
main factor common to all drug addictions is drug-seeking behaviour, and the 
ability to act as a positive reinforcer is the minimum requirement for maintaining 
drug-seeking behaviour. Drugs of abuse are very powerful reinforcers and can 
motivate high rates of operant responding even in conditions of limited access 
(where the subject is not dependent), and drugs readily self-administered
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intravenously (see Chapter 4) or orally by animals appear to correspond well 
with those of high abuse potential in humans. However, a drug serving as a 
positive reinforcer under certain circumstances may be ineffective in other 
conditions; drug dose, genetic factors, social circumstances and previous 
history of the individual are also important factors in determining reinforcing 
effectiveness (Stolerman 1992, Koob 1992). Environmental stimuli and rituals 
associated with drug taking behaviour (e.g. manual manipulation of cigarette) 
can also provide reinforcement and lead to relapse in an abstinent drug user 
(Le Foil & Goldberg 2005).
In a dependent subject, the termination or prevention of aversive withdrawal 
symptoms may constitute a source of negative reinforcement (Wise 1996). It is 
thought that environmental stressors may enhance signs of nicotine withdrawal, 
and that nicotine encourages adaptive changes in the brain, which facilitate 
coping with stress and anxiety (Stolerman & Shoaib 1991, Stolerman 1992, 
Koob 1992, Nestler 2002).
The strength of drug-seeking behaviour is seen as the result of a drug's positive 
reinforcing and discriminative stimulus properties. However, the ability of a drug 
to serve as a discriminative stimulus is not, by itself, sufficient to indicate that it 
will support drug-seeking behaviour. Almost all addictive drugs have 
discriminative stimulus effects, including psychomotor stimulants, anxiolytics 
and sedative/hypnotics, opioids, ethanol and nicotine (Stolerman 1992). 
Discriminative effects may directly promote drug-seeking behaviour due to 
previous association of such behaviour with the perceived effects of the drug 
(Nestler 2002). These "priming'' effects are distinct from a drug's reinforcing 
actions, since they occur with passively administered instead of self­
administered drugs, and appear to show pharmacological specificity: cocaine 
primes cocaine but not heroin self-administration, and vice versa. In contrast, 
self-administration behaviour maintained by a drug from one pharmacological 
class often persists when a reinforcing substance from another class is 
substituted (Stolerman 1992). Wild-type mice trained to self-administer cocaine 
maintained specific operant responding when the drug infusion was switched to 
nicotine, whereas in mutant mice lacking the (32 nAChR subunit a reduction in 
responding was observed over the nicotine substitution period (Picciotto et al 
1998). Knockout mice were also less able to discriminate between active (drug-
- 3 8 -
Chapter 1 - Introduction
associated) and inactive levers (see Chapter 4 for more detail on drug 
discrimination and self-administration procedures).
Withdrawal from chronic treatment is also often associated with clear 
discriminative stimulus effects. The ability to perceive and identify the 
characteristic subjective effects of a drug and its withdrawal symptoms may 
therefore mediate drug-seeking, by indicating the effects and potency of a 
substance and directing the organism towards one substance rather than 
another (Stolerman 1992).
In addition, the ability to produce changes in mood is recognised as an 
important factor in many addictions, and is not limited to the production of 
euphoria; subjective effects of drugs are often described in terms of reduction of 
negative mood states such as anxiety, or as a means for escaping from an 
unendurable reality. Nicotine can produce a subjective state of euphoria 
resembling the effects of classical addictive drugs, although the intensity may 
not be sufficient to make this the sole or major source of reinforcement for 
smoking (Stolerman 1992).
Furthermore, there is the ability of drugs to provide a resource for users in terms 
of perceived improvement in performance. This has been applied to nicotine in 
particular, which appears to enhance accuracy during tests of sustained 
attention and improve the ability to process information, which is presented very 
rapidly (Stolerman 1992).
Environmental stimuli can become associated with the effects of drug (or drug 
withdrawal), leading to previously neutral stimuli acquiring secondary reinforcing 
properties following association with reinforcing doses of drugs (Berridge & 
Robinson 2003). In tobacco smoking, sensory stimuli such as the sight, taste 
and smell of cigarette smoke exert powerful control over usage, possibly due to 
the numerous previous pairings of such stimuli with the effects of nicotine, the 
primary reinforcer (Le Foil & Goldberg 2005).
Conditioned stimuli have also been implicated in the development of tolerance 
(and sensitisation) to effects of several drugs (opiates, alcohol, amphetamine 
and cocaine). In many studies, tolerance and sensitisation appear to be 
situation-specific, with a greater development of tolerance (or sensitisation) 
observed when a drug is tested in an environment where it was administered 
previously than in a distinctly different environment (Stolerman 1992, Rose et al
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2000, Caggiula et al 2001). Attempts to treat nicotine addiction should therefore 
include not just pharmacotherapy to combat the reinforcing effects of nicotine, 
but also behavioural or psychotherapy to help deal with the conditioned stimuli 
associated with smoking (see section 1.6).
1.5 Tobacco consumption
Nicotine is the main psychoactive drug delivered by tobacco, producing most of 
the immediate pharmacological effects, including the addictive effects on brain 
and behaviour (Stolerman et al 1991). It is a peripheral vasoconstrictor and 
sympathetic stimulant, which probably has a weak causal role in some 
cardiovascular diseases (Foulds et al 2004).
Tobacco is available in the form of a variety of products, which can be divided 
into two categories: smoked tobacco and smokeless tobacco products.
1.5.1 Smoked tobacco
There are several forms of smoked tobacco, of which cigarettes are the most 
prevalent. Other forms include cigars, cigarillos and pipe tobacco. Tobacco 
smoke consists of volatile and particulate phases containing thousands of 
different substances, most of which are generated in the combustion process. 
Carbon monoxide gas preferentially binds to haemoglobin, thus reducing the 
oxygen-carrying capacity of the blood. “Tar” from tobacco smoke is a black 
sticky cocktail of chemicals containing more than 40 known carcinogens, which 
lodges in the lungs and upper airways and causes respiratory diseases by 
interfering with the normal functions of the airways (Stolerman et al 1991, 
Foulds et al 2004). Stated tar and nicotine yields are based on the way that 
machines, not people, smoke cigarettes. Smokers addicted to nicotine adjust 
their smoking (consciously and/or subconsciously) in order to achieve the 
desired nicotine intake and thereby avoid nicotine withdrawal. Even if a 
cigarette has a low nicotine yield, a smoker can extract a greater percentage of 
nicotine from each cigarette by taking deeper and longer inhalations, holding 
the smoke in the lung, and covering the perforations around the filter (Moxham 
2000).
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The cigarette is a very efficient device, which rapidly delivers the optimum dose 
of nicotine to the brain (Moxham 2000). Nicotine (typically 1-3 mg per cigarette) 
is absorbed from cigarette smoke, enters the arterial circulation, and is quickly 
distributed to body tissues (Benowitz 1996, Foulds et al 2004). It takes only IQ- 
20 s for nicotine to pass through the brain. Nicotine levels then fall, owing to 
uptake by peripheral tissues and elimination of nicotine from the body. 
Arteriovenous differences during cigarette smoking are substantial, with arterial 
levels exceeding venous levels six- to ten-fold. Rapid delivery of nicotine results 
in a more intense pharmacological response, due to higher arterial levels 
entering the brain and effects occurring rapidly, before there is adequate time 
for the development of tolerance in the naive smoker. Reinforcement of drug 
seeking is therefore immediate and is associated with the sensory, ritual and 
psychological effects of smoking (Schneider et al 2001). Nicotine levels in the 
brain decline between cigarettes, providing an opportunity for re-sensitisation of 
receptors so that positive reinforcement can to some extent occur with 
successive cigarettes despite the development of tolerance (Benowitz 1996). It 
is thought that in chronic smokers, on the other hand, tobacco consumption is 
maintained in order to avoid the withdrawal effects associated with nicotine 
abstinence (see section 4.5).
It is now accepted that tobacco smoking is highly addictive and that nicotine is 
the principal psychoactive component of tobacco smoke responsible for tobacco 
dependence. Tobacco smoking is the most prevalent form of drug abuse, and 
the treatment of tobacco dependence has been made a public health priority 
(US Dept of Health & Human Services 1989).
1.5.2 Smokeless tobacco products
Smokeless tobacco was the dominant form of tobacco until early in the 20th 
century when developments in tobacco cultivation, curing and manufacturing, 
along with the invention of the safety match, resulted in the increased popularity 
of cigarettes. Smokeless tobacco (ST) products are not burnt; instead they are 
placed in the cheek or between the lip and gum. ST is used in many countries 
around the world, including the Middle East and the Indian subcontinent, and is 
especially popular in Sweden (Rodu & Godshall 2006).
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Most of the medical and epidemiological evidence shows that ST users do not 
have elevated risks for cardiovascular disease. In distinct contrast to smokers, 
ST users do not exhibit any significant differences compared to non-smokers 
with regard to heart rate, blood pressure, cardiac output and maximal working 
capacity, or levels of haemoglobin, hematocrit and leukocytes. ST users also do 
not appear to develop smoking-associated vascular changes, such as 
increased thickness of blood vessels and atherosclerotic plaques, and have no 
or only a modestly increased risk for heart attacks or strokes. They also have a 
much lower incidence of oral cancer than smokers (Huhtasaari et al 1992, 
Accortt et al 2002, Hergens et al 2005, Rodu & Godshall 2006).
Oral leukoplakias ("white plaque", a thickening of the mouth lining) occur in up 
to 60% of ST users at the site of ST use and are largely a result of local 
irritation. Dysplasia (a pre-cancerous stage) is seen only infrequently in ST 
leukoplakias (< 3%), whereas in leukoplakias due to smoking, dysplasia is 
observed in -20%  of cases. Although oral leukoplakias occur commonly in ST 
users, they primarily present irritation and only very rarely progress to oral 
cancer (Silverman et al 1984, Kaugars et al 1989, Grady et al 1990, Rodu & 
Godshall 2006).
Widespread use of ST has been alleged to serve as a gateway to smoking. 
However data from studies in the US and Sweden do not support this. In fact 
the opposite appears to be the case among Swedish men, with snus serving as 
a pathway away from smoking (Foulds et al 2003, Bates et al 2003, Rodu & 
Godshall 2006).
Three main types of ST are described in more detail below:
Powdered dry snuff
Dry snuff is made from fermented, fire-cured tobacco, which is then pulverised. 
Nasal inhalation of dry snuff was widely practiced in Europe in the 17th and 18th 
centuries but declined thereafter. Manufacturers now provide an array of 
flavoured dry snuff products but on the whole the use of dry snuff is declining 
(Rodu & Godshall 2006).
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Loose leaf chewing tobacco
Loose-leaf chewing tobacco consists of air-cured leaf tobacco, which is 
shredded, coated with sweet flavouring solutions and then packaged. Chewing 
tobacco is typically used in large volumes, resulting in a golf ball-sized bulge in 
the user's cheek and large quantities of saliva, which users usually spit out. 
Consequently, the popularity of this product has waned, with consumption 
declining steadily over the past century (Rodu & Godshall 2006).
Moist snuff & "snus"
Moist snuff is currently the most popular form of ST in the US and consists of 
fire-and air-cured dark tobaccos, which are finely ground or cut. The user 
usually compresses a "pinch" between the thumb and forefinger, and places it 
inside the lip. Much less bulky than loose leaf chewing tobacco, moist snuff 
produces less saliva, but spitting is still common (Rodu & Godshall 2006).
There is a long tradition of moist snuff use in Scandinavia, especially in 
Sweden, where "snus" is essentially the only type of ST product in use. 
Traditional American products undergo fermentation, which imparts 
characteristic flavours but also results in higher concentrations of unwanted 
bacterially mediated by-products (tobacco specific nitrosamines (TSNAs) and 
nitrite). In Sweden, moist snuff is subjected to a heat treatment similar to 
pasteurisation during manufacturing, yielding virtually sterile products containing 
only very low levels of TSNAs (Foulds et al 2003, Rodu & Godshall 2006). 
Modern moist snuff products are sold in pre-portioned pouches similar to 
teabags, but much smaller. Because these products remain stationary in the 
mouth and generate very little juice, they can be used more discreetly. There is 
even a recent trend among manufacturers to offer a wide range of non-tobacco 
flavours (Foulds et al 2003, Rodu & Godshall 2006).
1.5.3 Health implications of tobacco consumption
The UK Medical Research Council (MRC) supported much of the early research 
into the hazards of smoking and in 1957 was the first national institution in the 
world to formally accept the evidence that cigarette smoking is a major cause of 
death (Peto 1994, Doll et al 2004). Several studies in the late 50s, comparing 
the life histories of patients with lung cancer with those of people without the
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disease, showed that the only major difference was that almost all those with 
lung cancer had been smokers (Peto 1994). Major prospective studies of 
smoking and death were established independently in Britain and the US, 
showing strong associations between smoking and death not only from various 
cancers, but also from respiratory disease, particularly chronic bronchitis, and 
vascular disease, especially heart attacks (Peto 1994, Doll et al 2004). In 1962 
the Royal College of Physicians published the first official report specifying the 
dangers of smoking. This was followed two years later by the US Surgeon 
General’s report on tobacco. Tobacco dependence is now recognised as a 
disease by the World Health Organisation (Foulds et al 2004).
Cigarette smoking remains the single largest cause of preventable death and 
disease. Worldwide there are an estimated 1.2 billion smokers, of whom half will 
lose ~8 years of life if they are unable to quit. According to projections by the 
World Bank, 180 million premature deaths caused by tobacco could be avoided 
during the next 50 years by halving the prevalence of cigarette smoking. 
Although smoking prevalence continues to fall slowly towards 20% in some 
Western countries, tobacco use remains high and rising in many developing 
countries and is >50% among men in many Asian countries, such as Japan, 
China and Vietnam (Foulds et al 2004).
In the UK, one in four of the adult population smoke, with much higher levels in 
deprived sections of society (Moxham 2000). Cessation can greatly improve 
health prospects, not only from the smoker’s perspective, but also from the 
perspective of the smoker’s family and society as a whole, as the health 
consequences of smoking extend to healthy non-smokers through passive or 
second-hand smoking (Jorenby 2001). Prolonged cigarette smoking from early 
adult life can triple age specific mortality rates compared to life-long non- 
smokers, however, quitting smoking even late in life can regain several years of 
life expectancy (Doll et al 2004). Due to nicotine's addictive properties it is not 
surprising that although two thirds of smokers want to quit, and each year about 
30-50% try to do so, only 2-5% succeed in remaining abstinent long-term 
(Moxham 2000, Foulds et al 2004).
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1.6 Smoking cessation and harm reduction
The prevention of smoking-related disease requires more than just smoking 
cessation services. Measures, which might contribute to this goal, include 
reduction/banning of advertising and promotion, mass media educational and 
motivational campaigns, restrictions on smoking in public places and at work, 
and increased taxation of tobacco products. Although it might be desirable to 
aim for complete exclusion or prohibition of nicotine use, it may be necessary to 
accept the place of nicotine in society but to use regulation to make nicotine 
products safer (Britton et al 2001).
In countries with comprehensive tobacco health education programmes and 
declining smoking prevalence (e.g. Australia, Canada, US & UK), the use of 
pharmacotherapy for smoking cessation has increased over time and is likely to 
rise even further as the anti-smoking climate continues to intensify and higher 
tobacco taxes and further legislation requiring smoke-free public places come 
into force (Foulds et al 2004). In 1999, the UK government initiated smoking 
cessation clinics within the National Health Service, providing a comprehensive 
treatment strategy for nicotine addiction, including the provision of bupropion 
and all forms of NRT (see section 1.6.1) on prescription and the introduction of 
specialist smoking cessation services to provide behavioural support to people 
wanting to stop smoking (Coleman & West 2001, Hajek et al 2007). In 2002, 
NRT was made available free of charge to most users in an attempt to 
encourage more smokers to attempt to break the grip of tobacco dependence 
(Hajek et al 2007).
The main diagnostic criteria for tobacco dependence are: unsuccessful attempts 
to stop smoking, difficulty controlling tobacco use and previous experience of 
withdrawal symptoms during a period of abstinence. A major part of the difficulty 
in quitting is the experience of intense craving for tobacco, combined with a 
nicotine withdrawal syndrome, which may include symptoms such as increased 
irritability, restlessness, depression, anxiety, insomnia, poor concentration and 
hunger. The extremely unpleasant nature of tobacco withdrawal helps explain 
why many people attempting to stop smoking relapse, often within a matter of 
hours or days, and many smokers have to make multiple quit attempts before 
they eventually succeed in remaining abstinent for good (Jorenby 2001, Hughes 
2003, Foulds et al 2004).
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Another reason why many quit attempts, especially in women, are 
unsuccessful, is that nicotine is an anorexic drug that gives a sense of satiety, 
suppressing appetite and increasing energy expenditure, which means that 
smokers tend to gain weight when they stop smoking (on average ~4 kg). 
Unfortunately, dieting appears to increase the risk of relapse. However, some 
studies suggest that post-cessation exercise not only prevents weight gain but 
also aids cessation, and both NRT and bupropion have been shown to prevent 
weight gain. Therefore one option is to encourage exercise and to use a 
medication initially, postponing any diets (if required) until abstinence is well 
established and medication levels have been reduced (Hughes 2003).
Most of the pharmacological treatments developed so far are aimed at relieving 
craving and withdrawal symptoms, and have primarily been licensed as aids to 
smoking cessation, which restricts their use to a discrete time period (~8-12 
weeks) after ceasing tobacco use. However, increasing attention is being given 
to broadening the indications to include use as an aid to reduced smoking, for 
long-term nicotine maintenance, or as a treatment for nicotine withdrawal during 
temporary abstinence (Foulds et al 2004).
Tobacco harm reduction is a relatively novel approach, aimed at minimising 
tobacco-related risks by substituting smoked tobacco with safer sources of 
nicotine for those smokers who are unable or unwilling to achieve total nicotine 
and tobacco abstinence. Switching to low tar/low nicotine cigarettes does not 
appear to have the desired effect, as smokers tend to compensate to maintain 
nicotine concentrations by inhaling more deeply and frequently. However, 
reduction of exposure to cigarettes and associated toxins (carbon monoxide, 
tar, carcinogens) can be achieved by reducing the amount smoked, switching to 
smokeless tobacco, or using NRT as a substitute for some or all of the nicotine 
obtained from smoking. This kind of approach is likely to benefit heavily 
addicted smokers, as these are often resistant to conventional cessation 
strategies emphasising complete tobacco and/or nicotine abstinence (Schneider 
et al 2001, Hughes 2003, Rodu & Godshall 2006).
Successful reduction of the quantity of cigarettes smoked appears to have a 
beneficial effect on future cessation likelihood, even after controlling for initial 
smoking level and other variables known to impact on smoking cessation (Falba 
et al 2004), and there is evidence to suggest that smokeless tobacco products
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are generally safer than smoking as they are associated with a lower incidence 
of cancers and other diseases, probably due to reduced exposure to toxins 
compared to cigarettes (Rodu & Godshall 2006). Substituting smokeless 
tobacco products or NRT for some cigarettes may reduce daily smoking without 
compensation through altered smoking patterns and with reduced "harm" to the 
individual from carcinogens; however, a relapse to full smoking is likely if 
substitution is stopped. The nicotine inhalator may be especially suited to a 
harm reduction approach because it replaces some of the oral and ritual 
reinforcement aspects associated with smoking, as well as delivering the 
required nicotine (Schneider et al 2001). Although some long-term reduction 
and increased interest in quitting have been demonstrated in studies using NRT 
as a substitute for smoking, doubts remain as to whether patients would persist 
with such treatment in the longer term, and also whether the smoking 
reductions achieved are large enough to result in significant improvements in 
terms of health outcomes (Foulds et al 2004).
There are fears that a harm reduction approach may interfere with the goal of 
smoking cessation by providing smokers with an "excuse" to continue smoking, 
believing they can escape health consequences with "harm reduction". At 
present it is also unclear exactly what constitutes a meaningful reduction in 
harm. Generally speaking, though, indefinite use of NRT or smokeless tobacco 
products is considered a preferable alternative to any smoking, while "harm 
reduction" may be viewed as a "stage of cessation" on the long road to a 
tobacco-free existence (Schneider et al 2001).
1.6.1 Pharmacotherapy options
1.6.1.1 Nicotine replacement therapy (NRT)
The most commonly used medication for smoking cessation is nicotine 
replacement therapy (NRT), which is available in a variety of forms. These 
products deliver nicotine to substitute for that previously derived from tobacco, 
without exposing the user to the carbon monoxide, tar, and carcinogens found 
in cigarette smoke (LeSage et al 2006, Hatsukami et al 2005, Fiore et al 1994, 
Fiore 2000, Ferry et al 2003, Hurt et al 1997, Jorenby 2001). NRT medications 
are generally well tolerated and most side effects are due to the irritant effect of 
nicotine, for example skin irritation from using patches (Coleman & West 2001).
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They primarily improve cessation efforts by reducing the severity of withdrawal 
symptoms and cravings, through the provision of an alternative source of 
nicotine. Most trials have compared one form of NRT with a placebo group or 
other cessation medication. However, in a trial comparing various NRT 
products, Hajek and colleagues did not observe any significant differences in 
terms of efficacy, with continuous validated abstinence rates (at 12 weeks) of 
20%, 21%, 24% and 24% for gum, patch, spray and inhalator groups, 
respectively (Hajek et al 1999).
Given that the central problem is nicotine addiction, nicotine replacement 
therapy (NRT) is a rational and indeed effective therapy, and has been shown 
to double quit rates. This is significant in public health terms because of the 
large number of smokers and relative cost-effectiveness (Moxham 2000, Foulds 
et al 2004). Although current FDA-approved labelling advises against combining 
NRT products, using various forms of NRT simultaneously does appear to 
increase quit rates without increasing side effects (Hughes 2003).
The need for pharmacotherapy for the treatment of nicotine withdrawal during 
temporary abstinence is likely to increase as more public places become 
smoke-free. Some smokers, for whom nicotine withdrawal symptoms may 
present a significant clinical or performance risk, could be required to work in 
such an environment for extended periods of time. While some NRT products 
have been licensed for this indication in countries such as Denmark, most have 
not been evaluated for withdrawal relief over relatively short periods of 
abstinence (Foulds et al 2004).
The recommended duration of NRT use is currently up to 3 months, but some 
patients continue to use the medication for longer. Extended use over a longer 
period of time may be pivotal to a successful quit attempt by more dependent 
smokers who are likely to be affected by protracted withdrawal discomfort and 
may therefore require more prolonged access to withdrawal relief medication 
(Hajek et al 2007).
NRT has been designed to alter reinforcement by changing the pharmacokinetic 
parameters of nicotine intake (see Figure 1.9). Inhalation of nicotine in smoke is 
considered to be the most dependence-producing form of administration 
because of the rapidly established concentrations of nicotine in brain and blood, 
which is a known factor in the abuse liability of drugs. Although there may be
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advantages to rapid nicotine delivery in terms of immediate craving relief, this 
tends to be correlated with the severity of minor side effects, which in turn 
adversely affect compliance. Reducing the speed and extent of drug delivery 
has been central to the development of nicotine treatment for tobacco 
dependence (Schneider et al 2001, Hughes 2003, Foulds et al 2004).
Figure 1.9: Comparison o f venous blood concentrations o f nicotine over time for
0 5 10 15 20 25 30 35 40 45 50 55 60
Plasma nicotine (ng/ml) increases sharply within minutes o f smoking a cigarette and 
then gradually decreases, whereas NRT gum, patch and straw result in a much more 
gradual increase. NRT nasal spray achieves a maximal plasma nicotine concentration 
within minutes, however this maximum is only ~1/5 o f that achieved by cigarette
Transdermal nicotine is available as a 24-hour (7, 14, and 21 mg) or 16-hour 
patch (15 mg). Absorption from patches is very slow, with plasma nicotine 
concentration rising gradually over 6-10 hrs, and levels obtained are also lower 
than after cigarette smoking. The major advantage of the patch is that it 
requires only a once per day dosage and is more socially acceptable and 
discreet than nicotine gum. The major disadvantage is that it cannot be used to
various nicotine delivery systems
25
Cigarette
8 mg straw —X— 1 mg nasal spray
Minutes
smoking, (from Foulds et al 2004)
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alleviate sudden cravings due to the slow rate of absorption (Coleman & West 
2001, Hughes 2003, Tutka et al 2005).
Nicotine gum and lozenges are available in 2 and 4 mg doses (for <25 and >25 
cigarettes/day smokers, respectively), and the provision of mint and citrus 
flavoured gum has significantly improved its taste. Absorption from both 
products is gradual and plasma nicotine concentrations obtained are lower than 
those found after cigarette smoking. Frequent dosing, and correct chewing 
technique in the case of the gum, is required in order to achieve adequate 
plasma nicotine levels. Side effects include jaw ache, nausea, and stomach 
ache (Hughes 2003, Foulds et al 2004, Tutka et al 2005).
A biphasic buccal adhesive nicotine tablet is being developed, which is 
designed to provide a steady supply of nicotine similar to the nicotine patch and 
also a slightly faster delivery of nicotine through the buccal membrane to help 
relieve initial cravings. In addition, it is intended to provide reasonable patient 
compliance by being easy to use, as it is applied to the upper gum and no 
further chewing (like with gum) or puffing (as with the inhalator) is required 
(Foulds et al 2004).
Nicotine nasal spray is available on prescription as a single dose. The major 
advantage of the spray is that it provides higher and more rapid nicotine 
absorption compared to other NRTs, and peak arterial plasma levels are 
reached within ~5 min after administration. However, this is still less than one 
tenth the arterial nicotine levels seen with cigarettes. Its major disadvantage is 
that nasal irritation, lacrimation, rhinitis, coughing, sneezing, and facial flushing 
are experienced by more than 75% of users (Hughes 2003, Tutka et al 2005).
The nicotine inhalator consists of a plug impregnated with nicotine in a plastic 
rod. When warm air is pulled through the rod, nicotine is inhaled and absorbed. 
The inhalator is available as a prescription item in a single dose. Although 
termed an inhalator, it actually delivers nicotine through the mouth, like gum, not 
via the lungs. The major advantage of the inhalator is that it replicates the habit 
feature of smoking, allowing smokers to also wean themselves off the 
secondary reinforcers of smoking (e.g. handling and oral manipulation of the
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cigarette). Its major disadvantage is the need for multiple puffs to obtain 
sufficient nicotine, and the most common side effect is throat irritation 
(Schneider et al 2001, Hughes 2003).
A true pulmonary delivery nicotine inhalator, which could deliver nicotine 
particles to the lungs, allowing it to enter the brain via the arterial system in a 
manner more like a cigarette, is under discussion. This could reduce acute 
cravings and increase cessation efficacy, and potentially replace smoking. 
However, it is difficult to formulate nicotine particles small enough to pass into 
the lungs in a vapour form, which are still tolerable to the senses. Additionally, 
the higher dependence potential may create difficulties in obtaining approval for 
regular use from the regulatory bodies (Foulds et al 2004).
The nicotine “Straw” is a single-use drinking straw containing a loose bead 
formulation of nicotine bitartrate. It has a fluid permeable plug at the bottom, 
facilitating the ingestion of the nicotine with the first sip of a beverage. The 
Straw aims to be more user-friendly than other forms of NRT, and the hand-to- 
mouth motion may also appeal to smokers as it replicates the habit feature of 
cigarette smoking to a certain extent. It appears to be well tolerated, though 
nausea and light-headedness have been reported as side effects. However, 
speed of delivery does not seem to be improved over other forms of NRT (apart 
from the patch), and the straw may also have a higher abuse potential. Perhaps 
the main problem with this product is the risk associated with a potential 
overdose from a single large dose accidentally ingested by a child or non- 
smoker with little tolerance to nicotine (Foulds et al 2004).
Another oral delivery method, which has been tested, is nicotine solution drops. 
Volunteer smokers were provided with the nicotine solution drops to add to 
beverages of their choice to control urges to smoke. Among the beverages 
used to dilute the drops were chocolate milk, water, alcoholic beverages and 
soda. The drops were well tolerated, and the solution provided levels of 
nicotine, which could assist with smoking cessation. The nicotine solution has 
the advantage of varied dosing, which can be more finely adjusted to treat 
different intensities of dependence. The slow absorption rate may reduce the
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dependence potential, but also reduces the solution’s utility as an acute craving 
rescue medication (Foulds et al 2004).
The rate of nicotine metabolism by an individual (see section 1.2) can predict 
cigarette consumption and smoking persistence, but it can also impact on the 
effectiveness of NRT as a treatment for smoking cessation. Smokers with 
higher nicotine metabolite ratios tend to have more severe cravings to smoke 
during the first week of abstinence, which could increase relapse liability. Such 
smokers might therefore best be advised to try a form of NRT other than 
patches (where the nicotine dose is fixed), so that they can titrate their nicotine 
intake according to the severity of cravings, or they could be prescribed a non­
nicotine medication (see below) (Lerman et al 2006). Smokers who have 
previously failed to remain abstinent after a quit attempt with one type of NRT 
could be encouraged to try again using another product, as some patients 
appear to respond better to the steady-state nicotine delivery from patches, 
whereas others have an increased chance of success with more acute dosing 
forms. And finally, smokers who have tried several NRT products 
unsuccessfully might benefit from using bupropion (see below), or a 
combination of the two (Shiftman et al 2004a).
1.6.1.2 Non-nicotine smoking cessation medications
In addition to NRT, the potential of a variety of agents as smoking cessation 
medications has been explored. Pharmacotherapies that do not contain nicotine 
can be roughly divided into several groups: drugs targeting nicotinic receptors 
or enzymes involved in the metabolism of nicotine, compounds acting on 
dopaminergic and/or noradrenergic systems, and a variety of other agents that 
do not fit in either of the above categories.
1.6.1.2.1 Drugs targeting nAChRs or nicotine metabolism
nAChR antagonism
Nicotine acts at a variety of nAChR subtypes in the CNS to produce its 
reinforcing effects. Blocking these receptors with an antagonist should reduce 
the reinforcing effects of cigarette smoking and promote abstinence.
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Mecamvlamine. a non-specific nicotinic antagonist, attenuates nicotine-evoked 
DA release from rat striatum (Puttfarcken et al 2000), effectively blocking the 
rewarding effects of nicotine, and has been shown to decrease nicotine self­
administration and attenuate cue-induced reinstatement of self-administration 
behaviour in rats (Liu et al 2007). The drug, which was originally used as an 
antihypertensive, has also been shown to enhance short-term smoking 
cessation (Rose et al 1998), especially in conjunction with transdermal nicotine 
patches. It does not appear to precipitate withdrawal in smokers (Eissenberg et 
al 1996, Rose et al 2001), unlike in rats, which displayed signs of nicotine 
withdrawal after mecamylamine administration (Malin et al 1992, O'Dell et al 
2007). At the lower doses used for smoking cessation, patients also do not 
experience the severity of side effects, which made the drug unpopular for the 
treatment of hypertension (Foulds et al 2004, Siu & Tyndale 2007).
nAChR partial agonists
Partial agonists at nAChRs are also being explored as potential smoking 
cessation medications. Such compounds are hypothesised to reduce nicotine- 
mediated activation of the dopaminergic system via partial blockade of nAChRs, 
thus lowering the rewarding effects of nicotine. In addition, by acting as weak 
agonists, they could also stimulate dopamine release in the mesolimbic region 
and reduce craving and withdrawal during abstinence (Foulds et al 2004). 
Cytisine (from Cytisus laburnum L.) is a partial agonist at cufo nAChRs (Abin- 
Carriquiry et al 2006), and has been used as a smoking cessation aid in 
Bulgaria since the 1960s (Tutka & Zatonski 2005). The drug is widely used 
throughout central and eastern Europe and appears to be well tolerated without 
many side effects. Cytisine has a mechanism of action similar to nicotine but 
with low toxicity and short-lived effects. In contrast to nicotine, it undergoes 
minimal metabolism and 90-95% appears to be excreted unchanged. Cytisine 
has been observed to reduce craving and withdrawal signs, and abstinence 
rates are similar to those achieved with NRT, although the majority of studies 
were performed in the 1960s and 1970s and showed several design and 
analysis shortcomings, such as a lack of controls, limited follow-up periods, or 
inadequate verification of abstinence criteria (Foulds et al 2004, Tutka & 
Zatonski 2005, Siu & Tyndale 2007).
- 5 3 -
Chapter 1 - Introduction
Varenicline (Chantix (US), Champix; Pfizer pharmaceuticals) is structurally 
similar to cytisine and is also a partial agonist at a4P2 nAChRs (Foulds et al 
2004, Coe et al 2005, Rollema et al 2006, Siu & Tyndale 2007, Smith et al 
2007). In Phase II clinical trials, continuous quit rates were higher with 
varenicline than with bupropion or placebo. Phase III studies have shown mixed 
results in terms of continuous abstinence levels; however they did demonstrate 
that varenicline provided significantly greater benefit compared with placebo, 
when examining the subjective effects associated with smoking. Overall, the 
adverse events observed were relatively mild, most commonly nausea, and the 
percentage of patients who discontinued the studies due to adverse events was 
comparable to bupropion and placebo (Siu & Tyndale 2007).
Varenicline was fast-track approved as a monotherapy by the Food and Drug 
Administration (US) in May 2006. Clinically significant drug-drug interactions 
have not been observed, and in vitro studies did not find any effects on 
cytochrome P450 enzyme activity (Rollema et al 2006). The safety of co­
administration of varenicline with NRT products has not been well established, 
although it is thought that the incidence of adverse events (nausea, headache, 
vomiting, dizziness etc) may be increased with combination therapy (Zierler- 
Brown et al 2006).
Inhibitors of CYP2A6 activity
In terms of smoking behaviour, slower metabolisers (<50% nicotine metabolism 
activity) consume fewer cigarettes per day and are at lower risk of becoming 
dependent smokers. They also smoke for shorter durations and are more likely 
to quit compared with normal metabolisers. Reducing nicotine metabolism 
through CYP2A6 inhibitors such as methoxsalen and tranylcypromine appears 
to increase plasma nicotine levels in abstinent smokers using NRT, as well as 
decreasing the desire to smoke. Use of CYP2A6 inhibitors alone might also 
reduce smoking and increase quitting, and Phase II clinical trials are being 
conducted using this approach (Siu & Tyndale 2007).
NNK, one of the most potent procarcinogens in tobacco smoke, is activated by 
CYP2A6. Epidemiology studies have found that poor metabolisers have a 
significantly lower risk for developing lung cancer, even after adjusting for the 
number of cigarettes smoked. In animal models, administration of methoxsalen
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reduced the formation of NNK-induced lung tumours, and in human smokers it 
appears to inhibit the activation of NNK. Therefore, in addition to enhancing 
smoking cessation, CYP2A6 inhibitors might also provide some harm reduction 
in smokers attempting to quit (Siu & Tyndale 2007).
1.6.1.2.2 Drugs acting on dopaminergic and/or noradrenergic systems
Stimulation of presynaptic nAChRs increases the release of dopamine (DA) and 
noradrenalin (NA), mediating the rewarding effects of nicotine. During 
abstinence, the lack on nAChR stimulation results in reduced neurotransmitter 
release, with abstinent smokers experiencing a variety of unpleasant withdrawal 
symptoms as a result. Cessation medications targeting dopaminergic and/or 
noradrenergic systems aim to restore this balance by increasing extracellular 
neurotransmitter levels, either by stimulating DA / NA receptors directly, or by 
reducing DA / NA uptake via their respective transporters. The most important 
compound in this category, and the only one currently licensed for first-line 
treatment of nicotine addiction, is bupropion.
Bupropion was the first non-nicotine medication to demonstrate efficacy in the 
treatment of tobacco dependence and was originally marketed as an atypical 
antidepressant (Wellbutrin®; GlaxoSmithKline) in the US (approved by the FDA 
in 1984). Since 1997 it has been used for smoking cessation under the trade 
name Zyban (Slemmer et al 2000, Foulds et al 2004, Siu & Tyndale 2007) and 
appears to work equally well in smokers with or without a history of depression 
(Hayford et al 1999, Hughes 2003).
Bupropion reduces DA and NA uptake through inhibition of their respective 
transporters, thus mimicking the action of nicotine by elevating extracellular 
catecholamine levels (LeSage et al 2006, Hatsukami et al 2005, Fiore et al 
1994, Fiore 2000, Ferry et al 2003, Hurt et al 1997). At high concentrations it 
also inhibits the firing of locus coerulus noradrenergic neurons projecting to the 
hippocampus, a region implicated in drug dependence (Cooper et al 1994, 
Slemmer et al 2000, Siu & Tyndale 2007). In addition, bupropion can act as an 
antagonist at nAChRs and appears to block nicotine-induced antinociception, 
motor effects, hypothermia, and convulsive effects in mice (Slemmer et al 
2000), as well as reducing activation of (I3P2, CX4P2, and 07 nAChRs (in oocytes) 
by nicotine with some degree of selectivity (~50 and 12 times more effective in
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blocking a3p2 and a4p2 than a7> respectively). On the other hand, bupropion 
failed to reduce nicotine self-administration, attenuate nicotine discrimination or 
modify aversive effects of nicotine in rats (Shoaib et al 2003), possibly due to its 
dopamine uptake blocking effects. However, it has been shown to attenuate 
somatic signs of nicotine withdrawal in rats (Lake et al 2001), suggesting that it 
may be effective because it attenuates the increases in depression, difficulty 
concentrating, irritability etc. associated with abstinence from nicotine (Shiftman 
et al 2000).
Bupropion roughly doubles long-term abstinence rates compared with placebo 
or no medication, similar to NRT. Sustained one-year abstinence rates average 
-20% , and when combined with NRT quit rates further increase slightly 
(Coleman & West 2001, Hughes 2003). Although bupropion has a relatively 
good side-effect profile for an antidepressant, a significant proportion of patients 
find its mild stimulant effects (jitteriness, insomnia) and other side effects 
(headache, dry mouth) unpleasant. Bupropion also carries a small increased 
risk of seizures, although at doses used for smoking cessation, this only affects 
about 1 in 1000 users (Coleman & West 2001, Hughes 2003, Foulds et al 2004, 
Siu & Tyndale 2007).
Bupropion metabolites are also pharmacologically active (Damaj et al 2004). 
CYP2B6, the main enzyme metabolising bupropion to hydroxybupropion, is 
subject to genetic variability (see section 1.2), which can alter enzyme activity 
and appears to be associated with an increase in craving and higher smoking 
relapse rates. However, alleles decreasing the metabolism of bupropion could 
lead to increased plasma levels of the drug, potentially resulting in a larger 
therapeutic impact (Lee et al 2007).
Several other compounds that act via dopaminergic and/or noradrenergic 
mechanisms are also being investigated as potential smoking cessation 
medications:
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Compound Likely mechanism Characteristics
Reboxetine - selective NA uptake 
inhibitor
- dose-dependently decreases 
nicotine self-administration
Nortriptyline - NA (& 5-HT) reuptake 
blocker
- reduces withdrawal
- cessation rates comparable to 
bupropion
- poor side-effect profile
Clonidine - a2-adrenoceptor agonist - reduces withdrawal
- similar efficacy to bupropion
- poor side-effect profile
1.6.1.2.3 Other therapeutic approaches
Finally, several other compounds have been proposed as possible candidates 
for the treatment of nicotine addiction; however, there is only limited safety and 
efficacy data available for the majority of these drugs.
Compound Likely mechanism Characteristics
Selegiline - irreversible MAO-B 
inhibitor
- reduces craving in combination 
with NRT patch
- possible concern over 
irreversible effects
Naltrexone - opioid receptor 
antagonist
- potential utility with concurrent 
alcohol problem
- side effects (mainly sedation) & 
lack of efficacy
Rimonabant - selective cannabinoid 
(CB1) receptor 
antagonist
- variable efficacy in trials
- reduced weight gain
- well-tolerated
Glucose/Dextrose - reduces carbohydrate 
craving
- variable efficacy in trials
- good safety
- low cost
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1.6.2 Psychosocial treatment programmes
Behavioural therapy focuses on a problem-solving approach, where smokers 
are encouraged to think about when they are likely to smoke and plan 
something to distract themselves when the urge strikes. This approach can 
increase quit rates by a factor of 1.5 -  2.1. Social support, in the form of 
encouragement, caring, and concern, can increase quit rates by a factor of 1.3 
-  1.5. This kind of support can come from both healthcare providers and from 
family, friends, and other community members (Jorenby 2001, Hughes 2003, 
Foulds et al 2004).
Behavioural and supportive therapies were developed initially for use in 
individual or group therapy formats. However, less than 5% of smokers attend 
such therapy. Written materials do not appear to be effective, however, 
delivering behavioural therapy via the telephone has been shown to increase 
quit rates by a factor of 1.2. Although less effective, this format is so much more 
acceptable that it has a bigger impact than group or individual counselling. 
Whether therapy could be delivered via the Internet is being investigated 
(Hughes 2003, Foulds et al 2004).
An important step towards improved tobacco dependence treatment comes 
from combining existing and new pharmacotherapies with effective behavioural 
therapy (Foulds et al 2004). There is evidence that counselling interventions 
can increase the success rates of pharmacological interventions, with part of 
the effect attributable to better compliance with medication use over a longer 
time period. Generally, the more intensive the psychosocial component is, the 
more effective the overall treatment appears to be, and tailoring behavioural 
support materials specifically to the smokers' needs appears to be more 
effective at encouraging abstinence than giving general advice (Shiftman et al 
2001, Coleman & West 2001). Integrated medication and behavioural therapies 
have also been adapted for use in subgroups of smokers, such as those with 
schizophrenia and depression, and more of these tailored behavioural- 
pharmacological interventions could be used in the future (Foulds et al 2004).
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However, even when behavioural therapy is combined with the most effective 
pharmacological treatments available, long-term tobacco abstinence rates are 
typically <30%. There is, therefore, a need to develop new treatments or 
components of treatment, which can be widely used and will increase cessation 
rates among dependent tobacco users who try to give up smoking (Foulds et al
2004).
One approach has been the development of vaccines to combat addiction. 
These are discussed in more detail in section 1.8. However, in order to better 
understand this approach, some basic knowledge of the immune system and 
the mechanisms behind immunotherapy in general is required.
1.7 The immune system
(The following sections are largely based on Parham P. The immune system. 2000. 
Garland Publishing/Elsevier Science Ltd.)
The skin is the human body's first defence against infection. It forms a tough 
impenetrable barrier; however this barrier can be breached by physical damage, 
such as wounds, burns, or surgical procedures, which exposes soft tissues and 
renders them vulnerable to infection.
The epithelia lining the respiratory, gastrointestinal, and urogenital tracts are 
continuous with the skin. On these internal surfaces, the impermeable skin 
gives way to tissues designed for communication with their environment, 
making them more vulnerable to microbial invasion. Such mucosal surfaces are 
continually bathed in the mucus they secrete, containing glycoproteins, 
proteoglycans and enzymes, to protect the epithelial cells from damage and 
help to limit infection.
Skin and mucosa usually provide a well-maintained physical and chemical 
barrier, which prevents most pathogens from gaining access to the cells and 
tissues of the body; however, when that barrier is breached and pathogens gain 
entry to the body's soft tissues, the defences of the immune system are brought 
into play.
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1.7.1 Immune responses
The body has two types of response to invasion by a pathogen -  the innate 
immune response and the adaptive immune response. Although the recognition 
mechanisms of these responses differ, the means used to destroy pathogens 
after their identification are common to both. Innate immune defences are 
present in vertebrates and invertebrates, but only vertebrates appear to have 
evolved adaptive immune responses.
1.7.1.1 Innate immune response
Innate immunity provides an immediate defence against infection, which is 
activated as soon as a pathogen is detected. These defences are always 
available and include physical barriers (skin and other epithelia), microbicidal 
proteins and complement, phagocytic cells (macrophages & neutrophils) and 
the cytokines they produce, as well as natural killer (NK) cells.
The cells and molecules involved in the innate immune response identify 
common classes of pathogen by means of recognition molecules. These 
proteins bind to distinctive biochemical features on the pathogen surface, which 
distinguish microbes from mammals. Soluble recognition molecules, such as 
mannose-binding protein (MBP), bind carbohydrates characteristic of bacterial 
cell surfaces. Once bound to a bacterium, MBP initiates a series of enzymatic 
reactions involving a group of plasma proteins known as complement. Binding 
of complement to a pathogen (opsonisation) flags it as something to be 
destroyed by phagocytes. Complement proteins bound to pathogens engage 
specific complement receptors on the surface of the phagocyte, triggering the 
engulfment and destruction of the complement-coated pathogen. Phagocytes 
also secrete cytokines, chemokines and inflammatory mediators, which are 
involved in activating other cells, inducing a local state of inflammation in the 
infected tissue, and recruiting more phagocytes to the site of infection. 
Inflammation is central to the innate immune response, and NK cells, which 
recognise and kill virus-infected cells, are activated by the various cytokines and 
inflammatory mediators produced by phagocytes.
Innate immunity has no specificity for particular antigens and does not produce 
a specific immunological memory of an infection. The components of the innate
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immune response act in concert to clear an infection or to contain it until the 
adaptive immune response develops.
1.7.1.2 Adaptive immune response
Most infections are highly localised and can be cleared by the innate immune 
response (see Figure 1.10). An adaptive immune response is only mounted if 
the infection spreads to the secondary lymphoid tissues, and its initiation 
depends on the inflammatory cytokines produced by the cells involved in innate 
immune responses. The main aim of adaptive immunity is to improve pathogen 
recognition.

































































The innate immune response consists o f immediate responses (complement activation, 
macrophage phagocytosis) and responses induced by inflammatory cytokines within a 
few hours o f infection. Effects of the adaptive immune response are seen only from 4
days onwards.
After termination o f an infection, effector cells and molecules produced in the primary 
response continue to provide protective immunity but gradually decline. Immunological 
memory provides long-term protection, enabling a rapid and much stronger secondary 
response in the event of re-infection, (adapted from Parham 2000)
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Adaptive immune responses are mediated by lymphocytes (B and T cells), 
which collectively have the ability to recognise a vast array of antigens (see 
Figure 1.10). An individual lymphocyte expresses receptors of a single and 
unique antigen-binding specificity, so any given pathogen stimulates only a 
small subset of lymphocytes, which recognise antigens derived from that 
particular pathogen. This helps to focus the adaptive immune response on the 
specific pathogen in question.
B and T cells recognise different forms of antigen: B cell immunoglobulin 
receptors bind whole molecules and intact pathogens, whereas T cell receptors 
recognise only short peptide antigens bound to major histocompatibility complex 
(MHC) molecules on cell surfaces. In the secondary lymphoid tissues, the 
presentation of pathogen-derived antigens to naive circulating T cells causes 
the pathogen-specific T cells to divide and differentiate into effector T cells. 
Effector Th1 cells and CD8 T cells travel in the lymph and blood to the site of 
infection and initiate the destruction of extracellular pathogens and infected host 
cells by macrophages upon recognition of peptides presented by MHC 
molecules. Effector Th2 cells remain mainly in the lymphoid tissues, where they 
help to activate pathogen-specific B cells, which differentiate into plasma cells 
and produce antibodies.
Figure 1.11: Structure o f antibodies and comparison of isotypes
Antibodies consist o f two light and two heavy chains, containing constant (blue) and 
variable regions (red). The site o f antigen binding is also indicated (circle). 
Heavy chains are longer in IgM and IgE isotypes than in IgG, IgD and IgA, and there 
are also differences between isotypes in terms of the hinge region and disulfide bonds 
linking the chains, and in the distribution of carbohydrate groups (turquoise), (adapted
from Parham 2000)
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Antibodies are Y-shaped molecules consisting of two different polypeptides: two 
identical heavy chains and two identical light chains (see Figure 1.11). Both 
types of polypeptide have a constant region, which is identical in amino-acid 
sequence from one antibody to another, as well as an amino-terminal variable 
region, which differs in amino acid sequence from one antibody to the next. 
These variable regions contain the sites involved in antigen recognition and 
binding, and the differences in amino acid sequence create a vast variety of 
binding sites that are specific for different antigens, and thus for different 
pathogens. The constant regions of antibodies contain binding sites for 
phagocytes and inflammatory cells, as well as for complement proteins. 
Antibodies therefore act as molecular adaptors, bringing together pathogens 
and effector cells molecules designed to destroy the pathogen.
There are several types of constant region, known as isotypes (IgA, IgD, IgE, 
IgG, and IgM), differing in their heavy-chain constant regions (see Figure 1.11), 
which have specialised effector functions:
Cell-surface IgM and IgD form the antigen receptors on circulating B cells, 
which have yet to encounter antigen. IgM is the first antibody isotype secreted 
in an immune response, with antibodies of other isotypes emerging as the 
immune response matures. IgM, IgA and IgG are the main antibodies present in 
blood, lymph and connective tissues. IgG antibodies facilitate the engulfment 
and destruction of pathogens and toxins by phagocytes, which bind to the 
constant regions of the IgG heavy chains with their cell-surface receptors. IgM 
bound to a pathogen's surface typically activates the complement system, 
facilitating uptake and phagocytosis of the pathogen. In response to worms and 
other parasitic infestations, IgE bound to mast cells can trigger a strong 
inflammatory reaction thought to help expel or destroy the parasite. However, in 
developed countries, IgE is most often associated with unwanted allergic 
reactions to innocuous substances.
As well as clearing the infection, a successful primary adaptive immune 
response also establishes a state of long-term protective immunity. A 
subsequent encounter with the same pathogen therefore provokes a faster and 
stronger secondary immune response. This is a result of antibodies and clones 
of long-lived B and T cells formed during the primary response. In a person 
possessing protective immunity, the infection is usually cleared before it
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produces any symptoms. The purpose of immunisation is to produce such a 
state of protective immunity against a particular pathogen or, in the case of this 
thesis, against cotinine.
1.7.2 Immunity
Immunity, or the ability to resist infection, can be achieved by two main 
approaches: active immunisation (vaccination) or passive immunisation.
1.7.2.1 Active immunity I vaccination
Active immunity is acquired naturally as a result of bacterial and viral infections, 
but can also be conferred artificially as a result of vaccination. The response of 
the immune system is identical in both cases. Active immunisation was first 
used against smallpox, after Edward Jenner showed that inoculation with 
cowpox virus offered protection against the related smallpox virus. Jenner 
called his procedure vaccination after vaccinia (lat. vaccus = cow), the name 
given to the mild disease produced by cowpox.
Vaccination involves the deliberate immunisation of healthy people with some 
form of a pathogen or its component antigens. It induces a protective immunity, 
which prevents subsequent infection with the same pathogen from causing 
disease by providing prior exposure to an infectious agent in a form that cannot 
cause disease. This gives the immune system the opportunity to gain the 
experience needed to mount a protective response with little risk to health or 
life. Antigen injected into the host is recognised as foreign by the host’s immune 
system, leading to an immune response and the production of antibodies. After 
an initial vaccination, the immune system keeps a memory of the antigen and is 
able to produce large amounts of antibodies relatively quickly upon re-exposure 
(see Figure 1.12). Booster shots may be used to stimulate and intensify the 
immune response at regular intervals if required (Foulds et al 2004).
Vaccination can occasionally induce an autoimmune reaction, resulting in the 
host's immune system mounting an attack against host cells. Vaccination 
against Ap showed encouraging results in preclinical trials, reversing memory 
deficits in amyloid depositing mice; however, a clinical trial investigating the 
benefits of anti-Ap vaccination in Alzheimer patients had to be cut short due to
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several patients developing meningoencephalitic symptoms after vaccination 
(Morgan 2006).
Figure 1.12: Effects o f vaccination - comparison o f primary and secondary
immune response
Antibody _ 
(|ig  m l-1 serum)
103 -  
102 -  
101 -  
10°  -  
10-1 -  
10 - 2 -  
1 0 -3 -
vaccine A




After immunisation with vaccine A, antibodies against pathogen A are gradually 
produced as the immune response develops (blue). The primary response eventually
subsides over time.
A second immunisation with vaccine A on day 60 results in an immediate secondary 
response within days that is orders of magnitude greater than the primary response. 
Simultaneous administration of vaccine B produces a typical primary response to 
pathogen B (yellow), demonstrating the specificity o f the secondary response for 
vaccine A. Responses are measured as pathogen-specific antibodies present in the 
blood over time, (from Parham 2000)
Many bacterial diseases are a result of the effects of toxic proteins secreted by 
the bacteria (diphtheria, tetanus). Vaccines against these pathogens are made 
by purifying the respective toxin -  diphtheria toxin or tetanus toxin -  and treating 
it with formalin to destroy its toxic activity. These inactivated proteins, known as 
toxoids, retain sufficient antigenic activity to provide protection against the 
disease when used in a vaccine. Less immunogenic molecules can be
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covalently coupled to a carrier protein, which provides antigenic peptides 
required to stimulate an immune response. Such vaccines are known as 
conjugate vaccines. The vaccine examined in this thesis is such a conjugate 
vaccine (see section 1.8,1.9 & Chapter 2), consisting of cotinine molecules, 
which are normally too small to be recognised by the immune system, coupled 
to tetanus toxoid, which acts as a highly immunogenic carrier protein to 
maximise the immune response achieved as a result of immunisation.
1.7.2.2 Passive immunity
An alternative strategy for protection is by passive immunisation. Passive 
immunity is conferred by injecting specific antibodies to provide protection 
against a given pathogen or toxin. It differs from active immunity, both in the 
antibody source and the degree of protection provided. Instead of being made 
by an individuals' own plasma cells, antibodies are obtained from the serum of 
an immune human or animal donor. As a result, the patient's B cells are not 
challenged by antigens, immunological memory does not occur, and the 
protection provided by the "borrowed" antibodies ends when they naturally 
degrade in the body. Passive immunity occurs naturally when a mother's 
antibodies cross the placenta and enter the foetal circulation. For several 
months after birth, the baby is protected from all the antigens to which the 
mother has previously been exposed (Marieb 1998). Passive immunity can also 
be artificially conferred when immune sera are used to treat poisonous snake 
bites (antivenom), botulism, rabies, and tetanus (antitoxin). These rapidly fatal 
diseases would kill a person before active immunity could be established, 
however the donated antibodies provide the immediate protection required, 
although their effect is relatively short-lived (2-3 weeks).
Immune sera contain a mixture of antibodies of varying specificity and affinity. 
Monoclonal antibodies arise from a single clone of antibody-producing cells and 
thus all have identical antigen-binding sites and are of the same isotype. They 
can be produced on a large scale from hybridoma cell lines, providing large 
quantities of identical antibodies required for diagnostic and therapeutic 
applications. Mouse monoclonal antibodies of a desired specificity can be made 
quite easily but are limited in their therapeutic use because the human immune 
system recognises them as foreign and mounts an immune response to
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eliminate them. By use of genetic engineering techniques, highly specific 
antigen recognition sites from the variable region of mouse antibodies can be 
combined with the constant regions of human antibodies, conferring the antigen 
specificity of the mouse antibody on the human antibody. This results in 
chimeric or humanised antibodies, depending on the relative contribution of the 
two species. Humanised antibodies are sometimes used in the treatment of 
cancer, as they can be raised against epitopes expressed only by the 
cancerous cells, which allows them to bind to these cells and direct the immune 
response against them.
1.7.3 Use of adjuvants
The term "adjuvant" is derived from the Latin (adjuvare = to help), and is used to 
refer to any material that helps to activate and direct the innate and adaptive 
immune responses, leading to an early, high and long-lasting immune response 
to an otherwise poorly immunogenic antigen. Adjuvants have been used for 
more than 80 years to make immunisations more efficient, thus saving on 
vaccine production costs (Gupta & Siber 1995, Schijns 2003).
Adjuvants form a highly heterogeneous group of compounds, both chemically 
and with regard to their mechanism of action. They facilitate the delivery of 
antigen to the secondary lymphoid organs for a sufficient period of time to 
evoke an immune response, and provide either a non-self, microbial signal, or a 
host-derived danger signal from stressed cells, both of which are essential for 
induction of co-stimulatory molecules. Several adjuvants are known to evoke 
tissue damage and associated cell stress, which may further enhance activation 
of the immune system. Adjuvant preparations can sometimes contain several 
substances with different mechanisms of action, such as Freund's adjuvant, 
which consists of an emulsion of mineral oil and killed mycobacteria, and 
contains elements of the bacterial cell-wall skeleton and other antigenic 
peptides. However, this potent adjuvant is only used in preclinical studies, due 
to its side-effect profile (Gupta & Siber 1995, Schijns 2003).
A number of problems are encountered in the development and use of 
adjuvants for human vaccines, the biggest of which, particularly in routine 
childhood vaccines, is the toxicity and adverse side effects of most adjuvant 
formulations. The choice of adjuvants for human vaccination tends to reflect a
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compromise between the need for efficacy and an acceptably low level of side 
effects. The most common adjuvants used in humans are aluminium hydroxide 
(alum) and aluminium phosphate, although calcium phosphate and oil 
emulsions are also used occasionally. Much progress has been made on 
development, isolation and chemical synthesis of alternative adjuvants such as 
derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS21, 
MF-59 and immunostimulating complexes (ISCOMS) (Gupta & Siber 1995), and 
GSK have developed several proprietary adjuvants for possible application in 
humans that are used in the experiments described in this thesis.
1.7.4 Effects of nicotine on the immune system
Nicotine is thought to contribute to the immunosuppressive effects of chronic 
smoking by inducing a state of anergy in lymphocytes, resulting in impaired 
responses of lymphocytes to antigen-induced signalling (Geng et al 1995 & 
1996).
In animal studies, nicotine, obtained by self-administration or from nicotine 
patches, as well as chronic exposure to cigarette smoke, has been shown to 
suppress antibody- and cell-mediated immune responses, as well as 
decreasing inflammatory responses and expression of proinflammatory 
cytokines (Kalra et al 2000, 2002, 2004). Treatment of rats with nicotine, but not 
cotinine, for 3-4 weeks inhibited both T cell-dependent and -independent 
immune responses (Geng et al 1995). Adolescent (postnatal (PN) day 30-37) 
chronic nicotine exposure elicited lasting deficiencies in T cell mitogenesis in 
rats, which were dose-dependent (nearly 50% reduction at the high dose).
These effects disappeared initially after termination of nicotine treatment, but re- 
emerged in young adulthood (PN65). Administration of the same total dose of 
nicotine as twice-daily injections did not result in such deficits in T cell function 
(Navarro et al 2003). In mice, a7 and a4p2 nAChR subtypes appear to be 
expressed on B lymphocytes and/or macrophages, and deficiency of these 
subunits has been observed to affect immune responses, with macrophages 
from a7-deficient mice producing elevated levels of inflammatory cytokines 
(Wang et al 2003, Skok et al 2005).
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Tobacco smoking appears to suppress the immune system in humans, and 
several studies have shown that tobacco smokers have lower levels of IgG and 
IgA, and higher levels of IgE than non-smokers, which may contribute to the 
propensity for respiratory infections observed in smokers. lgG2 levels are most 
affected with a reduction of mean levels by -40%  compared with non-smokers, 
which may help to explain why smoking is a risk factor for invasive 
pneumococcal infections, since antibodies produced in response to infection by 
such bacteria belong predominantly to the lgG2 subclass (Gyllen et al 2004, 
Kalra et al 2004). Interestingly, smokers have a lower incidence of some 
diseases (ulcerative colitis, endometriosis and Parkinson's disease among 
others), many of which are inflammatory in nature or have an inflammatory 
component (Kalra et al 2004).
The mechanisms by which smoking affects serum antibody levels is unclear, 
although there is evidence for a dose-response relationship (lower levels of IgG 
with increased smoking) and the effect appears to be reversible after smoking 
cessation. The cigarette smoke component responsible for this effect has not 
yet been identified, but animal and in vitro studies have implicated nicotine as a 
major factor (see above). Both nicotine and cotinine (at 100-fold higher 
concentrations than nicotine) have been shown to modulate immunoglobulin 
synthesis by human lymphocytes in vitro (Fischer & Konig 1994). However, 
smokeless tobacco or nicotine replacement therapy does not appear to 
significantly affect immunoglobulin levels in vivo (Gyllen et al 2004).
1.8 Development of vaccines to combat addiction
Drugs of abuse are a major public health problem, with millions of users 
worldwide taking some form of addictive substance (cocaine, heroin, nicotine 
etc). Pharmacotherapy approaches for the treatment of drug abuse do exist, 
however most have only a very low success rate, with the vast majority of 
patients undergoing treatment relapsing into drug taking (Anton & Leff 2006, 
LeSage et al 2006).
Drugs of abuse exert their reinforcing effects by binding to receptors in the 
CNS, causing neurotransmitter release and activation of the mesolimbic reward 
pathway (see section 1.4). Repeated stimulation of the reward pathway leads to
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neurobiological adaptations and the development of dependence, with drug 
users experiencing withdrawal symptoms upon abstinence from the drug. The 
receptors to which these drugs bind are found throughout the brain, which 
means that pharmacological treatments, such as receptor agonists or 
antagonists acting at these receptors, almost invariably produce undesirable 
side effects (Nutt & Lingford-Hughes 2004, Anton & Leff 2006).
Blocking the actions of an addictive drug at its receptor should prevent or at 
least reduce reinforcement of drug-taking behaviour. However, such 
antagonists can also prevent/reduce the binding of endogenous substances at 
their receptors (e.g. naltrexone & naloxone block the binding of enkephalins & 
endorphins at opioid receptors), causing negative emotional effects in patients 
(Anton & Leff 2006). The use of agonists mimicking the actions of a drug of 
abuse should help to alleviate withdrawal symptoms experienced during 
abstinence, however they can lead to the development of tolerance to the 
treatment agent and withdrawal from it when the treatment is terminated, such 
as with methadone treatment for heroin addiction (Anton & Leff 2006).
As current treatment options for drug abuse are somewhat inadequate, a new 
avenue is being explored -  immunotherapy. Immunotherapies for drug abuse 
are being developed primarily as therapeutic vaccines, designed for treating 
patients who already have a disease (i.e. addiction), as opposed to a 
prophylactic vaccine used to prevent the development of addiction before an 
individual has ever been exposed to the drug (Kosten et al 2005).
Drugs of abuse are small molecules (molecular weight <1000 Da), which readily 
cross the blood-brain barrier, while larger molecules such as antibodies 
(molecular weight ~150 kDa) normally cannot. Thus, any drug bound with high 
affinity to an antibody cannot cross the blood-brain barrier and therefore cannot 
enter the brain (Kosten et al 2005). After vaccination, antibodies bind a 
significant proportion of the drug dose and prevent it from entering the brain. 
This leads to a reduction in the effects of the drug, even at doses exceeding the 
apparent binding capacity of the antibodies. Provided the reduction of drug 
effect is sufficiently large, it could lead to a decrease in drug use or help to 
reverse a drug overdose (Kosten et al 2005).
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Targeting the drug molecules rather than the receptors they bind to should 
reduce the likelihood of side effects on normal neurotransmission, especially as 
the antibodies remain primarily in the circulatory system. Preventing the drug 
from binding to its target receptors could also help to weaken the cycle of drug 
taking by reducing the psychostimulant effects and abolishing the drug's 
reinforcing actions. However, the specificity of the antibodies raised by 
vaccination against a given drug also means that they are ineffective if an addict 
switches to another drug of abuse (Carrera et al 1995, Nutt & Lingford-Hughes 
2004, Kosten et al 2005).
As a general rule, immune responses are not generated against molecules of 
less than -10 kDa, which is substantially larger than any drug of abuse. In order 
to make a vaccine against such a small molecule, the drug must be covalently 
linked to a very immunogenic protein (see Figure 1.13), which is usually done 
by synthesising a derivative of the drug (hapten), containing a linker arm with a 
reactive chemical species. Frequently, proteins derived from bacterial toxins are 
used in the production of these conjugate vaccines, as they elicit a strong 
immune response (Foulds et al 2004). The precise molecular orientation and 
spacing of these drug haptens on the protein surface are critical factors for an 
optimal immune response (Kosten et al 2005).
Figure 1.13: General structure o f conjugate vaccine
Several hapten molecules (turquoise) 
are attached to a highly immunogenic 
carrier protein (purple) by means of 
linker arms (only 3 shown for clarity).
Immunotherapy has two immediate clinical applications in drug abuse 
treatment: to combat drug overdose and to reduce relapse to drug use in 
addicted patients. The specificity of antibodies, their lack of addiction liability, 
minimal side effects and long-lasting protection against drug use offer major 
benefits over conventional small molecule agonists and antagonists. It is 
conceivable that immunotherapies might also be used in combination with other 
anti-addiction medications and could enhance behavioural therapies (Kosten et 
al 2005).
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Active immunisation with drug-protein conjugate vaccines has been tested for 
cocaine, heroin, methamphetamine and nicotine in animals, and cocaine and 
nicotine vaccines are currently in clinical trials. In addition, the possibility of 
passive immunisation with high affinity monoclonal antibodies has been 
examined for cocaine, methamphetamine, nicotine and phencyclidine (PCP) in 
preclinical animal models. Current immunotherapies already show some 
efficacy, but improved antigen design and antibody engineering raise the hope 
for highly specific and rapidly developed treatments for both existing and future 
addictions (Kosten et al 2005).
1.8.1 “Anti-addiction” vaccines
Opiates
In 1974 Bonese et al provided the first proof of concept for the use of active 
vaccination in the treatment of drug dependence with a vaccine against heroin. 
However, this approach was abandoned due to concerns that individuals could 
easily switch to other opiates and thereby avoid the specificity of the anti-heroin 
antibodies. More recently, a vaccine against morphine/heroin has been shown, 
in rats, to result in high titres of antibodies showing equivalent specificity for 
both morphine and heroin. Structurally dissimilar opiate medications, such as 
buprenorphine, methadone and naltrexone, were not recognised, demonstrating 
the specificity of the antibodies. No major detrimental effects were detected, 
although there were some minor local injection reactions. Antibodies against 
heroin also appear to block its reinforcing effects in rodents, with rats failing to 
reacquire heroin-taking behaviour after immunisation against heroin, whereas 
self-administration was fully re-established in controls (Kosten et al 2005, Anton 
& Leff 2006).
Phencyclidine
Owens & Mayersohn (1986) conducted the first studies to demonstrate proof of 
concept for using passive immunisation in the treatment of drug abuse, showing 
that purified anti-phencyclidine (PCP) polyclonal antibodies could substantially 
alter the pharmacokinetics of PCP in dogs. This lead to the development of 
haptens, which could stimulate antibodies capable of recognising a whole class 
of PCP-like drugs, rather than exclusively PCP (Owens et al 1988). Thus, if the
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patient switched from one PCP-like designer drug to another, the therapy would 
still be effective (Kosten et al 2005). In rats, a single dose of anti-PCP mAb 
reduced the locomotor effects and brain concentrations of PCP in overdose 
studies (Owens & Mayersohn 1986, Valentine & Owens 1996, Valentine et al 
1996, Proksch et al 2000, Hardin et al 2002, Laurenzana et al 2003a). This 
antibody profoundly reduced a wide range of pharmacological effects and 
significantly improved PCP-induced adverse health effects for up to 1 month 
after a single dose, even in the presence of occasionally lethal doses of PCP 
(Proksch et al 2000a, Hardin et al 2002, Laurenzana et al 2003a). The long 
functional half-life of the antibody suggests an important clinical role for passive 
immunisation in the treatment of PCP dependence, acute overdose, and longer- 
term excessive drug use.
Methamphetamine
Production of antibodies after immunisation with an anti-methamphetamine 
vaccine has been demonstrated in rats, but methamphetamine-induced 
locomotor effects were not attenuated as a result (Bymes-Blake et al 2001). 
However, the same studies showed that administration of continuous high 
doses of methamphetamine during the entire course of immunisation had no 
effect on antibody production. This is important as it means that drug use during 
patient immunisation is unlikely to affect the production of antibodies. Passive 
immunisation with monoclonal antibodies against methamphetamine both 
reduced the dose of methamphetamine in the brain and slowed its rate of entry 
(Laurenzana et al 2003a&b, Byrnes-Blake et al 2003). These antibodies 
significantly attenuated locomotor activity in rats at low and moderate doses of 
methamphetamine, but not at doses, which significantly exceeded the antibody 
binding capacity. Self-administration of a low dose of methamphetamine was 
also completely blocked by the antibodies; however at higher unit doses of 
methamphetamine, rates of responding were increased, suggesting that the 
protective effects of the mAbs may be partially surmountable (Laurenzana et al 
2003a&b, Byrnes-Blake et al 2003, Kosten & Owens 2005).
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Cocaine
In rats, cocaine-specific antibodies from active or passive immunisation reduced 
early cocaine distribution to the brain and heart (by 25-80%) and decreased 
cocaine's locomotor, discriminative stimulus, and reinforcing behavioural 
effects. They also reduced the reinstatement of cocaine-seeking behaviour in a 
rat model of human relapse (Carrera et al 1995, 2000 & 2001, Fox et al 1996, 
Johnson & Ettinger 2000, Kantak et a! 2000 & 2001). Phase I & II clinical trials 
of the Xenova anti-cocaine vaccine (TA-CD) have shown that it is safe and can 
produce antibodies with high specificity for cocaine (Kosten & Owens 2005). In 
phase II trials, cocaine dependent outpatients in the high-dose vaccination 
group developed higher antibody levels and used significantly less cocaine than 
those in the lower dose group (Martell et al 2005).
1.8.2 Anti-nicotine vaccines
In view of the low success rates achieved with current treatment options (see 
section 1.6.1) there is a clear need for improved pharmacotherapies for nicotine 
addiction. nAChRs are located throughout the brain and play an important role 
in "normal'' neurotransmission within the CNS (see sections 1.3 & 1.4). 
Targeting these receptors with agonists or antagonists, in an attempt to treat 
nicotine addiction, could interfere with normal CNS processes and result in a 
range of unwanted side effects. However, if the nicotine molecules could be 
prevented from stimulating the receptors in the first place, the reinforcing effects 
of nicotine might be attenuated.
Vaccination against nicotine results in the production of nicotine-specific 
antibodies, which circulate in the bloodstream. When nicotine enters the 
circulation upon smoking a cigarette, it is bound by the antibodies and retained 
in the serum, preventing it from entering the brain. This should result in a 
reduction in smoking-related reward and decrease the drive for continued 
tobacco consumption (Foulds et al 2004).
Currently there are at least 5 companies involved in the development of nicotine 
vaccines (Cytos Biotechnology, Nabi Biopharmaceuticals, Xenova Group Ltd., 
Chilka Ltd., and Independent Pharmaceutica AB) (Siu et al 2007). These 
vaccines differ mainly in their ligand chemistry, and have been explored by
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various groups at the preclinical level, whilst several have also been examined 
in clinical trials (Hatsukami et al 2005, Maurer et al 2005).
All the vaccines have been shown to elicit an immune response, producing 
antibodies with high specificity for nicotine and low cross-reactivity with related 
compounds such as nicotine metabolites (typically <5%) (Maurer et al 2005, 
Hieda et al 1997, de Villiers et al 2002, Cerny et al 2002). In rats immunised 
against nicotine, 80-99% of nicotine in serum was bound to nicotine-specific 
antibodies, compared to less than 10% binding of nicotine to serum proteins in 
control rats (Hieda et al 1997, Pentel et al 2000, Keyler et al 2005, Satoskar et 
al 2003). As a consequence, brain nicotine levels were significantly reduced in 
vaccinated rats compared to controls (Cerny et al 2002, de Villiers et al 2004). 
Immunisation against nicotine has also been shown to attenuate nicotine- 
induced locomotor activity (Pentel et al 2000), reduce the incidence of seizures 
following a large dose of nicotine (Tuncok et al 2001), and prevent alleviation of 
nicotine abstinence syndrome through nicotine administration in rats (Malin et al 
2001).
Initial clinical findings appear to show similar trends of nicotine vaccines 
towards efficacy in terms of safety and immunogenicity, and a greater 
percentage of patients were able to achieve abstinence from smoking in the 
highest dose vaccine group compared with the control group (Hatsukami et al
2005).
Anti-nicotine vaccines could be used for various indications: they may decrease 
the rewarding effects of nicotine in present smokers, reducing dependence and 
leading to higher likelihood of success in a cessation attempt. Former smokers 
could also benefit in that a “slip” during abstinence would have less of a 
rewarding effect and would therefore be less likely to lead to a complete 
relapse. Also, if administered to never smokers, the vaccine has the potential to 
curb the rewarding effects of nicotine on the brain of “experimenting smokers” 
(including young people), thus reducing the likelihood of the development of 
dependence. Finally, anti-nicotine immunotherapy has potential benefits for 
both pregnant smokers and the developing foetus, as nicotine (along with 
various other components of tobacco smoke) has been implicated as a 
neurotoxin in developing foetal tissues. A reduction in nicotine exposure to the 
brains of foetal rats, mediated by binding of nicotine to antibodies in the
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maternal bloodstream, has been demonstrated. And with reductions in 
nicotine’s reward-producing effects, vaccinated pregnant smokers could be 
more likely to attempt to quit and remain abstinent (Foulds et al 2004).
1.9 An anti-cotinine vaccine to aid smoking cessation
There are several potential problems associated with the use of anti-nicotine 
vaccines as a treatment for smoking cessation. Firstly, smokers who are finding 
it a challenge to remain abstinent might attempt to overcome the effects of the 
anti-nicotine antibodies by increasing their nicotine intake. This could potentially 
result in toxic effects associated with the consumption of a large dose of 
nicotine and would also lead to an increase in the exposure to various other 
toxins / carcinogens present in tobacco smoke (Stolerman et al 1991, Foulds et 
al 2004).
Blocking nicotine from acting on nAChRs by means of specific antibodies would 
also render all forms of NRT-based smoking cessation medication ineffective. 
These products are designed to relieve the withdrawal symptoms experienced 
by smokers during abstinence by providing an alternative source of nicotine 
without the additional toxins contained in tobacco smoke, and deliver the drug 
at a lower dose and slower rate than achieved through smoking, limiting the 
reinforcing effects and associated abuse potential in the process (see sections
1.5.1 & 1.6.1.1).
Cotinine has been shown to antagonise the actions of nicotine in vitro (see 
section 1.2.2.1). In clinical studies, cotinine has been reported to enhance 
withdrawal symptoms experienced by abstinent smokers, indicating that it may 
be antagonising the effects of nicotine on a functional level (Keenan et al 1994). 
In abstinent smokers treated with a nicotine or control patch, plus oral cotinine 
(80 mg) or placebo for 14 days, the group receiving cotinine reported no 
difference from placebo with respect to withdrawal symptoms, whereas a 
decrease in withdrawal symptoms was observed in the group receiving NRT. 
However, in combination with NRT cotinine appeared to antagonise the 
alleviating effects of nicotine (Hatsukami et al 1998).
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Preclinical studies have suggested that high brain concentrations of cotinine 
(~0.3 |jM) may be achieved with chronic smoking since cotinine does not 
appear to be metabolised in the brain and shows slower outflow to the periphery 
relative to nicotine (Crooks et al 1997, Crooks & Dwoskin 1997, Ghosheh et al 
1999). As a result, cotinine may limit the efficacy of nicotine replacement 
therapy (NRT) in promoting abstinence from smoking, likely through 
desensitisation of nAChRs. Therefore, if the effects of cotinine could be 
minimised or blocked, NRT might be more efficacious.
Immunisation with an anti-cotinine conjugate vaccine should elicit the 
production of cotinine-specific antibodies, which would bind any cotinine 
entering the bloodstream as a result of nicotine intake and subsequent 
metabolism, preventing it from passing into the brain. This should help to 
reduce the antagonism of nicotine's effects by cotinine.
Such a vaccine would be expected to increase the efficacy of NRT by 
enhancing the ability of nicotine to alleviate the withdrawal symptoms 
associated with nicotine abstinence, which are a major cause of relapse in 
abstinent smokers. Reduction of the antagonism of nicotine's actions by cotinine 
should also help to make the reduce-to-quit approach to smoking cessation a 
more viable option, as fewer cigarettes would need to be smoked to achieve the 
desired subjective effects.
1.9.1 Previous work on the anti-cotinine vaccine
This thesis continues the work begun as a previous PhD project (Pashmi 2004). 
With the help of collaborators, Pashmi synthesised several structural derivatives 
of cotinine for evaluation as potential anti-cotinine vaccines and established a 
basic immunisation regime.
In an initial trial, each of these derivatives was conjugated to bovine serum 
albumin (BSA), and rats were vaccinated with these conjugate vaccines. The 
levels of anti-cotinine antibodies raised in response to vaccination were 
examined. Of the cotinine derivatives tested, fra/?s-4-thio-cotinine (CotSH) was 
found to produce the best immune response, and was therefore taken forward 
for further evaluation.
To maximise the immune response, and consequently the production of anti- 
cotinine antibodies, the carrier protein was switched from BSA to the more
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immunogenic tetanus toxoid, giving TT-CotSH. This was found to further 
improve the antibody titres raised in response to immunisation.
The anti-cotinine antibodies obtained as part of these experiments were also 
evaluated in terms of their specificity for cotinine, compared to nicotine and a 
variety of other nicotine and cotinine metabolites. They were shown to be 
specific for cotinine with only very little cross-reactivity for norcotinine, a 
relatively minor metabolite of cotinine with no known pharmacological action 
(see section 1.2.2.3).
1.9.2 Aims of this PhD and layout of thesis
The aims of this PhD project were as follows:
- to confirm the hypothesis that cotinine could be acting as an antagonist 
to nicotine, using a model of striatal dopamine release
- to further characterise the immune response to anti-cotinine vaccination 
by measuring anti-cotinine and anti-tetanus toxoid antibody levels, as 
well as seeking to confirm the specificity of anti-cotinine antibodies
- to study whether immunisation against cotinine impacts on nicotine and 
cotinine distribution in the body
- to examine the effect of anti-cotinine vaccination on the upregulation of 
nicotine binding sites observed after prolonged nicotine exposure
- and finally, to use a wide range of behavioural measures of nicotine 
dependence to assess the effects of vaccination against cotinine in vivo.
The experiments described in this thesis were conducted as a series of 5 trials, 
with each consisting of an immunisation period (usually ~3 months) followed by 
behavioural experiments on the immunised animals and subsequent in vitro 
work on tissues and blood samples taken at the end of each trial. In the interest 
of clarity, this thesis has been subdivided into 3 results chapters based on 
experiments (rather than by trial), in order to facilitate the comparison of results 
from similar experiments between trials:
- In Chapter 2 the rationale for targeting cotinine in smoking cessation is 
examined, and the immune responses to anti-cotinine immunisation for each 
trial are summarised and compared.
- 7 8 -
Chapter 1 - Introduction
- In Chapter 3 the impact of anti-cotinine immunisation on in vivo nicotine 
administration, assessed by in vitro measurements, are described. These 
experiments were carried out on tissue and blood samples taken from 
immunised and control rats at the end of each trial.
- Chapter 4 examines the effects of immunisation against cotinine on various 
behavioural measures relating to nicotine dependence.
- In the final discussion (Chapter 5), the results from each chapter are put into 
context, allowing overall conclusions to be drawn, and future avenues for 
research are indicated.





Chapter 2 -  Target Validation & Immune Response
Chapter 2 
Target validation & immune response
2.1 Introduction
Preclinical studies have shown that cotinine possesses weak activity at nicotinic 
acetylcholine receptors (nAChRs) and appears to antagonise the actions of 
nicotine both in vitro and in vivo (see Chapter 1) in a manner consistent with 
nAChR desensitisation. In clinical studies, cotinine has been reported to 
enhance withdrawal symptoms experienced by abstinent smokers (see Chapter 
1), again indicating that it may be antagonising the effects of nicotine at a 
functional level. As high levels of cotinine are sustained in smokers, these data 
suggest that it might diminish the central effects of nicotine by desensitising 
nAChR.
Immunisation with an anti-cotinine conjugate vaccine should elicit the 
production of cotinine-specific antibodies, which would bind any cotinine 
entering the bloodstream as a result of nicotine intake and subsequent 
metabolism, and prevent it from entering the brain. This would reduce 
antagonism by cotinine in the CNS. Such a vaccine would enhance the efficacy 
of NRT with respect to alleviating withdrawal symptoms, which are a major 
cause of relapse in abstinent smokers.
In this chapter we studied the ability of cotinine to evoke the release of 
dopamine (DA) from the striatum of naive rats in vitro, as well as comparing it 
with nicotine, to examine whether it might act as a (weak) agonist at nAChRs. 
The immune response induced by repeated vaccination of rats with the anti- 
cotinine conjugate vaccine was then characterised.
-81  -
Chapter 2 -  Target Validation & Immune Response
2.2 Dopamine release in naive rats
2.2.1 Introduction
The striatal and mesolimbic dopaminergic systems are implicated in the control 
of many important functions such as movement and posture, reward 
mechanisms, reinforcement, and motivational behaviours (Corrigall et al 1992 & 
1994). Nicotine, like many drugs of abuse, activates the mesolimbic dopamine 
(DA) system (Nestler et al 2001, Mansvelder & McGehee 2002). Stimulation of 
nAChRs in the ventral tegmental area (VTA) leads to increased firing of DA 
neurons projecting from the VTA to the nucleus accumbens (NAcc) and other 
regions of the limbic forebrain, resulting in an increase of DA release in these 
areas (Benwell et al 1993, Nisell et al 1994, Stolerman & Shoaib 1991, Nestler 
2001, Dani & Heinemann 1996, Picciotto et al 1998, Dani & De Biasi 2001).
This implies that nicotine exerts its effects on DA overflow by influencing 
impulse flow to the terminal field. Indeed, systemic injections of nicotine have 
been shown to increase burst firing of DA-secreting neurones in the VTA, and 
this effect is enhanced in animals pre-treated with nicotine (Nisell et al 1996). 
Several groups have shown that repeated administration of nicotine results in 
sensitisation of the mesolimbic DA system to the effects of the drug, a 
phenomenon that may be necessary for the development of drug dependence 
(Pierce & Kalivas 1997, Robinson & Berridge 2000, Ferrari et al 2001). 
Accordingly, repeated nicotine administration results in sensitisation of 
locomotor stimulation and DA release in the NAcc (Ksir et al 1985, Benwell & 
Balfour 1992, Shim et al 2001) induced by a nicotine challenge. On the other 
hand, continuous infusion of nicotine has been observed to desensitise 
nAChRs, which mediate the DA release from neurons originating in the VTA 
(Pidoplichko et al 1997), and the DA overflow evoked by nicotine is substantially 
attenuated by the constant infusion of nicotine (Benwell et al 1995, Benwell & 
Balfour 1997)
Evidence that NAcc DA levels are important in reward has also come from VTA 
lesion studies and microperfusion of the NAcc with DA receptor antagonists, 
both of which lead to reduced self-administration of many addictive drugs, 
including nicotine, as well as a reduction in locomotor activity and diminished 
nicotinic binding in terminal areas (Stolerman & Shoaib 1991, Corrigall et al
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1992 & 1994, Vezina et al 1994, Museo & Wise 1995, Louis & Clarke 1998, 
Balfour et al 2000).
DA release can be measured using a variety of techniques:
Microdialysis (and voltammetry) techniques enable the experimenter to examine 
DA overflow in awake, behaving animals, and can provide an opportunity to 
examine behavioural measures such as locomotor activity at the same time.
Due to the high sensitivity and the small size of the probes used, it is possible to 
take measurements from distinct brain structures, providing good spatial 
resolution (Wonnacott et al 2002). The disadvantages are that this is a relatively 
invasive and technically demanding technique: a probe has to be inserted into 
the brain of each subject with great accuracy in order to ensure that release is 
being measured in the desired brain structure, making the procedure quite time- 
and work-intensive, and resulting in a low throughput. Microdialysis also 
measures DA overflow, rather than synaptic DA, and provides relatively low 
temporal resolution (although in vivo voltammetry can offer somewhat higher 
temporal resolution (Nisell et al 1997)). Drug concentrations reaching the 
nAChRs can only be estimated as they are frequently administered 
systemically, however local delivery of antagonists via the dialysis probe can 
help to define the site of action (Nisell et al 1994).
Continuous superfusion of brain slices or synaptosomes (Rapier et al 1990, 
Grady et al 1992) is a medium throughput assay, which allows the 
measurement of DA release over a period of time and in response to stimulation 
by agonists. However it is an in vitro technique, so behaviour and activity cannot 
be monitored in parallel. Superfusion of synaptosomes (Rapier etal 1990,
Kaiser & Wonnacott 1998, Sharpies et al 2000, Mogg et al 2004) only permits 
the experimenter to examine presynaptic effects, whereas brain slices (Dwoskin 
et al 1995, Sacaan et al 1995, Marshall et al 1996, Sershen et al 1997) maintain 
a reasonable level of local connectivity between individual neurons within a 
slice, making the preparation more representative of the intact brain. This allows 
some interaction to take place between the neurons within the terminal field, 
though not between the terminal field and the VTA. However, this can also 
complicate the interpretation of results due to indirect effects on transmitter 
release via synaptic connections between neurons within a slice.
- 8 3 -
Chapter 2 -  Target Validation & Immune Response
Finally, the 96-well plate assay we chose to use in this thesis (Anderson et al 
2000, Puttfarcken et al 2000, Jacobs et al 2002, Abin-Carriquiry et al 2006,
Barik & Wonnacott 2006) is a simple and relatively high throughput technique, 
which maintains some limited connectivity within the brain minces used, 
compared to synaptosomes, and enables the measurement of DA release in 
response to agonist stimulation at a given time point compared to baseline 
release in response to buffer. It is less laborious than the commonly used 
superfusion method and permits the experimenter to simultaneously examine 
the effects of several compounds on transmitter release over a range of 
concentrations. Using this technique, several groups have characterised [3H]DA 
and [3H]NA release from a number of brain regions in the rat in response to 
nicotine and a variety of other nAChR agonists, as well as antagonists 
(Puttfarcken et al 2000, Anderson et al 2000, Mogg et al 2004, Cao et al 2005, 
Barik & Wonnacott 2006), while Abin-Carriquiry and colleagues have used the 
assay to compare the ability of several cytisine analogues to evoke striatal 
[3H]DA and hippocampal [3H]NA release (Abin-Carriquiry et al 2006).
Although nicotine-evoked DA release from minced nucleus accumbens (NAcc) 
in vitro has been described (Rowell et al 1987), the tiny size of this brain region 
precludes its use for most studies (Whiteaker et al 1995). We therefore chose to 
examine both nicotine- and cotinine-induced DA release from rat striatal minces 
(comprising dorsal striatum & NAcc).
2.2.2 Methods & Materials
Unless otherwise stated, chemicals were obtained from standard commercial 
sources.
2.2.2.1 Dopamine release from striatal slices
Assessment of [3H]dopamine ([3H]DA) release from striatal minces was 
performed using a 96 well assay (Anderson et al 2000, Jacobs et al 2002, Barik 
& Wonnacott 2006). For each experiment, 2 untreated rats were killed by 
cervical dislocation. Brains were rapidly removed and striata dissected and 
transferred to ice cold Krebs buffer (KB: NaC1118 mM, KCI 2.4 mM, CaCI2 2.4 
mM, KH2P 04 1.2 mM, MgS04.7H20  1.2 mM, NaHC03 25 mM, D-glucose 10
- 8 4 -
Chapter 2 -  Target Validation & Immune Response
mM, ascorbic acid 1 mM; gassed with 95% 0 2 and 5% C 0 2 for at least 1 h at 
37°C; pH adjusted to 7.4). Tissue was chopped 3 times (2 rotations at 60°) 
using a Mcllwain tissue chopper to give prisms of 250 pm. Following 2 washes 
with warm KB, striatal slices were incubated for 30 min with 50 nM [3H]DA in 5 
ml KB supplemented with 10 pM pargyline (to prevent [3H]dopamine 
degradation) at 37°C. To remove excess of tritium, 5 washes were performed 
over 25 min in KB containing 10 pM pargyline and 0.5 pM nomifensine (to 
prevent [3H]DA reuptake). Slices were then loaded onto a 96 well filter plate 
(model MABVN1250, Millipore, Hertfordshire, UK) and incubated at 37°C for 5 
min with buffer (KB + pargyline + nomifensine) in the presence or absence of 
antagonist. Following this, buffer was removed by filtration (basal values) and 
collected in a 96-well Packard Optiplate™ (Perkin Elmer, Belgium). Buffer (70 
pi) containing agonists and/or antagonists was then added to slices in each well 
(in each experiment, a buffer stimulation was included to determine the 
fractional release of [3H]DA in the presence of buffer alone). After a further 5 
min at 37°C, buffer was collected by filtration in an Optiplate™ to determine the 
fraction of [3H]DA released. Microscint™ (170 pi per well) was added to 
optiplates and each well was counted for 1 min using a Microbeta liquid 
scintillation counter (Wallac 1450 Microbeta Trilux, Perkin Elmer, Finland), 
counting efficiency 30%. To determine the amount of tritium remaining in the 
slices, 30 pi HCI (0.1 M) was added to each well of the filter plate and incubated 
at 37°C for 1 h, before being centrifuged for 3 min at 1000 rpm with an optiplate 
to collect the filtrate. HCI was added to the wells again, and the process 
repeated twice. Microscint™ (170 pi per well) was added to the optiplate and 
each well was counted for 1 min as above. The amount of [3H]DA released was 
expressed as a percent of total radioactivity taken up in the slices prior to 
stimulation (i.e. amount of tritium released + tritium remaining in the tissue), 
giving a fractional release of [3H]DA.
2.2.3 Results
In order to confirm previous data obtained by Pashmi (2004), we examined the 
ability of cotinine to activate nAChR, using [3H]dopamine release from rat 
striatal minces as a well-defined system.
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Nicotine (1 nM -  100 | jM )  evoked the concentration-dependent release of 
[3H]dopamine (see Figure 2.1), consistent with previous studies (Puttfarcken et 
al 2000, Grilli et al 2005, Abin-Carriquiry et al 2006). Roughly 1000-fold higher 
concentrations of cotinine (1 pM -  10 mM) were required to elicit comparable 
levels of [3H]dopamine release, which was also dependent on cotinine 
concentration. The estimated EC50 values for nicotine and cotinine, assuming 
the maximal response had been reached, were 0.5-1.0 pM and 0.5-1.0 mM, 
respectively.
Figure 2.1: Concentration dependence o f nicotine- and cotinine-evoked 
[3H]dopamine ([3H]DA) release from rat striatal minces
Striatal minces were-loaded with 
[3H]DA and pre-incubated with 
buffer containing nomifensine for 
5 min (see section 2.2.2.1). 
Nicotine (1 nM -  100 pM) or 
cotinine (1 p M -  10 mM) was 
then applied for 5 min and 
[3H]DA released into the medium 
was collected by filtration. [3H]DA 
release is expressed as a 
0 in M  io n M  io onM  iu M  io um  ioouM  im M  io m M  fraction o f the total [3H]DA in the 
[Drug] tissue at the start o f the
stimulation period.
Mean ±  S.E.M. (n =  3 independent experiments).
2.2.4 Discussion
To confirm that cotinine is able to activate nAChRs, we examined the ability of 
nicotine and cotinine to evoke [3H]dopamine release from rat striatal minces. 
Application of each drug lead to the release of DA from striatal tissue in a 
concentration-dependent manner (see Figure 2.1), although approximately 
1000-fold higher concentrations of cotinine were required to elicit comparable 
levels of release under the same conditions. Also indicated in Figure 2.1 is the 
basal 3H outflow under buffer control conditions.
An important consideration in evaluating these data is the purity of commercial 
cotinine that is derived from nicotine: - 0 .11% contamination with nicotine would
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be sufficient to achieve the agonist potency observed. Importantly, GCMS 
analysis of the cotinine used throughout these studies found only 0.0022% 
impurity of nicotine present. This is insufficient to account for the shift in 
potency.
The estimated EC5o values obtained here are slightly higher than those of -380  
nM (nicotine) and ~340 pM (cotinine) measured previously by Pashmi (Pashmi 
2004). The EC5o value for nicotine is also a little higher than that measured by 
others using the same 96-well technique (0.1-0.2 pM; Puttfarcken et al 2000, 
Abin-Carriquiry et al 2006), although it is within the range (0.1-4.0 pM) 
measured by groups utilising superfusion techniques (Grady et al 1992 & 1994, 
Sacaan et al 1995). Nicotine-induced striatal DA release is calcium dependent 
and can be inhibited by the nicotinic antagonists mecamylamine and DHpE 
using superfusion (Teng et al 1997, Grady et al 1992) and 96-well plate 
techniques (Puttfarcken et al 2000, Abin-Carriquiry et al 2006).
Cotinine has also been shown to act as an agonist at nAChRs, evoking DA 
release from rat striatal slices in a dose-dependent manner (Dwoskin et al 
1999). However, cotinine displayed a much lower potency (EC5o = 30 pM) than 
either nicotine or nornicotine (Dwoskin et al 1993 & 1999, Teng et al 1997). The 
EC5o value for cotinine obtained by Dwoskin and colleagues is roughly 10-fold 
lower than that observed in our experiments, which may be due to differences in 
technique, as this group were measuring DA release from superfused striatal 
slices, whereas we used striatal minces in 96-well plates. Superfusion with a 
low calcium buffer or administration of the nicotinic antagonists mecamylamine 
or DHpE has been observed to inhibit cotinine-stimulated DA release (Dwoskin 
et al 1999, Pashmi 2004). Pashmi also found that pre-incubation of striatal 
minces with cotinine (100 pM -  1 mM) reduced DA release in response to 
nicotine, while Dwoskin and colleagues were able to show that desensitisation 
to the effect of cotinine occurs in superfused striatal slices, providing further 
evidence that cotinine acts at nAChRs to evoke DA release in these 
preparations (Dwoskin et al 1999, Pashmi 2004).
Targeting of cotinine with specific antibodies raised in response to vaccination 
with an anti-cotinine vaccine would remove the antagonism of nicotine's actions 
by cotinine, which should improve the efficacy of NRT.
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2.3 Immune response
2.3.1 Introduction
In response to an antigen challenge, the immune system mounts a response, 
which involves the production of antibodies that recognise epitopes on the 
antigen and are specific for the particular antigen in question (reviewed in 
Chapter 1). The ability of a vaccine to elicit an immune response and initiate the 
production of specific antibodies is essential for the clinical effectiveness of the 
vaccine. This is also the case for therapeutic vaccines against drugs of abuse, 
including nicotine.
Numerous anti-nicotine vaccines are currently being developed (Hieda et al 
1997, de Villiers et al 2002, Sanderson et al 2003, Cerny et al 2002, Maurer et 
al 2005, Meijler et al 2003), with several now being evaluated in clinical trials 
(Maurer et al 2005, Hatsukami et al 2005). Although the formulation varies 
between these vaccines, their mechanism of action is the same, as all are 
designed to target nicotine by initiating the production of antibodies that 
recognise nicotine (see Chapter 1). The antibodies bind nicotine when it enters 
the body and retain it in the bloodstream (Pentel et al 2000, Satoskar et al 2003, 
Cerny et al 2002, Keyler et al 2005, de Villiers et al 2004), preventing it from 
crossing the blood-brain-barrier and acting on nAChRs in the CNS. This leads 
to a reduction in the effects of nicotine administration (Pentel et al 2000, Malin 
et al 2001a & 2002). A possible problem with this approach is that it may lead 
smokers to attempt to compensate for the reduced rewarding effects of a 
cigarette by smoking more cigarettes or changing inhalation patterns in an 
attempt to maximise the amount of nicotine obtained from each cigarette. Also, 
it is likely to reduce the efficacy of NRT at relieving nicotine withdrawal 
syndrome in abstinent smokers during a quit attempt.
As discussed in the initial section of this chapter, the ability of cotinine to act as 
a weak agonist at nAChRs (see Figure 2.1), and the evidence that it can 
desensitise nAChRs (Vainio et al 1998b, Dwoskin et al 1999), make cotinine a 
possible target for the development of a new smoking cessation therapy. 
Vaccination against cotinine should lead to the production of anti-cotinine 
antibodies that could bind the metabolite and prevent it from acting on nAChRs 
in the brain, thus effectively removing the cotinine-mediated antagonism of 
nicotine's actions. This should make NRT more efficacious, as well as allowing
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a smoker to decrease the number of cigarettes smoked as each one would 
have a greater effect. Such a vaccine could therefore be used to assist with a 
smoking cessation attempt in conjunction with NRT, but also in a reduce-to-quit 
approach to smoking cessation.
In previous work relating to this anti-cotinine vaccine, Ghazaleh Pashmi 
evaluated several cotinine derivatives conjugated to bovine serum albumin 
(BSA) in terms of their immunogenicity in rats (Pashmi 2004). Trans-4-thio- 
cotinine (CotSH) was found to be the most effective derivative of cotinine for 
eliciting the production of anti-cotinine antibodies, and was therefore taken 
forward for further studies. Conjugation of this derivative to tetanus toxoid (TT- 
CotSH) instead of BSA further increased the immune response.
In this project, 5 trials (see table in section 2.3.2.3 for an overview) were 
undertaken at Bath (Trials 1 - 3 )  and Newcastle-upon-Tyne (Trials 4 & 5). The 
immunisation regimes for each trial are described in section 2.3.2.3, while 
neurochemical and behavioural experiments performed as part of these trials 
are recorded in Chapters 3 & 4.
As a starting point for the work described in this thesis, we further optimised the 
anti-cotinine vaccine by examining the immune response to vaccination with TT- 
CotSH in conjunction with several different adjuvants/adjuvant combinations 
(Trial 1). Adjuvants are a critical factor in determining the efficacy of a vaccine 
since they help to maximise the immune response upon immunisation (see 
Chapter 1). In this chapter, anti-cotinine antibody titres achieved in all trials 
undertaken are compared, and the development of anti-tetanus toxoid antibody 
titres was also monitored and compared across trials. In addition, we sought to 
confirm the specificity of antibodies raised against TT-CotSH for cotinine, as 
observed by Pashmi (2004).
2.3.2 Methods & Materials
Unless otherwise stated, chemicals were obtained from standard commercial 
sources.
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2.3.2.1 Vaccine preparation
2.3.2.1.1 Synthesis of frans-4-thio-cotinine (CotSH)
Synthesis of the cotinine derivative (CotSH) was originally carried out as part of 
a previous PhD project (G. Pashmi) by Professor Tim Gallagher and Dr Sharn 
Ramaya at the University of Bristol in 2001. All experiments carried out at the 
University of Bath as part of this thesis were conducted using conjugates made 
from this batch of derivative. In 2006 Dr Stephen Husbands (University of Bath) 
was asked to synthesise a fresh batch of CotSH, due to concerns over the age 
of the original derivative. Conjugates from this derivative were used in the 
behavioural experiments performed at the University of Newcastle (Trials 4 &
5).
(±)-fra/7s-4-Cotinine carboxylic acid was employed for attachment of a 
sulphydryl group. The reaction was conducted under nitrogen, and all glassware 
was pre-dried in an oven at 150°C for 12 h prior to use. (±)-fra/7S-4-Cotinine 
carboxylic acid (200 mg, 0.9 mmol), 2-aminoethanethiol.HCI (103 mg, 0.9 
mmol) and triethylamine (0.13 ml, 1.8 mmol) were dissolved in dry 
dimethylformamide (DMF; 1.5 ml). The reaction mixture was cooled to 0°C in an 
ice bath, and EDCI.HCI (174 mg, 0.9 mmol) was then added. The reaction 
mixture was warmed to room temperature and stirred for a further 12 h. The 
solvent was removed in vacuo, and water (5 ml) and CH2CI2 (5 ml) were added 
to the residue. The aqueous phase was washed with CH2CI2 ( 4 x 5  ml). The 
combined organic extracts were dried over Na2S0 4 , filtered, and the solvent 
removed in vacuo. Purification by flash chromatography, using 5 % methanol / 
dichloromethane as eluent, gave the product (136 mg, 54 % yield) as a 
colourless oil.
[Found; (M+), 279.1045. C13H17O2N3S requires (M+) 279.1041]; 5H (400MHz, 
CDCI3) 8.58 (1 H, d d, J 4.9), 8.50 (1 H, d, J 2.0), 7.60 (1 H, d t, J2.0, 7.8), 7.38 
(1 H, d d, J 4.9, 7.8), 6.77 (1 H, br t, J 5.4), 4.79 (1 H, d, J 6.8), 3.51-3.35 (2 H, 
m), 2.92-2.68 (5H, m), 2.64 (3 H, s, CH3), 1.32 (1 H, t, J 8.3, SH); vmax (thin 
film)/cm'1 3500-3100 (br NH), 2543 (S-H), 1684 (C=0); m/z (E f) 279 [M \ 65%]. 
The product is racemic.
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2.3.2.1.2 Conjugation to Tetanus Toxoid
CotSH was conjugated to tetanus toxoid (TT) using an NHS ester-maleimide 
heterobifunctional cross-linker. TT was activated with S-GMBS through its 
amino groups: TT (5 mg/ml in 100 mM sodium phosphate buffer pH 7.2) was 
stirred at room temperature with an 80-fold molar excess of SGMBS (Pierce) for 
2 h. The maleimide-activated TT was then purified by applying the reaction 
mixture to a desalting column (PD-10 desalting column, Amersham Pharmacia 
Biotech) to remove excess reagent and reaction by-products. Fractions (1 ml) 
were collected using 100 mM sodium phosphate buffer (pH 6.8) to elute the 
activated TT. Fractions containing TT, determined by measurement of 
absorbance at 280 nm, were pooled and the protein concentration was 
measured by the Lowry method (Lowry 1951). The number of activated sites on 
the TT molecules was then determined using Ellman’s assay (Hermanson 
1996).
CotSH was added to the activated TT in a 2:1 ratio (mole:mole) of 
CotSH/number of maleimide functions, and incubated for 1 h at room 
temperature under agitation (TT-CotSH). Cysteine (4 mg/ml in sodium 
phosphate buffer 100 mM, pH 6.8) was then added to quench any unattached 
sites present on TT-CotSH, and incubated for 30 min at room temperature 
under agitation. Conjugate solutions were dialysed against sodium phosphate 
buffer (2 mM, pH 6.8) overnight (4 °C), filtered using a millex filter (0.22 pm) in a 
sterile environment, and stored at 4 °C until use. Control vaccine was prepared 
by coupling cysteine to TT (TT-Cysteine), instead of CotSH. Conjugates were 
dialysed against phosphate buffer (2 mM, pH 6.8) for 2 h using Slide A-lyzer 
discs (3500MWCO - Pierce) with 3 buffer changes.
Lowry’s and Ellman’s assays were conducted to determine the number of 
activated sites still remaining. Comparison of the number of maleimide functions 
before and after quenching determined the number of CotSH attachments per 
TT molecule (typically 8 - 1 4 ) .
After the conjugations for Trial 1, which I carried out under the supervision of 
staff at GSK Biologicals in Rixensart, Belgium, all subsequent conjugates were 
produced there and then shipped to me at Bath / Newcastle. A fresh batch of 
conjugates (TT-CotSH and TT-Cysteine) was produced for each trial. Using the 
fresh batch of derivatives synthesised in 2006, new conjugates (TT-CotSH and
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TT-Cysteine) were produced for Trials 4 & 5. Unfortunately, it appears that the 
vials containing these new conjugates were mislabelled, i.e. TT-CotSH labelled 
“TT-Cysteine”, and vice versa (for more details see section 2.3.4).
2.3.2.1.3 Formulation of vaccine
Conjugate solutions were mixed with AS02v adjuvant in a 1:1 ratio. In the 
adjuvant optimisation study (Trial 1) other adjuvants were also used; these were 
coded (X, Y & Z) on request of GSK (see section 2.3.2.3.1). AS02v, a GSK 
proprietary adjuvant system, is an oil-in-water emulsion-based adjuvant system 
containing MPL and QS21. AS02v has been shown to elicit a high immune 
response (unpublished).
2.3.2.2 Animals
For all behavioural experiments carried out at the University of Newcastle upon 
Tyne (see sections 2.2.3.4, 2.2.3.5, and Chapter 4), male Hooded Lister rats 
(Harlan UK) were used. They were housed in rooms maintained at 20-22 °C, 
under a 12:12 h light:dark cycle (lights on 0700-1900 h). Rats had access to 
food and water ad libitum, except for those involved in the taste aversion 
experiments (see section 4.4), which had restricted access to water.
Rats used in the intravenous self-administration experiments were housed in 
pairs; all others were housed in groups of 4. For the conditioned taste aversion 
experiments, rats were housed individually and allowed to acclimatise for a 
week prior to the experiment. After completing the taste aversion procedures, 
rats were re-housed in their original groups of 4 for all further procedures 
(locomotor activity, additional immunisation and mecamylamine precipitated 
withdrawal).
All experiments carried out at the University of Bath utilised male Sprague- 
Dawley rats, 6-7 weeks old at the start of the immunisation regime, which were 
obtained from the University of Bath breeding colony or Charles River UK, and 
housed in groups of 3-4 with access to food and water ad libitum in rooms 
maintained at 22 ± 2 °C under a 12:12 h light:dark cycle (lights on 0700-1900 
h).
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All studies complied with local and national ethical requirements, and were 
carried out according to the Animals (Scientific Procedures) Act of 1986 under 
license from the UK Home Office.
2.3.2.3 General immunisation regime and overview of trials
The immunisation schedule used was taken from Hieda et al (2000) with 
variations. Rats were immunised (i.m.) with TT-CotSH (5 pg) or TT-Cysteine (5 
pg) in a final volume of 250 pi (125 pi per leg, i.m.), typically on days 0, 21 and 
35. TT-Cysteine was used to control for effects of immunisation with the carrier 
protein. In order to maintain antibody titres, rats were boosted at regular 
intervals, typically on days 63 and 77. Blood samples were also taken at 
immunisation time points (and between immunisations in some studies) in order 
to monitor the development of antibody titres (see section 2.2.4).
The following table gives an overview of the experiments carried out as part of 
each of the 5 trials, in addition to the series of immunisations:
Trial No Location Experiments carried out
1 Bath Adjuvant comparison (Chapter 2)
Trial run of 5-day locomotor experiments (Chapter 4)
2 Bath 5-day locomotor experiments (Chapter 4) 
Radioligand binding (Chapter 3)
3 Bath 12-day locomotor experiments (Chapter 4) 
Radioligand binding (Chapter 3)
Blood / brain nicotine & cotinine levels (Chapter 3)
4 Newcastle Intravenous self-administration (Chapter 4)
5 Newcastle Conditioned taste aversion (Chapter 4)
Acute locomotor experiments (Chapter 4) 
Mecamylamine-precipitated withdrawal (Chapter 4) 
Radioligand binding (Chapter 3)
Blood / brain nicotine & cotinine levels (Chapter 3)
Immunisation schedules for each individual trial are given in more detail below.
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2.3.2.3.1 Trial 1 -  Comparison of adjuvants (Bath)
40 male Sprague-Dawley rats (6-7 weeks old) were divided into four groups of 
10 animals, each of which received the conjugates with a different adjuvant 
treatment (adjuvant X, adjuvant Y, adjuvant Z or AS02v). Half of each group (5 
rats) was immunised with the active conjugate (TT-CotSH), the other half with 
the control (TT-Cysteine).
Timeline:
Day 0 -  Bleed & immunisation 
Day 21 -  Bleed & immunisation 
Day 35 -  Bleed & immunisation 
Day 49 -  Bleed
Day 63 -  Bleed & immunisation 
Day 77 -  Bleed
After completion of the initial immunisation schedule, rats immunised with 
conjugates plus AS02v were given an additional booster immunisation. All other 
groups were used for a trial run of locomotor experiments.
Adjuvants X, Y & Z:
Day 98 -  Bleed
Day 101-105 -  Locomotor activity experiments 
Day 105 -  Cull (blood & brain collection)
AS02v:
Day 110 -  Bleed & immunisation 
Day 115-118:  Cull & final bleed
2.3.2.3.2 Trial 2 -  5-day conditioned locomotor experiments (Bath)
96 male Sprague-Dawley rats (6-7 weeks old) were divided into 8 groups with 
12 rats per group. 48 rats were immunised with TT-CotSH plus AS02v, the 
other 48 with the TT-Cysteine control conjugate plus AS02v. Half the rats from 
each group started their immunisation regime a week after the other half; 
staggering of immunisations and locomotor experiments by a week was 
necessary due to limits on the equipment available.
Timeline:
Day 0 -  Bleed & immunisation 
Day 21 -  Bleed & immunisation 
Day 35 -  Bleed & immunisation 
Day 63 -  Bleed
Day 91 -  Bleed & immunisation
Day 105 -  Bleed & immunisation
Day 119 -  124 -  Locomotor activity experiments
Day 124 -  Cull (Blood & brain collection)
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2.3.2.3.3 Trial 3 -  12-day locomotor experiments (Bath)
48 male Sprague-Dawley rats (6-7 weeks old) were divided into 4 groups with 
12 rats per group. Half the rats were immunised with TT-CotSH plus AS02v, the 
other half with the TT-Cysteine control conjugate plus AS02v.
Upon completion of the locomotor experiments, half the animals were culled 
immediately. The remaining half was given further daily injections of nicotine or 
saline and culled 5 min after their final injection.
Timeline:
Day 0 -  Bleed & immunisation 
Day 21 -  Bleed & immunisation 
Day 35 -  Bleed & immunisation 
Day 49 -  Bleed
Day 63 -  Bleed & immunisation
Day 77 -  Bleed & immunisation
Day 91 -  103 -  Locomotor activity experiments
Day 103 -  Cull 1st half (blood sample collection)
Day 103 -  106 -  Additional nicotine/saline injections (once daily)
Day 106 -  Cull 2nd half (blood & brain collection)
2.3.2.3.4 Mislabelling of conjugates
The final two trials were undertaken in Newcastle. Newly prepared conjugates, 
produced at GSK Rixensart, were received after the start of these trials and all 
immunisations were then switched to the new conjugates. As immunisation was 
staggered, some rats’ immunisation schedule had already been started, using 
the old conjugates. This meant that due to the mislabelling of the vials, control 
rats were unintentionally immunised with the active conjugate (TT-CotSH), and 
rats supposedly receiving the active conjugate were immunised with the control 
(TT-Cysteine) instead. As a result, control rats in Trials 4 & 5 started to raise 
antibodies against cotinine.
In an attempt to restore active and control groups in Trial 5, rats were given an 
extra large booster dose (25 pg instead of the usual 5 pg) of “old” conjugates 
(i.e. conjugates used at the start of the trial before the fresh batch arrived).
2.3.2.3.5 Trial 4 -  Intravenous self-administration (Newcastle)
Surgery to implant the intravenous catheter for self-administration experiments 
was performed on a total of 58 male hooded Lister rats. Of an initial 37 animals,
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one was culled because of infection post-surgery. In order to replace rats, which 
had been excluded due to blocked catheters and/or lack of acquisition of intra­
venous self-administration, a further 21 animals were implanted with catheters 
(2 were culled post-surgery due to a blocked catheter and infection, 
respectively). In all, a total of 55 rats proceeded to the acquisition phase. Of 
these, only 18 satisfied the criteria for stable maintenance and completed the 
immunisation schedule (5 injections of TT-CotSH / TT-Cysteine plus adjuvant 
AS02v). A further 3 rats were lost during the extinction and reinstatement 
phases, leaving 15 rats which completed the entire series of self-administration 
experiments.
Timeline:
Surgery & Recovery ( 1 0 - 1 4  days)
Acquisition (21 -  132 sessions)
Maintenance (~65 sessions (average), including immunisation period)
Day 0 -  Bleed & immunisation 
Day 21 -  Bleed & immunisation 
Day 35 -  Bleed & immunisation 
Day 63 -  Bleed & immunisation 
Day 77 -  Bleed & immunisation 
Extinction ( 3 - 1 7  sessions)
Reinstatement (~30 -  55 sessions)
Cull (blood sample collection)
2.3.2.3.6 Trial 5 -  Conditioned taste aversion I locomotor activity I 
mecamylamine-precipitated withdrawal (Newcastle)
48 male hooded Lister rats (6-7 weeks old) were used in this study. Half the rats 
were immunised with TT-CotSH plus AS02v, the other half with the TT-Cysteine 
control conjugate plus AS02v.
Timeline:
Day 0 -  Bleed & immunisation
Day 21 -  Bleed & immunisation
Day 35 -  Bleed & immunisation
Day 63 -  Bleed & immunisation
Day 77 -  Bleed & immunisation
Day 89 -  113 -  Conditioned taste aversion
Day 119 -  124 -  Locomotor experiments
Day 125 -  Bleed & immunisation (large dose)
Day 138 -  158 -  Mecamylamine-precipitated withdrawal (staggered)
Cull (blood & brain collection)
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Once the initial immunisation schedule had been completed, 32 of the 48 rats 
were used in the conditioned taste aversion and locomotor procedures. The 
other 16 rats were kept as nicotine-naive controls for the mecamylamine- 
precipitated withdrawal experiments.
Due to the mislabelling of a batch of conjugates (see section 2.2.1.2.1), rats 
immunised with "control" vaccine had started to develop anti-CotSH titres, and 
the titres of those receiving "active" vaccine were much lower than anticipated. 
For this reason, all 48 rats received a further extra large booster immunisation 
(25 pg conjugate per rat instead of the usual 5 pg, plus AS02v; see section 
2.2.1.2.1) once the locomotor experiments had been completed.
In order to maximise the chance of seeing a vaccine effect in the behavioural 
tests in this trial (mecamylamine-precipitated withdrawal), we selected only 
those rats with the lowest and highest anti-CotSH titres for control and active 
groups, respectively. The idea of having nicotine-naive control groups was 
abandoned as a result, and a mixture of nicotine-naive animals and rats with a 
history of nicotine treatment (previously used in conditioned taste aversion and 
locomotor experiments) was consequently divided into treatment groups for the 
withdrawal experiments.
2.3.2.4 Blood sampling & treatment
Blood samples (-300 pi) taken from the lateral tail vein (under isofluorane 
anaesthesia) at vaccination time points and at sacrifice (mainly trunk blood) 
were centrifuged at 4 °C, 1500 x g, for 30 min, and the supernatant centrifuged 
again. Aliquots of sera were stored at -20 °C. These samples were used to 
monitor antibody titres by ELISA (see section 2.2.5), and to determine blood 
nicotine and cotinine levels as a result of treatment with nicotine (see section 
3.2).
2.3.2.5 ELISA Methods
2.3.2.5.1 ELISA for measuring anti-CotSH titres
Maxisorp 96 well plates were coated with CotSH (1 pg/ml in carbonate buffer (1 
carbonate-bicarbonate buffer capsule in 100ml deionised water); 50 pi per well) 
overnight at 4 °C. Plates were incubated with saturation buffer (phosphate 
buffered saline, pH 7.4, Tween-20 (0.1 % v/v), deactivated foetal bovine serum
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(4 % w/v), bovine serum albumin (1 % w/v)) plus 1 % w/v casein (100 jul/well, 
pH 7.4) for 1 h at 37 °C, before being washed 3 times with PBS-Tween (0.1 %). 
Sera from immunised rats were serially diluted (1:2 times each time) in 
saturation buffer, and 50 pi of each dilution added to the plate and incubated at 
37 °C for 1 h. Plates were washed again, and biotinylated anti-rat Ig from sheep 
(1:3000 in saturation buffer) was added (50 pl/well). Plates were incubated for 2 
h at 37 °C, then washed and incubated with streptavidin-biotinylated HRP 
(1:1000 in saturation buffer, 50 pl/well) for 30 min at 37 °C. After washing, 
plates were incubated with TMB peroxidase (100 pl/well) for 10 min in the dark. 
Sulphuric acid was added (0.4 N, 50 pl/well) and absorbance measured at 450 
nm and 620 nm, using a plate reader. Sera with known titre levels (from 
previous trials) were used as controls.
2.3.2.5.2 ELISA for measuring anti-TT titres
For the anti-TT ELISA, plates were coated with TT-cysteine (1 pg/ml in 
carbonate buffer), and the ELISA performed as above. Sera with known titre 
levels (from previous trials) were used as controls.
2.3.2.5.3 Competitive ELISA
For the competitive ELISA, sera were incubated with 7 dilutions of competitors 
(1 mM -  1 nM) at 4 °C overnight. The competitors used were nicotine and 
cotinine, plus 5 further metabolites of nicotine: nornicotine, norcotinine, trans-3- 
hydroxycotinine, nicotine-1-oxide and cotinine-N-oxide (purchased by GSK). An 
ELISA was then performed as above, but using plates coated with 0.05 pg/ml 
CotSH, and adding 100 pi of the sera-competitor solutions in duplicate instead 
of serial dilutions of sera. Sera (from rats immunised with active and control 
vaccine, respectively), and incubated with saturation buffer alone were used as 
controls.
2.3.2.6 Data analysis
Antibody titres are expressed as the dilution producing a 50% maximal optical 
density on ELISA (i.e. mid-point titres), and data shown as means ± S.E.M.
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2.3.3 Results
2.3.3.1 Chemistry, vaccine formulation & overall safety profile
Cotinine was chemically modified to introduce a thiol group attached to an 
amide spacer via the C4 position of cotinine (see Figure 2.2) to give trans-A- 
thiol cotinine (CotSH). This was coupled to the carrier protein tetanus toxoid 
(TT) prior to vaccination, using an NHS ester-maleimide heterobifunctional 
cross-linker, which resulted in the attachment of 8 -  14 molecules of derivative 
per TT molecule. Cysteine conjugated to TT was used as the control vaccine, 
with similar levels of conjugation achieved.
Figure 2.2: Synthesis of trans-4-thio-cotinine (CotSH) from (±)-trans-4-cotinine
carboxyiic acid
A thio group, attached to an amide spacer, was introduced into trans-4-cotinine by 
reaction of trans-4-cotinine carboxyiic acid with 2-aminoethanethiol and triethylamine in
DMF (see section 2.3.2.1.1).
Safety of vaccination & blood sampling
Rats were immunised repeatedly with TT-CotSH or TT-Cysteine plus one of 
four adjuvants/adjuvant combinations, and blood samples taken at regular 
intervals to monitor the development of antibody titres. Vaccination with either 
conjugate plus the various adjuvants/adjuvant combinations appeared to be 
safe and well tolerated. No adverse reactions to the vaccines or adjuvants were 
observed in any of the rats.
In order to minimise irritation of the tail, rats were bled alternately from the left 
and right lateral tail veins. With the exception of (very rare) minor bruising to the 
tail the following day, no adverse reactions to the bleeding protocol were 
observed and none of the rats appeared to be in any pain or discomfort as a 
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2.3.3.2 Anti-CotSH titres: General immune response
No anti-cotinine antibodies were detected in any of the rats prior to the start of 
vaccinations (in any of the trials). Repeated vaccination with TT-CotSH resulted 
in the production of anti-cotinine antibodies. These could be detected by day 21, 
however at this point the levels were often still too low to determine mid-point 
titres. Antibody titres increased with each vaccination; however titres tended to 
wane over time and booster injections were required in order to maintain 
antibody levels (see below).
TT-Cysteine did not produce any titres in the anti-CotSH ELISA, consistent with 
the specificity of the method and the absence of cross-reacting antibodies after 
immunisation with TT-Cysteine.
2.3.3.3 Anti-CotSH titres: individual trials
Trial 1 (Adjuvant comparison)
Mid-point titres of anti-cotinine antibodies gradually increased in all groups 
vaccinated with TT-CotSH (see Figure 2.3).
Figure 2.3: Immune response to anti-cotinine vaccination (Trial 1)
Rats were immunised 
with 5 jug TT-CotSH, 
plus one o f 4 adjuvants/ 
adjuvant combinations, 
on the days indicated 
(arrows). Blood samples 
were collected at each 
timepoint and serum 
mid-point titres o f 
vaccinated rats (n = 5) 
were determined by 
ELISA, using trans-4- 
thiol cotinine coated 
plates.
Antibody titres are expressed as the dilution producing 50% maximal optical density on
ELISA (i.e. mid-point titres).
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By day 77, after 3 initial injections (day 0, 21 & 35) and one booster dose (day 
63), a comparison of anti-cotinine antibody levels between adjuvant treatment 
groups revealed that the mean mid-point titre of the group treated with AS02v 
was slightly greater than the other treatment groups (see Figure 2.4), however 
this was not significant. Treatment with adjuvant Y produced significantly higher 
anti-cotinine antibody levels than adjuvant X (1:3093 ± 420 and 1:1552 ± 324, 
respectively; p=0.0197), however the mean mid-point titre for both these 
groups, and that for adjuvant Z (1:2140 ± 655), was iower than that for AS02v 
(1:3926 ± 1500). AS02v was therefore used as an adjuvant in all subsequent 
trials (see Figure 2.9 for comparison of titres between trials).
The AS02v-treated group was given another booster injection on day 110 and 
anti-cotinine titres measured again. The final booster resulted in a marked 
increase in antibody levels to 1:7061 ± 1973 (see Figure 2.3), so in subsequent 
trials 2 booster injections were given prior to behavioural experiments.
Rats from the other three adjuvant groups (X, Y & Z) were used for a vaccinated 
pre-trial of the conditioned locomotor experiments (see section 4.2.2.3). Their 
titres were monitored by taking blood samples prior to behavioural experiments, 
and when they were culled, by which time anti-cotinine antibody levels had 
decreased slightly in these groups (see Figure 2.3).
Figure 2.4: Immune response to anti-cotinine vaccination -  comparison of
adjuvants
samples collected on day
expressed as the dilution 
producing 50% maximal 
optical density on ELISA
Serum mid-point titres o f
groups were determined
17, using trans-4-thiol 
cotinine coated plates. 
Antibody titres are
by ELISA from blood
rats (n = 5) in the 4 
adjuvant treatment
adjuvant X adjuvant Y adjuvant Z AS02v
(i.e. mid-point titres).
Data presented are means ± S.E.M.; *p<0.05
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Trial 2
Anti-cotinine titres in rats immunised with TT-CotSH plus AS02v increased from 
one immunisation to the next, and had reached similar levels (1:7266 ± 545) to 
those achieved in Trial 1 (AS02v group) by day 105 (see Figure 2.5 & 2.9), 
when rats were given a final booster injection. Blood samples obtained at the 
end of the experiment (day 124) revealed that antibody levels had increased 
even further (1:9832 ± 826) over the course of the locomotor experiments (see 
section 4.2.2.4). There were no significant differences in post-locomotor titres 
between locomotor treatment groups, i.e. no effects of drug or pairing (data not 
shown).
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Rats were immunised with 5 
fjg TT-CotSH in AS02v 
adjuvant on the days 
indicated (arrows). Blood 
samples were collected at 
each timepoint and serum 
mid-point titres o f vaccinated 
rats (n = 48) were 
determined by ELISA, using 
trans-4-thiol cotinine coated 
plates.
Antibody titres are expressed as the dilution producing 50% maximal optical density on
ELISA (i.e. mid-point titres).
Data presented are means ± S.E.M.
Trial 3
The anti-cotinine antibody titres achieved in rats immunised with TT-CotSH plus 
AS02v increased from one immunisation to the next over the course of Trial 3 to 
a maximum of 1:3272 ± 355, but were markedly lower (see Figure 2.6) than 
those obtained in Trial 2 (see Fig 2.9). This might have been due to the age of 
the cotinine derivative (~3-4 years), which prompted the decision to produce a 
fresh batch of CotSH from which the conjugate for Trials 4 & 5 could be made.
-102-
Chapter 2 -  Target Validation & Immune Response
Figure 2.6: Immune response to anti-cotinine vaccination (Trial 3)
4000
0
Rate were immunised with 5 
jug TT-CotSH in AS02v 
adjuvant on the days 
indicated (arrows). Blood 
samples were collected at 
each timepoint and serum 
mid-point titres of vaccinated 
rats (n = 24) were 
determined by ELISA, using 
trans-4-thiol cotinine coated 
plates.
Time (days)
Antibody titres are expressed as the dilution producing 50% maximal optical density on
ELISA (i.e. mid-point titres).
Data presented are means ± S.E.M.
Trial 4
Anti-cotinine antibody titres obtained in Trial 4 are summarised in Figure 2.8. 
Rats entered the vaccination phase of the experiment individually once they had 
fulfilled stability criteria for self-administration behaviour (see section 4.3.2.5). A 
couple of weeks after the first rat had received its first vaccination, the new 
batch of conjugates arrived from GSK Rixensart, and all subsequent injections 
consisted of these new conjugates. This meant that while some rats received an 
injection of "old" conjugate (and one rat was given 2 injections of "old" 
conjugate), approximately half the animals were only vaccinated with "new" 
conjugates, as they did not fulfil stability criteria until after the switchover point. 
Due to the mislabelling of the vials containing the fresh conjugates, rats were 
effectively mis-vaccinated, resulting in 3 categories of treatment groups based 
on vaccination history.
(For both Trial 4 and Trial 5, "active" & "control" groups are used here to define 
the original treatment the rats were assigned to, prior to the mislabelling of vials 
becoming apparent, whereas active & control (without inverted commas) refer 
to the final groups based on antibody titres raised.)
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- "Active" & "control" groups that had only been injected with "new" conjugates: 
While vaccination entirely with "new" TT-Cysteine resulted in measurable anti- 
cotinine antibody levels from day 21 onwards (Figure 2.7), rats injected with 
"new" TT-CotSH throughout raised no measurable anti-cotinine titres 
whatsoever. Based on these findings it was clear that the conjugate vials must 
have been mis-labelled (i.e. swapped).
- "Active" & "control" groups that had been given an initial injection of "old" 
conjugates, but had received "new" conjugates from the second vaccination 
onwards:
Rats given one injection of "old" TT-CotSH exhibited initial antibody titres at day 
21 (Figure 2.7), however these diminished again very quickly, as the "new" TT- 
CotSH administered thereafter was actually the control conjugate (TT- 
Cysteine). Those animals initially vaccinated with "old" TT-Cysteine on one 
occasion, did not at first produce measurable anti-cotinine antibodies, however 
after repeated injections of "new" TT-Cysteine, antibody titres rose to similar 
levels as seen in the rats that had received "new" control conjugate (actually 
TT-CotSH) only.
- One rat that was vaccinated with "old" conjugate (TT-CotSH, i.e. active) twice 
before the switch to the "new" conjugate took place:
At first this rat developed titres similar to the group vaccinated entirely with 
"new" TT-Cysteine (Figure 2.7), however, after being switched to injections of 
"new" TT-CotSH, antibody production began to level off and decreased 
progressively until levels were undetectable by the end of the experiment.
Rats were assigned to an overall active or control group, depending on whether 
they had raised sustained anti-cotinine antibody titres or not: Rats immunised 
entirely with "new" TT-CotSH that had raised no antibodies, and those only 
given one initial "old" TT-CotSH injection, that had hardly raised any antibodies, 
were combined to form the mean control group, while all others were assigned 
to the mean active group. Overall, the maximum titres measured at the end of 
this Trial were extremely low (1:492 ± 70) compared to previous Trials (see 
Figure 2.9 for titre comparison across trials).
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Active ("new" only, n=4)
Control ("new" only, n=5)
Active (1x"old", then "new", n=4)
Controls (1x"old", then "new", n=4)
Active (2x"old", then "new", n=1)
Mean actual active (ie rats with titres, n=10) 




Rats were immunised with 5 /jg TT-CotSH in AS02v adjuvant on the days indicated 
(arrows). Blood samples were collected at each timepoint and serum mid-point titres of 
all vaccinated rats (n = 18) were determined by ELISA, using trans-4-thiol cotinine
coated plates.
Antibody titres are expressed as the dilution producing 50% maximal optical density on 
ELISA (i.e. mid-point titres). Data presented are means ± S.E.M.
“Old” refers to conjugates initially used at the time the first rats entered the vaccination 
phase; once the “new” (i.e. fresh batch of) conjugates arrived, these were used for 
subsequent injections. For detailed background on groups and vaccination problems,
see section 2.3.3.3 (under “Trial 4 ”).
Brightly coloured symbols give titres o f rats grouped by their original intended category 
(active /  control) as well as the number o f injections o f “old “ /  “new” conjugates they 
received. The darker symbols give means of those animals assigned to control /  active 
after determination of anti-CotSH titres.
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Trial 5
All 48 rats were initially vaccinated twice with conjugates produced from the 
original ("old") batch of cotinine derivative (CotSH). Once the conjugates 
derived from the fresh batch of CotSH arrived from GSK Rixensart ("new" 
conjugates), these were used for vaccinations. Rats were immunised over 3 
days in groups of 16. Due to the timing of the arrival of the new conjugates, the 
first 16 rats received a third injection of "old" conjugates; whereas the remaining 
rats were given "new" conjugates for their third vaccination. For all rats, the 2 
subsequent booster injections consisted of "new" conjugate.
Anti-cotinine titres were initially determined for "active" and "control" vaccinated 
groups. It was not until the determination of antibody levels in samples taken on 
day 77 (which took place while the locomotor experiments (see section 4.2.2.6) 
were underway) that suspicions were confirmed that the vials containing the 
new conjugates might have been labelled incorrectly. Splitting the "active" and 
"control" vaccinated groups into those that had received 3 doses (1-16) and 
those that had received only 2 injections of "old" conjugates (remaining rats), 
provided further evidence (see Figure 2.8): in "control" (TT-Cysteine 
immunised) animals among rats 1-16, titres were still non-existent at day 77, 
whereas the remaining "control" rats had developed anti-cotinine titres similar to 
the rats in the "active" group (among rats 1-16). On the other hand, in the group 
of "active" (TT-CotSH immunised) rats that had been switched to the "new" 
conjugate after only 2 injections, anti-cotinine titres decreased more rapidly than 
in "active" rats among subjects 1-16, that had received 3 vaccinations with "old" 
conjugates.
Rat 41 provided further confirmation: this "control" rat had been erroneously 
immunised with "new" TT-CotSH conjugate on one occasion. However, the 
level of anti-cotinine antibodies for this rat was lower, not higher, than those 
found in the other rats belonging to the "control" group vaccinated with "new" 
conjugates on 3 occasions, and very similar to the titres of the "control" rats 
among individuals 1-16. Titres for rat 41 were therefore included in the results 
for the latter group of rats (see Figure 2.8).
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Figure 2.8: Immune response to anti-cotinine vaccination (Trial 5)
Rats were immunised 
with 5 fug TT-CotSH 
in AS02v adjuvant on 
the days indicated 
(arrows). Blood 
samples were 
collected at each 
timepoint and serum 
mid-point titres o f 
vaccinated rats were 
determined by 
ELISA, using trans-4- 
thiol cotinine coated 
plates.
2000
Active (3 x "old")
Control (3 x "old", & rat41) 
Active (2 x "old")
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Antibody titres are expressed as the dilution producing 50% maximal optical density on 
ELISA (i.e. mid-point titres). Data presented are means ± S.E.M.
For detailed background on groups and vaccination problems, see section 2.3.3.3 
(under “Trial 5’). In brief: conjugates used for initial vaccinations (“old’) were replaced 
by a fresh batch after 2-3 injections (depending on animals). Rats are grouped 
according to the number o f injections of “old” conjugates received before the switch 
took place. Rat41 was erroneously injected with “new TT-CotSH” instead o f “new TT- 
Cysteine”, developing lower, instead of higher, antibody titres than comparable animals
as a result.
Animals received a final vaccination o f 25 /jg “old” conjugates in an attempt to restore
original active /  control groups.
On day 125, all rats were given an additional booster, consisting of 25 |jg of 
"old" conjugates plus AS02v, in an attempt to increase the levels of anti-cotinine 
antibodies in "active" rats and reduce any further increases of anti-cotinine titres 
in "control" rats. Although this did help to restore the original "active" and 
"control" groups to a certain extent (see Figure 2.8), the increase in titres in the 
"active" rats was not as large as anticipated, resulting in very low final anti- 
cotinine antibody titres (1:806 ±114) compared to previous trials (see Figure 
2.9 for titre comparison across trials). For the withdrawal experiments (see 
Chapter 4), the original designation of rats to active and control groups was
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maintained (with the exception of rat 41; see above), however rats from within 
these groups were selected on the basis of titres raised, i.e. only those with the 
highest anti-cotinine antibody titres were used for active groups, and those with 
the lowest titres for controls.
Figure 2.9: Comparison of anti-cotinine antibody titres across triais
Trial Mean ± SEM Range
1 1:7061 ±1973 1:1951 -1:13709
2 1:9832 ±826 1:3258-1:27315
3 1:3008 ±413 1:635-1:9428
4 1:397 ±61 1:213-1:621
5 1:806 ± 114 1:158-1:2234
Titres shown are the final titres for animals immunised with TT-CotSH, or, in the case 
of Trials 4 & 5, those animals designated as belonging to the “active” group.
2.3.3.4 Anti-TT titres
No anti-TT antibodies were detected in any of the rats prior to the start of 
vaccinations (in any of the trials). As for antibodies against cotinine, mid-point 
titres of antibodies against TT increased from one vaccination to another, and 
also required regular booster injections for maintenance of titres. Levels of anti- 
TT antibodies were generally 10-fold greater than those of anti-cotinine 
antibodies (see Figure 2.9 -2 .11) .
Trial 1 (Adjuvant comparison)
In Trial 1, anti-TT antibody levels increased in all adjuvant groups as a result of 
repeated vaccinations (see Figure 2.10) in a similar pattern to the anti-cotinine 
antibody titres (see section 2.3.3.3J; however anti-TT titres were much higher. 
As with the anti-cotinine antibodies, levels dropped off over time and increased 
again after the booster injection on day 63. A comparison between groups on 
day 77 revealed a significant effect of conjugate (F(conjugate)ii32 = 14.625, 
p=0.0006), with titres in groups vaccinated with control vaccine (TT-Cysteine) 
generally higher (~1:80 000 — 1:130 000) than those in rats vaccinated against 
cotinine (-1:60 000 -  1:70 000; data not shown).
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Figure 2.10: Immune response to TT component o f vaccines (Trial 1)
Rats were immunised 
with 5 /jg TT-CotSH or 
TT-Cysteine, plus one 




collected at each time 
point and serum mid­
point titres o f 
vaccinated rats (n = 5) 
were determined by 
ELISA, using trans-4- 
thiol cotinine coated 
plates.
Antibody titres are expressed as the dilution producing 50% maximal optical density on 
ELISA (i.e. mid-point titres). Data presented are means ± S.E.M.
In the groups vaccinated with AS02v adjuvant, an increase in anti-TT antibody 
levels was observed after their second booster injection on day 110 (see Figure
2 .10); however it was not as marked as that observed for the anti-cotinine 
antibodies (see Figure 2.4). Final titres for the AS02v adjuvant groups were 
-1 :40 000 for rats immunised with TT-CotSH and -1 :70 000 for the controls 
(immunised with TT-Cysteine).
Trial 2
Anti-TT antibody levels increased from one vaccination to the next (see Figure
2 .11) and were generally higher in the control group compared to the rats 
receiving active vaccine.
Titres of -1:55 000 (TT-CotSH) and -1:75 000 (TT-Cysteine) were reached by 
day 105, prior to locomotor experiments. There was a significant difference in 
final titres between control and active groups (p<0 .0001) at the end of the 
behavioural experiments, and mean titres had increased further to -1 :60 000 
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Trial 1 (see above). There were no further significant differences in anti-TT 
antibody levels post-locomotor between treatment groups, i.e. no effects of 
treatment or pairing (data not shown).
Figure 2.11: Immune response to TT component o f vaccines (Trial 2)
Rats were immunised 
with 5 /jg TT-CotSH or 
TT-Cysteine in AS02v 
adjuvant on the days 
indicated (arrows). 
Blood samples were 
collected at each 
timepoint and serum 
mid-point titres of 
vaccinated rats (n = 
48) were determined 
by ELISA, using trans- 
4-thiol cotinine coated 
plates.
Antibody titres are expressed as the dilution producing 50% maximal optical density on 
ELISA (i.e. mid-point titres). Data presented are means ± S.E.M.
Trial 3
Anti-TT antibody titres for Trial 3 are shown in Figure 2.12. Again, anti-TT 
antibody levels increased steadily as a result of repeated vaccinations (see 
Figure 2.12), however the final booster injection failed to produce a further 
increase, with titres decreasing from day 77 to sacrifice (day 103-106). Final 
mean titres for control animals were significantly greater than those receiving 
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Figure 2.12: Immune response to TT component o f vaccines (Trial 3)
Rats were immunised 
with 5 pg TT-CotSH or 
TT-Cysteine in AS02v 
adjuvant on the days 
indicated (arrows). 
Blood samples were 
collected at each 
timepoint and serum 
mid-point titres of 
vaccinated rats (n = 
24) were determined 
by ELISA, using trans- 
4-thiol cotinine coated 
plates.
Antibody titres are expressed as the dilution producing 50% maximal optical density on 
ELISA (i.e. mid-point titres). Data presented are means ± S.E.M.
2.3.3.5 Competitive ELISA -  specificity of anti-CotSH antibodies
The specificity of anti-CotSH antibodies for cotinine versus nicotine was 
examined by means of a competitive ELISA.
Antibodies showed much greater specificity for cotinine than nicotine (see 
Figure 2.13), in agreement with previous findings (Pashmi 2004). Cotinine was 
able to compete with the CotSH plate coating for antibody binding causing a 
significant reduction from a concentration of 1 pM upwards (compared to pre­
incubation with buffer alone), whereas competition by nicotine was not 
significant, with only a trend starting to occur from around 100 pM upwards.
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Figure 2.13: Specificity o f anti-CotSH antibodies for cotinine
Sera taken on day 17 
from rats immunised 
with 5 /jg TT-CotSH (n 
= 4 replicates of 
pooled sera; Trial 3) 
were assayed in a 
competitive ELISA, 
using plates coated 
with 0.05 pg/ml trans- 
4-thiol cotinine. Sera 
were pre-incubated 
with nicotine or 
cotinine (1 nM -  1 mM) 
overnight at 4 °C prior 
to ELISA.
Data presented are means ± S.E.M.; *p<0.05, **p<0.01 (compared to baseline)
2.3.4 Discussion
The main characteristics of a vaccine that are relevant to the treatment of 
nicotine addiction are its immunogenicity (i.e. the ability to raise antibodies in 
response to vaccination), and the affinity and specificity of the antibodies 
produced. Specificity refers to the ability of antibodies to recognise immunogen 
(in this case cotinine) over other metabolites, whereas affinity describes the 
strength with which the target is bound by the antibody.
The ability of TT-CotSH to elicit the production of anti-cotinine antibodies in 
response to vaccination is key to the efficacy of the anti-cotinine vaccine. 
Previous studies have focussed on optimising the cotinine derivative used, as 
well as the carrier protein to which it is conjugated, with a much greater immune 
response induced after coupling to tetanus toxoid (TT) compared to bovine 
serum albumin (BSA; Pashmi 2004). Anti-nicotine conjugate vaccines have 
utilised keyhole limpet hemocyanin (KLH; Hieda et al 1997, de Villiers et al 
2002, Carrera et al 2004), recombinant cholera toxin B subunit (Cerny et al 
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In order to maximise the antibody production as a result of vaccination, we 
compared several adjuvants/adjuvant combinations for their ability to enhance 
the immune response to the vaccine (see Chapter 1), including AS02v, which 
Pashmi had found to produce a greater immune response than alum alone as 
adjuvant (Pashmi 2004). As we observed no huge differences in terms of mean 
anti-cotinine antibody titre between groups, and the group receiving AS02v had 
the highest mean antibody levels (see Figure 2.4), AS02v was used as adjuvant 
in all subsequent experiments. Studies on anti-nicotine vaccines, on the other 
hand, have used Freund’s adjuvant in preclinical studies. This is a relatively 
aggressive adjuvant (and therefore not licensed for use in humans), which is 
able to elicit a substantial immune response. This explains why antibody titres 
achieved in these studies are consistently greater than 1:10 000 (Hieda et al 
1997, de Villiers et al 2004, Satoskar et al 2003).
The second booster vaccination significantly increased anti-cotinine antibody 
levels in the first trial (see Figure 2.3), so this additional injection was included 
in the vaccination schedules thereafter (see section 2.3.2.3). The anti-cotinine 
titres achieved in Trial 2 (see Figure 2.5) were the highest, compared with the 
other trials (see Figure 2.9), which may have been the result of the longer 
interval between the third vaccination and the first booster injection, giving the 
immune response more time to develop. Unfortunately we were unable to 
repeat this time schedule in the other trials, due to time constraints on 
equipment usage.
It is unclear why titres achieved in Trial 3 (see Figure 2.6) were only half as 
great as those obtained in Trial 1, although a possible cause might be the 
shorter gap between the two booster injections in Trial 3. The other possibility is 
that the derivative (CotSH), from which the active conjugate was derived, might 
have started to degrade. We therefore synthesised a fresh batch of CotSH and 
had new conjugates made (by GSK Biologicals in Belgium). Due to the mis­
labelling of these new conjugates (i.e. TT-CotSH labelled as TT-Cysteine and 
vice versa), anti-cotinine antibody titres obtained in Trials 4 & 5 were very low. 
But even in those rats that had received only "new" conjugates (Trial 4; see 
Figure 2.7), titres did not reach levels comparable to previous trials. This might 
have been the result of reduced conjugation of the new derivative to TT, 
possibly due to slight differences in chemistry between the two batches of
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derivative as they were produced by different laboratories. To complicate 
matters further, rats used for Trials 4 & 5 were of the Lister hooded strain, 
whereas the preceding three trials had used Sprague-Dawleys. In addition, rats 
in Trial 4 were also self-administering nicotine during the vaccination phase, 
which might have had an impact on the magnitude of the immune response as 
chronic nicotine administration has been shown to suppress immune responses 
in rats (Kalra 2002).
In order to get a better idea of the overall magnitude of the immune response 
elicited by vaccination with TT-CotSH and evaluate the immune response to the 
control vaccine (TT-Cysteine), the levels of antibodies raised against the TT 
portion of the conjugates were also examined. These were found to be 
consistently much higher than those raised against cotinine, an indication of the 
much greater immunogenicity of TT compared to cotinine. However, the anti-TT 
antibody levels observed in control-vaccinated rats were also much higher than 
those in rats injected with active vaccine. This might, at least in part, be a result 
of some of the anti-TT antibodies from rats vaccinated with TT-Cysteine 
recognising the TT-Cysteine used to coat the ELISA plates for this assay 
slightly better than anti-TT antibodies raised by rats injected with TT-CotSH. 
Antibodies recognise a very specific epitope on the antigen, and some of the 
anti-TT antibodies might have been raised against a part of the linking portion of 
the conjugate, connecting the cysteine molecules to the TT carrier protein. Such 
a sequence would be much less likely to be recognised by an anti-TT antibody 
raised against the linking portion between CotSH and TT.
Generally, the anti-cotinine antibody titres obtained in response to vaccination 
with TT-CotSH were disappointing. Only Trial 2 came close to the antibody 
levels achieved by vaccination against nicotine (Hieda et al 1997, de Villiers et 
al 2004, Satoskar et al 2003). This might be at least partially due to the larger 
dose of conjugate (25 -  100 pg) administered in studies examining anti-nicotine 
vaccines (Hieda et al 1997, Lindblom et al 2002, Satoskar et al 2003, LeSage et 
al 2006). Previous work (Pashmi 2004) on the anti-cotinine vaccine involved the 
comparison of anti-cotinine antibody titres across several doses of TT-CotSH, 
with the conclusion that 5 pg was the optimum dose (over 1 and 25 pg). 
However, upon closer examination the titres obtained in that study were very
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variable, ranging from - 1 :4000 to - 1 :54000 in the 5 |jg group, with a mean titre 
o f-1:24000.
The specificity of antibodies produced can have a bearing on the safety profile 
of a vaccine, with greater specificity reducing the risk of competition for binding 
by other compounds, leading to improvements in safety and a reduced risk of 
side effects. The anti-cotinine antibodies raised as a result of vaccination with 
TT-CotSH were shown to be specific for cotinine with only a tendency towards 
cross-reactivity for nicotine, which was not significant even at the highest 
nicotine doses examined. This confirms previous findings by Pashmi (2004), 
who observed that anti-cotinine antibodies were specific for cotinine with little or 
no cross-reactivity for any of the metabolites studied, although a small degree of 
competition by norcotinine was detected. However, while norcotinine has been 
shown to be present and metabolised in rat brain, there is no literature to 
suggest that it has any pharmacological activity (Crooks & Dwoskin 1997, 
Ghosheh et al 2001).
2.4 Chapter conclusions
We were able to establish the methodology for generating an anti-cotinine 
vaccine, as the first step in evaluating a novel approach to combating tobacco 
smoking. The rationale for this approach is that this primary metabolite of 
nicotine competes with nicotine, reducing its effect, and therefore causing 
smokers to increase their intake of nicotine. The presence of cotinine would 
also compromise the efficacy of nicotine replacement treatments. The weak 
pharmacological activity of cotinine was verified in in vitro assays of dopamine 
release from striatal slices. As an agonist, cotinine is approximately 1000 times 
less potent than nicotine, in agreement with previous reports (Anderson et al 
2000). This is also reflected in its weak interaction with nicotinic receptor 
binding sites (Ghosheh et al 2001, Dwoskin et al 1999).
Pashmi (2004) had previously shown that brief exposure of striatal slices to a 
high concentration of cotinine significantly decreased responses to a 
subsequent stimulation with nicotine. This is compatible with receptor 
desensitisation by cotinine. Given that the average smoker sustains high 
plasma cotinine concentrations (-15 times higher than peak concentrations of
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nicotine; Hatsukami et al 1998), this ability to “antagonise” nicotine’s actions is 
likely to influence smoking patterns. Using immunisation to raise antibodies that 
bind cotinine, thus preventing it from entering the brain, should combat this 
antagonism, thereby rendering nicotine replacement therapy more effective.
Both nicotine and cotinine are too small to be recognised by the immune system 
under normal circumstances. In order to elicit an immune response they need to 
be linked to an immunogenic carrier protein, resulting in a conjugate vaccine. 
Several anti-nicotine vaccines have been created by conjugating nicotine or a 
structurally related compound (i.e. hapten) to a carrier protein (Hieda et al 1997, 
de Villiers et al 2002, Carrera et al 2004, Cerny et al 2002, Pentel et al 2000). In 
the present study we chose TT as the carrier, because of its use in human 
vaccines. Coupling cotinine to TT required introduction of a linker arm bearing a 
reactive group. Introduction of a thiol group attached to an amide spacer via the 
C4 position of cotinine facilitated the efficient coupling to TT, without 
compromising the antigenic recognition of cotinine, as endorsed by the 
specificity of the anti-cotinine antibodies.
Repeated immunisation of rats with TT-CotSH resulted in the production of anti- 
cotinine antibodies and titres increased with each booster. Preclinical studies of 
anti-nicotine vaccines have reported higher titres (Hieda et al 1997, de Villiers et 
al 2004, Satoskar et al 2003) but this is likely to reflect differences in the 
adjuvants used: most of the protocols for studies of anti-nicotine vaccines have 
used the more immunogenic Freund’s adjuvant, whereas we used an adjuvant 
developed with a view towards future use in humans, to give a more realistic 
picture of the magnitude of the immune response which might be achieved in 
patients.
In order to maximise the therapeutic effect and minimise potential side effects of 
an anti-cotinine vaccine, antibodies raised against cotinine need to be specific. 
Antibodies raised in response to immunisation with TT-CotSH recognised 
cotinine with very little cross-reactivity for other nicotine metabolites or nicotine 
itself, and no antibodies were detected in any control animals, demonstrating 
that the structure of the conjugate vaccine permits recognition of the cotinine- 
specific component by the immune system. Studies on anti-nicotine vaccines
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have observed similar specificity (Hieda et al 1997, de Villiers et al 2002, Cerny 
et al 2002, Maurer et al 2005).
Having characterised the immune response induced by vaccination with TT- 
CotSH, the effects of anti-cotinine antibodies on a variety of nicotine-induced 
responses were examined both in vitro and in vivo.
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Chapter 3
Effects of immunisation on nicotine I cotinine 
distribution and nicotine binding sites
3.1 Chapter introduction
As discussed in Chapter 2, immunisation of rats with TT-CotSH elicited an 
immune response, which resulted in the production of anti-cotinine antibodies. 
These antibodies are specific for cotinine and do not recognise nicotine or other 
nicotine metabolites.
According to the hypothesis set out in the Chapter 1 (see section 1.9), such 
anti-cotinine antibodies should bind cotinine, retaining it in the bloodstream and 
preventing it from crossing the blood-brain-barrier. In order to see whether this 
was the case, we studied the distribution of nicotine and cotinine, in both the 
blood and the brain, after different schedules of nicotine administration (see 
section 3.2).
Preventing cotinine from entering the brain should also remove or at least 
reduce any cotinine-mediated antagonism of nicotine's actions. Nicotine 
administration is known to upregulate nicotine binding sites. We therefore 
examined the effect of vaccination on [3H]epibatidine and [125l]aBungarotoxin 
binding levels after administration of nicotine by daily injection or chronic 
subcutaneous infusion to see whether antagonism of cotinine's actions had any 
effect on nicotine-induced nAChR upregulation (see section 3.3).
3.2 Nicotine & cotinine distribution in blood and brain
3.2.1 Introduction
Nicotine is absorbed rapidly from cigarette smoke, enters the arterial circulation 
and is quickly distributed to body tissues. Nicotine levels then start to fall, as a 
result of uptake by peripheral tissues and elimination from the body. It takes just 
10-20 s for nicotine to pass through the brain (Benowitz 1996). This rapid 
delivery of nicotine results in a relatively intense pharmacological response, due 
to high arterial levels entering the brain and effects occurring rapidly, before 
there is adequate time for the development of tolerance. While tolerance to the
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effects of nicotine takes days or even weeks to develop and can persist for a 
similar length of time after discontinuation of nicotine administration, 
desensitisation of nAChRs can occur within seconds of smoking a cigarette. 
However, nicotine levels in the brain decline between cigarettes, providing an 
opportunity for resensitisation of receptors so that positive reinforcement can 
occur to some extent with successive cigarettes (Dani & Heinemann 1996).
In contrast to cigarette smoking, slow release of nicotine, as seen with 
transdermal NRT, is much less reinforcing, since blood nicotine levels rise 
gradually, allowing tolerance to develop (Benowitz 1996). Peak arterial levels 
are also much lower with transdermal nicotine compared to cigarette smoking 
(see section 1.6.1.1), even with a similar daily nicotine intake. The lack of quick 
relief from withdrawal symptoms as a result of the slow nicotine delivery is one 
of the major drawbacks of transdermal NRT, and one of the key reasons why so 
many quitters are unable to remain abstinent.
Since the elimination half-life of nicotine is approximately 2-3 hours, nicotine 
levels can accumulate over 6-8 hours during regular smoking or nicotine dosing 
(Benowitz 1996). Nicotine is rapidly metabolised to cotinine by cytochrome 
P450 enzymes (see section 1.2). Cotinine, the major metabolite of nicotine, has 
a half-life of 15-19 hours in humans and therefore accumulates in the body to a 
much greater extent than nicotine (Herzig et al 1998).
Immunisation against nicotine or administration of anti-nicotine antibodies has 
been shown to significantly increase blood nicotine levels and reduce 
distribution of nicotine to the brain (Hieda et al 1997 & 1999, Keyler et al 1999, 
Pentel et al 1999, Satoskar et al 2003, de Villiers et al 2004). Maternal 
vaccination has also been observed to reduce foetal exposure to nicotine 
(Keyler et al 2003 & 2005). These effects appear to be due to an increase in 
levels of bound nicotine in the blood, as brain nicotine concentration was found 
to be inversely related to both serum nicotine concentration and nicotine protein 
binding in serum, indicating that nicotine was being sequestered by anti-nicotine 
antibodies in the vaccinated animals (Hieda et al 1999). Antagonism of nicotine 
in this manner might reduce the rewarding effects of the drug, but it would also 
significantly reduce the ability of NRT to alleviate the withdrawal symptoms 
usually associated with smoking cessation.
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In order for the anti-cotinine vaccine to improve the efficacy of NRT in smoking 
cessation, the antibodies raised as a result of immunisation would need to bind 
and retain cotinine in the bloodstream, preventing it from crossing the blood- 
brain-barrier and antagonising nicotine’s actions. To see if this was the case, we 
examined the distribution of both nicotine and cotinine in blood and brain 
following different nicotine administration schedules.
3.2.2 Methods
3.2.2.1 Nicotine regimes
To study the effect of intermittent nicotine exposure, we used rats that had been 
given daily nicotine (0.5 mg/kg) or saline injections for 15 days (see section 
4.2.2.5) as part of locomotor experiments. Animals were culled 5 min after their 
last injection.
We also examined the effects of chronic nicotine exposure. Rats used for these 
experiments had received a chronic infusion of nicotine (3.16 mg/kg/day) for 7 
days via osmotic minipumps (OMP) as part of the mecamylamine-precipitated 
nicotine withdrawal experiments (see section 4.5.2.3). Control rats were 
implanted with a "blank". After the behavioural experiments, blood samples 
were taken and rats were perfused transcardially with PBS (see section 3.2.2.3) 
prior to dissecting out the brain.
3.2.2.2 Preparation of brain tissue for analysis of nicotine & cotinine 
levels
3.2.2.2.1 Unperfused brain
Rats were killed by cervical dislocation and the brain dissected on ice. One 
hemisphere was added to a tube containing 1 ml of 0.1 M HCI. After 
determining the weight of the tissue, 1:2 homogenates of brain:HCI were 
prepared. These were stored at -20°C  and shipped to ABS Laboratories for 
analysis (see section 3.2.2.3). The other hemisphere was quickly frozen in liquid 
nitrogen and used for radioligand binding experiments (see section 3.3).
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3.2.2.2.2 Perfusion
After completing the mecamylamine-precipitated withdrawal experiments (see 
section 4.5), rats were given a lethal dose of sodium pentobarbital (1 ml/kg) by 
intraperitoneal injection. Once the footpad reflex was no longer present, the 
ribcage was exposed by cutting away the fur and skin. A small incision was 
made to locate the xyphoid cartilage (sternum), and, holding the cartilage firmly, 
the ribcage was opened up towards the head, exposing the heart. A cannula 
was inserted into the left ventricle and clamped in place. A small incision was 
made in the right atrium to create an outlet for blood and perfusion fluids, and 
the pump turned on immediately to allow perfusion to commence. Each rat was 
perfused transcardially with ~100 ml chilled PBS (0.1 M, pH 7.4).
Once perfusion was complete, the pump was switched off and the cannula 
removed. The brain was dissected out as quickly as possible, and the brain 
tissue prepared as described above (see section 3.2.2.2.1). The second 
hemisphere was again quickly frozen in liquid nitrogen for use in radioligand 
binding experiments (see section 3.3).
3.2.2.3 Analysis of blood nicotine & cotinine levels
Blood samples taken when the animals were culled were treated as described 
in section 2.2.4 to obtain sera. The samples were shipped to ABS Laboratories, 
London, for determination of nicotine and cotinine concentration by gas 
chromatography.
3.2.2.4 Data Analysis
Data shown are means ± S.E.M. for each group. Unpaired t-tests were used to 
examine significant differences between treatment groups.
3.2.3 Results
3.2.3.1 Nicotine I cotinine distribution following once-daily injections
of nicotine for 15 days
All saline-treated rats consistently had nicotine and cotinine levels (blood & 
brain) of £ 1 ng/ml (data not shown).
Cotinine levels were markedly lower than nicotine levels in all nicotine-treated 
groups. This was due to the short interval (5 min) between administering the
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nicotine and obtaining the samples, during which only a fraction of the dose was 
converted to cotinine. Rats that had been immunised with control vaccine (TT- 
Cysteine) and had been administered nicotine for 15 days had mean serum 
nicotine and cotinine levels of 215 ± 37 and 23 ± 3 ng/ml, respectively (see 
Figure 3.1). Their mean brain nicotine concentration was 262 ± 42 ng/g, with 
brain cotinine levels again much lower (7 ± 1 ng/g).




Serum Nic Serum Cot Brain Nic Brain Cot
Rats that had been immunised with either active (TT-CotSH) or control (TT-Cysteine) 
vaccine were given daily nicotine (0.5 mg/kg) or saline injections for 15 days. Animals 
were culled 5 min after their last injection. Blood samples were taken and treated as 
described in section 2.2.4 to obtain sera, and nicotine & cotinine concentration 
determined by gas chromatography.
Data shown are means ± S.E.M (n = 6). ** p<0.01
Nicotine levels in both serum (245 ± 35 ng/ml) and brain (272 ± 33 ng/g) of rats 
immunised against cotinine did not differ from those receiving control vaccine 
(see Figure 3.1). On the other hand, in rats immunised against cotinine, serum 
cotinine levels were significantly higher (177 ± 36 ng/ml; p=0.0017) compared to 
control, indicating that cotinine was being retained in the bloodstream by the 
anti-cotinine antibodies. Brain cotinine levels were also significantly elevated 
(11 ± 1 ng/g; p=0.0098) in rats receiving active vaccine (TT-CotSH) compared
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to controls; however the increase in cotinine concentrations observed in serum 
(670 %) was much greater than in brain (57 %).
Because these results could reflect the contamination of brain tissue with blood 
occurred during dissection, animals were perfused with PBS prior to dissecting 
the brain in subsequent experiments (see section 3.2.2.2.2), in order to remove 
as much blood as possible from the brain itself and any surrounding tissue 
containing blood vessels likely to be damaged during dissection.
3.2.3.2 Nicotine I cotinine distribution following 7-day chronic 
nicotine infusion
Saline-treated rats consistently had nicotine and cotinine levels (blood & brain) 
of < 1 ng/ml (data not shown).





Serum Nic Serum Cot Brain Nic Brain Cot
Rats received a chronic infusion of nicotine (3.16 mg/kg/day) for 1 days via osmotic 
minipumps (OMP). Control rats were implanted with a "blank". On day 7, blood 
samples were taken and rats were perfused transcardially with PBS (see 3.2.2.2.2)
prior to removing the brain.
Blood samples were taken and treated as described in section 2.2.4 to obtain sera, and 
nicotine & cotinine concentration determined by gas chromatography.
Data shown are means ± S.E.M (n = 6-8). ** p<0.01
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Control immunised animals had mean serum nicotine and cotinine levels of 104 
± 7 and 586 ± 43 ng/ml, respectively (see Figure 3.2), and brain concentrations 
of 73 ± 10 ng/g (nicotine) and 84 ± 7 ng/g (cotinine).
Nicotine levels (serum and brain) in the active (TT-CotSH) vaccine groups were 
not significantly different compared to controls (109 ± 4 ng/ml and 97 ± 8 ng/g, 
respectively). Cotinine levels in the brain were also not significantly different 
(107 ± 9 ng/g; p=0.0725) from controls, although a small trend towards higher 
levels was observed with immunisation against cotinine. This supported the 
suspicion that in the previous experiment the difference in brain cotinine levels 
had been due to contamination of the brain samples with blood (see section
3.2.3.1). As had been the case in the previous experiment, serum cotinine 
levels (857 ± 41 ng/ml; p = 0.0011) were significantly higher in rats immunised 
against cotinine compared to those given control vaccine (TT-Cysteine).
3.2.4 Discussion
Nicotine and cotinine distribution in control groups
In our first study, serum cotinine levels measured were relatively low compared 
to nicotine levels, most likely because the samples were taken quite soon (5 
min) after nicotine administration, before much of the dose had been 
metabolised to cotinine. In the second study, after chronic infusion of nicotine 
for a week, the plasma cotinine concentration was much greater, due to the 
gradual accumulation of cotinine over time.
In a moderate smoker, plasma nicotine levels average 10-50 ng/ml, whereas 
cotinine levels can reach up to 250-350 ng/ml (Lockman et al 2005). In rats, 
chronic infusion of nicotine (4.5 mg/kg/day) for 28 days produces comparable 
plasma levels (72 and 469 ng/ml for nicotine and cotinine, respectively;
Lockman et al 2005). These values are not that dissimilar from those observed 
in our second (chronic) study, although the dose we used was slightly lower, 
and the animals only received nicotine for 7 days.
Nicotine and its metabolites have very different half-lives: Ghosheh et al 
determined that in rats, brain half-lives of nicotine, cotinine and nornicotine were 
52, 333, and 166 min, respectively (Ghosheh et al 1999). Due to their different 
elimination rates, the relative balance of these metabolites in the body also 
varies depending on the time point, at which a measurement is taken, as well as
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the route and frequency of administration. Chronic infusion of 2.4 mg/kg/day for 
10 days resulted in plasma and brain nicotine levels of 43 ng/ml and 120 ng/g, 
respectively (Rowell & Li 1997). The same dose given in the form of multiple 
injections on the other hand produced very different plasma & brain 
concentrations: 140 ng/ml & 520 ng/g (8 x 0.3 mg/kg), 202 ng/ml & 688 ng/g (4 
x 0.6 mg/kg), or 535 ng/ml & 1133 ng/g (2 x 1.2 mg/kg). Brain nicotine levels 
tended to be several times higher than plasma levels in all injection regimes 
examined (Rowell & Li 1997), whereas we observed quite similar nicotine 
concentrations in serum and brain in both of our studies. However, we observed 
a tendency towards lower nicotine and higher cotinine levels (blood & brain) 
after chronic nicotine administration (see Figure 3.2), compared to the repeated 
injection regime (see Figure 3.1).
Four hours after a single s.c. injection of 0.54 mg/kg nicotine, Crooks & Dwoskin 
observed brain concentrations of nicotine and cotinine in the rat of 12 and 45 
ng/g, respectively (Crooks & Dwoskin 1997). The brain nicotine levels we found 
after injection of 0.5 mg/kg are much higher than that (~250 ng/g), and the 
cotinine levels much lower (~10 ng/g); however, our samples were collected just 
5 min after nicotine administration. As nicotine has such a short half-life in the 
rat (<1 h), nicotine levels could conceivably fall to a level comparable to that 
detected by Crooks & Dwoskin in the space of 4 hours, while cotinine levels 
could rise accordingly as more nicotine is metabolised.
Effects of vaccination on nicotine & cotinine distribution 
In Chapter 2 we showed that the antibodies raised in response to immunisation 
against cotinine are specific for cotinine and do not recognise nicotine or other 
metabolites. This is supported by the observation that there was no significant 
difference between vaccinated and control rats in terms of nicotine levels in 
serum or brain after intermittent nicotine administration or chronic infusion (see 
Figures 3.1 & 3.2).
Plasma cotinine levels, on the other hand, were significantly increased (7.7-fold 
after repeated injections and 1.5-fold following chronic administration) in those 
rats immunised against cotinine. This is consistent with the hypothesis that 
antibodies raised in response to anti-cotinine vaccination bind cotinine,
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preventing it from entering the brain, and retain it in the blood (still bound to the 
antibody).
Results have confirmed a similar hypothesis for anti-nicotine vaccines: Total 
and bound serum nicotine concentrations appear to be significantly higher in 
vaccinated rats compared to controls after administration of a bolus infusion of 
nicotine (Hieda et al 1997, Keyler et al 1999, de Villiers et al 2004), while 
unbound serum nicotine is lower (Satoskar et al 2003), resulting in a reduced 
clearance rate. Distribution of nicotine to the brain is also significantly reduced 
in rats vaccinated against nicotine (Keyler et al 1999, Hieda et al 1999, Pentel 
et al 1999, Satoskar et al 2003, de Villiers et al 2004). Chronically infused 
nicotine showed a similar pattern of distribution, but differences were generally 
smaller than after a single nicotine dose. Vaccine efficacy in reducing nicotine 
distribution to the brain does not appear to be compromised by concurrent 
nicotine administration (Hieda et al 2000).
Passive immunisation with anti-nicotine antibodies prior to nicotine 
administration also reduced brain nicotine levels in a dose-related manner (65% 
reduction at the highest IgG dose) and increased serum nicotine dose- 
dependently (Pentel et al 1999). No differences in serum cotinine levels were 
observed as a result of either active or passive immunisation against nicotine 
(Pentel et al 1999, de Villiers et al 2004).
Furthermore, active or passive maternal immunisation reduced nicotine 
distribution to both maternal brain (44-47%) and foetal brain (17-39%) after a 
single maternal nicotine dose administered on gestational day 20, but had a 
smaller effect on nicotine distribution to brain after continuous nicotine infusion 
(Keyler et al 2003 & 2005). The nicotine-specific antibody concentration in foetal 
serum was 10% (foetal brain 1%) of that in maternal serum. Overall these data 
support the idea that vaccination against nicotine reduces distribution of nicotine 
to the brain by sequestering it in the serum.
Due to the mislabelling of conjugates (see Chapter 2) antibody titres in the rats 
immunised against cotinine were relatively low (-1:3,000 for the repeated 
nicotine injections, and - 1 :800 in the chronic administration study; see Figure 
2.10 in Chapter 2), compared to those achieved in the studies of anti-nicotine 
vaccines (£ 1:10,000). This could explain why there wasn’t a greater effect of 
antibodies on cotinine levels, especially in the brain. Based on the findings of
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the anti-nicotine vaccine studies, a significant decrease in cotinine 
concentration should have been observed in the brains of animals immunised 
against cotinine, rather than just a “lack of increase”, as anti-cotinine antibodies 
should sequester cotinine in the blood and prevent it from entering the brain. 
The elevation in brain cotinine levels observed in our first experiment (see 
Figure 3.1) could have been due to contamination of the brain samples with 
blood during dissection procedures. In order to address this issue, rats were 
perfused with PBS after the chronic infusion study in an attempt to remove as 
much blood as possible from the brain and surrounding tissues. Although brain 
cotinine levels were again slightly higher in vaccinated rats in this study, the 
difference was no longer significant. Some contamination with minor traces of 
blood may have remained even after perfusion, which could account for some 
of the cotinine measured in these brain samples. Serum cotinine levels were 
found to be very high in the second study, so even a small amount of blood 
could have had an impact on brain cotinine levels measured.
3.3 Radioligand binding
3.3.1 Introduction
Nicotine addiction is characterised by the repeated administration of nicotine 
through cigarettes or other tobacco products, resulting in sustained blood 
nicotine levels. The effects of chronic exposure to nicotine and other nicotinic 
agonists on nAChR levels have been studied both in vitro and in vivo using a 
variety of radioligands.
High-affinity binding of [3H]nicotine and [3H]cytisine has been correlated with 
nAChRs comprised of a4 and p2 subunits (Whiting et al 1991, Flores et al 1992, 
Zoli et al 1998), a subtype that appears to be particularly easily upregulated by 
nicotine, possibly due to its high affinity compared to other receptor subtypes 
(Perry et al 1999, Nguyen et al 2003). [3H]epibatidine on the other hand also 
labels a number of other subtypes in addition to a4p2 nAChRs, including a3p2* 
and p4* receptors (Houghtling et al 1995, Ridley et al 2001,Nguyen et al 2003, 
Xiao & Kellar 2004, Marks et al 2006). Binding of [125l]aBgt and 
[3H]methyllycaconitine ([3H]MLA) correlates with the a l  subunit, however 
upregulation of this subtype is less robust than that observed for [3H]nicotine
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binding sites and requires higher nicotine concentrations that may not be 
relevant to human smokers (Wonnacott 1990, Pauly et al 1991, Barrantes et al 
1995, Peng et al 1997, Orr-Urtreger et al 1997, Davies et al 1999, Whiteaker
1999).
Several groups have demonstrated that in cells stably expressing defined 
heterologous nAChR subtypes, incubation with nicotine for several hours to 
several days can increase the density of nAChR binding sites corresponding to 
the a4p2, a3p2, and a3p4 subtypes, as well as several others (Peng et al 1994 
& 1997, Bencherif et al 1995, Gopalakrishnan et al 1996 & 1997, Wang et al 
1998, Whiteaker et al 1998, Meyer et al 2001). For example, comparing 6 
different nAChR subunit combinations, Xiao and Kellar observed that culturing 
HEK 293 cells in the presence of nicotine (0.2 -100 pM) for 5 days resulted in a 
concentration-dependent increase in [3H]epibatidine binding in membrane 
preparations from all transfected cell lines (Xiao & Kellar 2004). However, the 
extent of the increase varied markedly depending on the subtype of rat nAChR 
expressed, with the largest increases seen in subtypes containing the p2 
subunit (a3p2 > a2p2 > a4p2) rather than the p4 subunit.
In cell lines, upregulation of surface nAChRs by nicotine was shown to include 
both a3* (Meyer et al 2001, Ridley et al 2001) and a6*, as well as a4* (Nelson 
et al 2003) and a7 receptors (Quik et al 1996).
Chronic administration of nicotine (by intravenous or subcutaneous infusion, 
administration in drinking water or through repeated injections) elicits a dose- 
dependent increase in the density of [3H]nicotine and [125l]aBgt binding sites in 
the brains of rodents (Wonnacott 1990, Flores et al 1992, Rowell & Li 1997). 
This upregulation is reversible, and after discontinuation of nicotine treatment, 
[3H]nicotine binding levels return to control values within 7-10 days in mice 
(Marks et al 1985) and 15-20 days in rats (Collins et al 1990), whereas 
[125l]aBgt binding returns to control levels within 2-4 days in both rat and mouse 
(Miner & Collins 1989, Collins et al 1990). In contrast, a-conotoxin Mil-sensitive 
a6* nAChR subtypes appear to decrease in mouse striatum (Lai et al 2005) but 
increase in rat brain (Parker et al 2004) as a consequence of nicotine 
administration.
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Both in vivo and in vitro the upregulation of binding sites by nicotine reflects an 
increase in total receptor number (Bmax) rather than a change in affinity (KD) 
(Wonnacott 1990, Gopalakrishnan et al 1997) and does not appear to involve 
an increase in nAChR subunit mRNA (Marks et al 1992, Peng et al 1994, 
Bencherif et al 1995), indicating that upregulation occurs through a post- 
transcriptional mechanism.
Humans self-administer nicotine in the form of cigarettes and other tobacco 
products. Significant increases in [3H]nicotine, [3H]cytisine, and [3H]epibatidine 
binding are seen in human post mortem brain tissue (cortex, cerebellum, 
hippocampus & thalamus) of smokers, compared to non-smokers (Benwell et al 
1988, Breese et al 1997, Perry et al 1999). In white blood cells from smokers, 
[3H]epibatidine binding is also significantly increased compared to non-smoking 
controls, but there is no difference in [125l]aBgt binding (Cormier et al 2004). As 
in rodents, the upregulation of nAChRs by nicotine appears to be due to an 
increase in total receptor number, rather than receptor affinity, and is dose- 
dependent. Receptor levels in the brains of ex-smokers who quit at least 2 
months before death are comparable to those found in non-smoking subjects, 
indicating that smoking-induced changes in nAChR numbers are reversible after 
cessation of nicotine intake (Breese et al 1997).
In order to determine whether immunisation against cotinine has any effect on 
nicotine-induced receptor upregulation, we performed radioligand binding 
assays with [3H]epibatidine and [125l]a-Bungarotoxin on brain homogenates from 
rats after various nicotine administration schedules.
3.3.2 Methods
3.3.2.1 Membrane preparation
Rats were culled by cervical dislocation or transcardiac perfusion (see section 
3.2.2.2.2). Brains were quickly removed, and hemispheres frozen in liquid 
nitrogen and stored at -20°C  until use.
Brain membranes were prepared as previously described (Davies et al 1999, 
Sharpies et al 2000). Hemispheres (minus cerebellum) were homogenised in 
ice-cold 0.32 M sucrose buffer (containing 1 mM EDTA, 0.01% NaN3 (pH7.4,
10% w/v) 0.1 mM PMSF; pH 7.4). The homogenate was centrifuged (15,000 x
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g) for 30 min at 4°C to give a membrane pellet (Beckman Avanti J-25 centrifuge 
with JA25-50 rotor). The pellet was resuspended in 50 mM phosphate buffer (40 
mM K2H P04i 10 mM KH2P 0 4, 1 mM EDTA, 0.01% w/v NaN3> 0.1 mM PMSF; 
pH 7.4), and again centrifuged as above. The wash step was repeated, and the 
final pellet was resuspended in ice-cold 50 mM phosphate buffer (2.5 ml/g 
tissue). Aliquots were then frozen until use.
Protein concentration was estimated using a colorimetric protein dye reagent 
(Bradford 1976).
3.3.2.2 [3H]epibatidine binding
[3H]epibatidine binding was carried out as previously described (Sharpies et al.
2000). Membrane preparations (final concentration 1 mg/ml) were added to 
assay buffer (118 mM NaCI, 4.8 mM KCI, 2.5 mM CaCI2.2H20 , 2 mM MgS04,
20 mM HEPES, 20 mM Tris, 0.1 mM PMSF, 0.01% w/v NaN3; pH 7.4), 
containing [3H]epibatidine (54 Ci/mmol; Amersham Biosciences, 
Buckinghamshire, UK; final concentration 1 nM) to give a total volume of 1 ml. 
Non-specific binding was determined in the presence of 1 mM nicotine.
Samples were incubated at room temperature for at least 1 h, before being 
chilled to 4°C for at least 30 min. Then samples were filtered at 4°C through a 
double thickness of Gelman GFA filters (pre-soaked overnight at 4°C in 0.3% 
polyethylene immine (PEI)), using a Brandel cell harvester. Filters were washed 
3 times with ice cold PBS (150 mM NaCI, 8 mM K2H P04, 10 mM KH2P 04,
0.01% w/v NaN3; pH 7.4). Filter discs were then counted for radioactivity using 
a Packard 1600 Tricarb scintillation counter (efficiency ~ 45%) and liquid 
scintillation cocktail (Microscint™ 40, Packard Bioscience Company, Groningen, 
Netherlands).
3.3.2.3 [125l]aBungarotoxin binding
[125l]-a-bungarotoxin ([125l]aBgt) binding was carried out according to Whiteaker 
et al 2000 with some modifications. Membranes (final concentration 0.5 mg/ml) 
and [125l]aBgt (Amersham Biosciences, Buckinghamshire, UK; final 
concentration 10 nM) were diluted in 50 mM phosphate buffer (see section
3.3.2.1) supplemented with 0.1% BSA (final volume 100 pi). Non-specific 
binding was determined in the presence of 1 mM nicotine. Samples were
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incubated for ~3 h at 37°C. Then 1 ml of buffer was added to each tube, and 
samples were incubated for a further hour at 37°C. Samples were cooled to 4°C 
for at least 30 min before filtration through two layers of Gelman GFA filters 
(pre-soaked overnight at 4°C in 0.3% PEI and 4% milk powder, respectively), 
using a Brandel cell harvester. Filters were then washed and counted as 
described for [3H]epibatidine binding (see section 3.3.2.2). Counting efficiency 
for this assay was -60%.
3.3.2.4 Data Analysis
Data shown are means ± S.E.M for each group. Initially, a 2-way ANOVA 
(treatment x vaccination) was used to examine the data. Where significant 
differences were found, unpaired t-tests were performed to follow up.
3.3.3 Results
3.3.3.1 Sub-chronic intermittent nicotine administration (4 days)
As part of the locomotor experiments (see section 4.2.2.4), rats had been given 
daily injections of nicotine (0.5 mg/kg) or saline for 4 days. On day 5 all rats 
received a saline injection. After completing the last locomotor session, they 
were sacrificed and the brains harvested for radioligand binding. As a result, 
binding was effectively measured after one day of nicotine withdrawal.
r3H1epibatidine binding:
Non-specific binding accounted for -17%  of total [3H]epibatidine binding. For all 
four groups specific binding averaged around 1 0 0 -1 2 5  fmol/mg protein (see 
Figure 3.3 A). There was no evidence of upregulation of nicotinic binding sites 
after nicotine administration, although a small trend in this direction was 
observed in the groups immunised with TT-Cysteine (control vaccine). There 
were no significant differences in [3H]epibatidine binding levels between any of 
the treatment groups.
- 1 3 2 -
Chapter 3 -  Metabolite distribution & nicotine binding sites
Figure 3.3: Effects o f vaccination on [3H]epibatidine and [ 125l]-a-bungarotoxin
Rats were given a daily injection of nicotine (0.5 mg/kg) or saline for 4 days as part of 
locomotor experiments (see section 4.2.2.4). On day 5 all rats received saline; they 
were culled and brain membranes prepared.
Brain homogenates were incubated with 1 nM [3H]epibatidine (A; see section 3.3.2.2) 
or 10 nM (125l]a-Bungarotoxin (B) (see section 3.3.2.3) and specific binding determined
(expressed as fmol/mg protein).
Data shown are means ± S.E.M (n = 12).
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f125llaBat binding:
Non-specific binding accounted for ~63% of total [125l]aBgt binding. For all four 
groups specific binding was approximately 8 5 - 1 0 5  fmol/mg protein (see Figure
3.3 B). There was no sign of nicotinic binding site upregulation in any of the 
groups, and no significant differences were observed between any of the 
groups.
There are two possible explanations for the lack of upregulation of nicotinic 
binding sites: either the nicotine treatment schedule was not sufficient to cause 
upregulation of nAChRs, or any upregulation that had occurred could no longer 
be detected due to reversal of the effect during the one day of nicotine 
withdrawal. We therefore decided to look at [3H]epibatidine binding levels after a 
longer period of daily nicotine administration.
3.3.3.2 Chronic intermittent nicotine administration (15 days)
As part of the locomotor experiments in Trial 3 (see section 4.2.2.5), rats were 
injected daily with either nicotine (0.5 mg/kg) or saline for 15 consecutive days 
and were culled 5 min after receiving their final dose.
Non-specific binding accounted for -18.5%  of total [3H]epibatidine binding. For 
all four groups specific binding averaged around 1 7 0 -1 8 0  fmol/mg protein (see 
Figure 3.4).
Despite the longer exposure to nicotine compared to Trial 2, no significant 
nAChR upregulation was observed in the nicotine-treated groups, and there 
were no significant differences in [3H]epibatidine binding between any of the 
treatment groups (see Figure 3.4).
As daily nicotine injections did not appear to be sufficient to cause nAChR 
upregulation, we decided to examine [3H]epibatidine binding after chronic 
nicotine infusion.
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Figure 3.4: Effects o f vaccination on [3H]epibatidine binding after 15-day nicotine
treatment
200 i
Ctrl/Sal Ctrl/Nic Vacc/Sal Vacc/Nic
Rats were given daily nicotine (0.5 mg/kg) or saline injections as part of locomotor 
experiments for 15 days. Animals were culled 5 min after their last injection.
Brain homogenates were incubated with 1 nM [3H]epibatidine (see section 3.3.2.2) and 
specific binding determined (expressed as fmol/mg protein).
Data shown are means ± S.E.M (n = 6).
3.3.3.3 Chronic nicotine infusion (7-day OMP)
In Trial 5, rats received a chronic infusion of nicotine (3.16 mg/kg/day) for 7 
days via subcutaneous osmotic minipumps as part of the mecamylamine- 
precipitated nicotine withdrawal experiments (see section 4.5.2.3). Control rats 
were implanted with a "blank". Having completed the behavioural experiments, 
rats were perfused transcardially with PBS (see section 3.2.2.2.2) to enable the 
determination of brain nicotine and cotinine levels (see section 3.2) without 
blood contamination.
Non-specific binding accounted for -33% of total [3H]epibatidine binding. For 
both saline-treated groups (control and active vaccine) specific binding 
averaged around 200 fmol/mg protein (see Figure 3.5), while in the two 
nicotine-treated groups specific [3H]epibatidine binding levels were 
approximately 260 -  300 fmol/mg protein.
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Rats received a chronic infusion of nicotine (3.16 mg/kg/day) for 7 days via osmotic 
minipumps as part of the mecamylamine-precipitated nicotine withdrawal experiments 
(see section 4.5.2.3). Control rats were implanted with a "blank". After the behavioural 
experiments, rats were perfused transcardially with PBS (see section 3.2.2.2.2), and
brain homogenates prepared.
Brain homogenates were incubated with 1 nM [3H]epibatidine (see section 3.3.2.2) and 
specific binding determined (expressed as fmol/mg protein).
Data shown are means ± S.E.M (n = 6-8). * p<0.05, ** p<0.01
A 2-way ANOVA revealed a significant effect of nicotine treatment (p<0.0001), 
but no vaccine effect (p=0.7378). Unpaired t-tests revealed significant increases 
in [3H]epibatidine binding after nicotine treatment: specific binding was 
increased by 54% for the group immunised with TT-Cysteine (control vaccine; 
p=0.0011) and by 31% for the active vaccine group (TT-CotSH; p=0.0203), 
compared to their respective controls (see Figure 3.5). The differences between 
nicotine-treated control animals and those immunised against cotinine, 
however, were not significant.
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3.3.4 Discussion
Binding methods:
Radioligand binding on whole brain homogenates is a relatively quick and 
simple method used to examine the effect of nicotine administration on nicotinic 
binding sites. It provides an overall measure of the mean change in binding 
sites across the entire brain; however, it is not possible to determine whether 
such changes are uniform throughout the tissue or only restricted to certain 
brain structures. In order to build up a more detailed picture it is possible to 
perform binding studies on individual brain structures, although the small 
quantity of tissue obtained from an individual animal can be a limiting factor with 
this approach.
Autoradiography on brain sections is an alternative option, which can be used to 
define brain regions enriched (or depleted) in particular binding sites. This 
technique enables the systematic scanning of the entire brain for changes in 
binding sites and provides much greater resolution than radioligand binding on 
whole brain homogenates; however, it is also much more complex and time- 
consuming to perform, and even with this technique it not possible to determine 
cellular or subcellular localisation of binding sites.
Two main classes of nAChR have been identified in mammalian brain using 
receptor binding methods: one is selectively labelled by [125l]aBungarotoxin (see 
Figure 3.6) and correlates with the a7 homomeric subtype (Orr-Urtreger et al 
1997); the other has higher affinity for acetylcholine, nicotine, and cytisine 
(Nguyen et al 2003). There are several different subtypes of these high-affinity 
nAChRs: the major form is thought to be a4p2 (Flores et al 1992), of which 
multiple forms may exist based on variable stoichiometry or the inclusion of 
additional subunits such as a5. A second form closely resembles ganglionic 
nicotinic receptors, believed to be a3p4*. This subtype may also exist in several 
variations, with additional subunits or variable stoichiometry. A third subtype of 
high-affinity nAChRs consists of a heterogeneous mix of subunits: a6 (and/or 
a3) paired with p2 subunits, with the possible addition of p3 or a4 subunits in 
some cases (Le Novere et al 1999, Lena et al 1999, Quik et al 2000, Klink et al 
2001, Azam et al 2002, Champtiaux et al 2002, Whiteaker et al 2002, Marubio 
et al 2003).
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Figure 3.6: Binding affinities of nicotinic radioligands
Radioligand
Kd (nM)
a4p2* a l a3p4 a3p2*
[3H]nicotine 0.89-9 - - -
[3H]cytisine 0.15-0.96 - - -
[3H]epibatidine 0.011-0.086 - 0.306-4.9 0.013-0.14
[125l]aBgt - 0.4-1.66 - -
Binding affinities derived from saturation binding experiments on brain membranes /  
primary cultured neurones (a4(32 & a7) or heterologously expressed nAChRs. 
(adapted from Sharpies & Wonnacott 2001)
The alkaloid (±)-epibatidine (from the skin of the Ecuadorian frog Epipedobates 
tricolor) is a very high-affinity agonist at most nAChRs (see Figure 3.6; Parker et 
al 1998, Xiao et al 1998, Zoli et al 2002, Champtiaux et al 2003). After initially 
measuring both [3H]epibatidine and [125l]aBgt binding, we focussed on 
[3H]epibatidine binding as an indicator of nAChR upregulation, as epibatidine- 
binding nAChR subtypes are generally more readily upregulated than the a7 
receptor subtype. We used whole brain homogenates for the radioligand 
binding experiments, since epibatidine labels a number of nAChR subtypes, 
and any upregulation occurring was therefore likely to be widespread and 
readily detectable even in whole brain homogenates.
Upregulation after repeated daily injections of nicotine:
Chronic nicotine administration, by means of repeated injections or continuous 
infusion (i.v. or s.c.), has been shown to cause upregulation of nAChR 
(Wonnacott 1990). This increase in nAChRs by long-term nicotine 
administration in the rat may strongly depend on the dosage and mode of 
delivery of nicotine, as well as on the rat strain used (Parker et al 2004).
We did not observe any upregulation in [3H]epibatidine or [125l]Bgt binding sites 
after intermittent nicotine treatment by daily injection (0.5 mg/kg) for 4 days (see 
Figure 3.3 A & B). Ksir et al showed increases of 18 - 26% in [3H]acetylcholine 
binding levels in the cerebral cortex of rats injected subcutaneously with 
nicotine doses of 0.1 - 0.4 mg/kg/day (Ksir et al 1985). Several other groups
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have also shown that nAChRs are upregulated following repeated nicotine 
administration, however, these studies have utilised twice-daily (or more 
frequent) injections or a continuous infusion of nicotine (Wonnacott 1990). It 
seems likely that with our once-daily injection regime the plasma nicotine levels 
achieved were too low for most of the day to result in a measurable 
upregulation of receptors.
Examining a range of doses (0.6 - 4.8 mg/kg/day), Rowell & Li observed that 
with a twice-daily injection schedule, 2.4 or 4.8 mg/kg/day (total) for 10 days 
produced significant upregulation of [3H]cytisine binding sites in all brain areas 
examined (Rowell & Li 1997). Our dose of 0.5 mg/kg is much lower than this, 
and although we administered nicotine for 15 days (instead of 10) in our second 
experiment (see section 3.3.3.2), we did not observe any upregulation of 
[3H]epibatidine binding sites (see Figure 3.4). Jacobs et al found only a 
relatively small increase in binding by 15-25% in all brain areas examined, 
following administration of 2 mg/kg nicotine tartrate twice daily for 10 days 
(Jacobs et al 2002). It is therefore possible that the dose used in our first two 
studies was just not large enough to produce a substantial increase in binding 
sites.
Others have shown nicotine-induced nAChR upregulation using somewhat 
higher doses: twice daily injections of 1 mg/kg nicotine produced significant 
upregulation at 5 days, which increased further by 10 and 21 days (Schwartz & 
Kellar 1985). No change in binding was observed after just one day of nicotine 
administration. In rats treated with nicotine for 10 days, upregulation was 
significantly reduced, though still present, after 7 days of nicotine withdrawal.
Upregulation following chronic nicotine administration:
Mugnaini et al have shown that chronic infusion of rats with 3 mg/kg/day of 
nicotine for 14 days resulted in higher levels of [3H]nicotine binding in 11 out of 
15 brain regions analysed, but that [3H]MLA binding was increased in only 4 
regions (Mugnaini et al 2002). Using autoradiography, Nguyen et al observed a 
significant upregulation of a4p2-like binding in rat brain after chronic nicotine 
infusion for 14 days (6 mg/kg/day, s.c.), with relatively little effect on a3/a6p2- 
like and a3p4-like binding (Nguyen et al 2003). This upregulation also showed 
considerable regional variation across the 33 brain regions studied. These
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doses are somewhat higher than those used in our chronic infusion protocol; 
however Rowell & Li observed that chronic subcutaneous infusion of 2.4 or 4.8 
mg/kg/day of nicotine for 10 days resulted in a significant increase in 
[3H]cytisine binding sites in all 3 brain areas studied, whereas at their 1.2 
mg/kg/day dose, upregulation was only seen in the cortex. The doses used in 
this study were more comparable to ours, and the upregulation observed is 
largely in agreement with the increase in binding we observed at 3.16 
mg/kg/day for 7 days (see Figure 3.5).
Role of nAChR uprealation in nicotine dependence:
After an initial peak in nicotine levels following a subcutaneous injection, blood 
nicotine concentrations decline rapidly due to the short half-life of nicotine 
(Rowell & Li 1997), and the same is also true for a human smoking a cigarette 
(see Chapter 1). Initially, nicotine entering the blood stream activates nAChRs, 
but with prolonged exposure the receptors desensitise (see section 1.3.2), 
decreasing the impact of subsequent cigarettes smoked. Although it is not clear 
exactly how nAChR desensitisation is linked to receptor upregulation, it has 
been hypothesised that nAChRs are turned over in the cell membrane more 
slowly when they are in a desensitised conformation, leading to an overall 
increase in the number of receptors in the cell membrane (Dani & De Biasi 
2001). When nicotine is removed from the brain, for example by overnight 
abstinence, the receptors recover from desensitisation, resulting in an excess of 
excitable receptors available for stimulation. This hyperexcitability is thought to 
contribute to the nicotine withdrawal symptoms experienced by smokers 
attempting to quit. After a night of abstinence, nicotine from the first cigarette is 
able to activate the re-sensitised receptors, stimulating dopamine release in the 
reward circuitry (see Chapter 1), which provides further reinforcement. By 
continued smoking, more and more of the excess nAChRs are gradually 
desensitised towards a more "normal" level of active receptors (Dani & De Biasi
2001). This could explain why smokers often consider the first cigarette of the 
day the most pleasurable (Russell 1989).
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Effect of vaccination against cotinine:
Cotinine is thought to antagonise the actions of nicotine through its weak 
agonist activity at nAChRs. Vaccination against cotinine should remove this 
antagonism by raising antibodies that bind cotinine and prevent it from entering 
the brain. This should lead to a potentiation of nAChR upregulation in nicotine- 
treated animals, resulting in upregulation at relatively low nicotine doses, which 
do not usually produce upregulation, or a general increase in levels of 
upregulation observed in vaccinated rats treated with nicotine, compared to the 
control vaccinated nicotine-exposed group. However, we did not observe any 
effect of vaccination on the upregulation of [3H]epibatidine binding sites after 
chronic nicotine exposure (see Figure 3.5), the only treatment schedule that 
produced upregulation in the nicotine-treated groups. It is possible that higher 
anti-cotinine antibody titres than those achieved in our studies (see Figure 2.10) 
are required to produce a measurable effect on nAChR upregulation.
3.4 Chapter conclusions
Having established that immunisation with TT-CotSH resulted in the production 
of cotinine-specific antibodies, we went on to look at whether these anti-cotinine 
antibodies could impact on the distribution of cotinine in rats.
Nicotine and cotinine levels in both brain and blood were dependent on the 
dose of nicotine administered. Anti-cotinine vaccination had no impact on 
nicotine concentrations measured in plasma or brain, providing further evidence 
for the specificity of the antibodies raised in response to vaccination. We were 
able to demonstrate a significant increase in plasma cotinine levels in animals 
immunised against cotinine, compared to controls, after both intermittent and 
continuous nicotine administration. This supports the hypothesis that anti- 
cotinine antibodies retain cotinine in the bloodstream and prevent it from 
crossing the blood-brain-barrier. Although we also observed an increase in the 
level of brain cotinine in the vaccinated group in our first study, this was most 
likely due to contamination of the brain samples with blood during dissection. By 
perfusing rats prior to dissection for the second study, the likelihood of
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contamination was reduced and the brain cotinine levels of vaccinated and 
control groups were no longer significantly different.
Since prolonged administration of nicotine has been shown to result in 
upregulation of nAChRs, we also examined whether removing the antagonism 
by cotinine through immunisation would have any effect on receptor 
upregulation, as measured by radioligand binding.
We did not observe any significant increase in [3H]epibatidine or [125l]aBgt 
binding levels as a result of intermittent administration of nicotine for 4 or 15 
days, possibly due to the low dose of nicotine used compared to some other 
studies. However, chronic infusion of nicotine (3.16 mg/kg/day) for 7 days did 
lead to a significant upregulation of nicotinic receptors. Immunisation against 
cotinine should have enhanced the level of nAChR upregulation as a 
consequence of removing cotinine-mediated antagonism of nicotine's actions; 
however no vaccine effects were observed. This may have been due to the low 
anti-cotinine antibody titres achieved in Trial 5 as a result of an error in the 
labelling of conjugate vials (see Chapter 2).
Upregulation of nAChRs has been shown to occur in human smokers (Benwell 
et al 1988, Breese et al 1997, Perry et al 1999) and appears to be dose- 
dependent, as there is a positive correlation between the level of upregulation 
and the number of packs of cigarettes smoked per day. This indicates that the 
increase in nicotinic binding sites is related to the blood and brain 
concentrations of nicotine achieved during smoking.
It has been hypothesised that having an increased number of nAChRs may lead 
to heightened or abnormal potentiation of ordinary synaptic activity during times 
of abstinence, contributing to the agitation and discomfort of withdrawal 
symptoms, which often cause abstinent smokers to relapse. NRT aims to 
provide a low level of nicotine to help alleviate such withdrawal symptoms, so 
reducing the antagonism by cotinine through cotinine-specific antibodies (as a 
result of vaccination) should make NRT more effective.
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In summary we have shown that, as a consequence of anti-cotinine vaccination, 
cotinine is sequestered in the blood and prevented from entering the brain by 
cotinine-specific antibodies, without affecting the distribution of nicotine. The 
removal of cotinine-mediated antagonism in this manner should enhance the 
effects of nicotine, here measured in terms of upregulation of nAChR after 
prolonged nicotine administration. Whilst we were able to demonstrate 
upregulation of nicotinic receptors after chronic nicotine treatment, the low 
antibody titres achieved in this trial prevented us from ruling out any vaccine- 
related effects on binding levels.
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Chapter 4
Effects of vaccination on behavioural measures of 
nicotine dependence
4.1 Chapter Introduction
Addiction is a complex behavioural phenomenon with causes and effects 
ranging from molecular mechanisms to social interactions. Over time, the initial 
molecular interactions, which alter the activity and metabolism of neurons 
sensitive to the drug, lead to changes in the properties of individual neurons and 
circuits, resulting in the expression of complex behaviours such as dependence, 
tolerance, sensitisation, and craving (Mansvelder & McGehee 2002, Laviolette 
& van der Kooy 2004).
As discussed in Chapter 3, physiologically relevant nicotine concentrations have 
been shown to upregulate a4|32* receptors (Schwartz & Kellar 1985, Flores et al 
1992, Buisson & Bertrand 2001). In correlation with this upregulation of nicotinic 
binding sites following nicotine pre-exposure, several laboratories have also 
reported increases in various functional and behavioural responses (Ksir et al 
1987, Clarke et al 1988, Rowell & Wonnacott 1990, Yu & Wecker 1994, Buisson 
& Bertrand 2001). For example, pre-exposure to nicotine appears to sensitise 
rats to its locomotor and self-administration effects (Clarke & Kumar 1983, 
Walter & Kuschinsky 1989, Shoaib et al 1997), and upregulation of nicotinic 
binding sites has been reported after nicotine self-administration (Donny et al
2000).
Reinforcing and subjective stimulus effects of nicotine 
Nicotine is known to elicit rewarding effects (positive reinforcement) in humans 
and other species, and stimulus properties of nicotine are thought to control 
nicotine-taking behaviour in both humans and laboratory animals (Stolerman & 
Shoaib 1991, Rose & Corrigall 1997). The reinforcing stimulus effects of 
nicotine can be assessed using the intravenous self-administration technique 
(see section 4.3). This is considered to be the animal model of nicotine-taking 
behaviour that comes closest to the situation of the human smoker, because of
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the pattern of nicotine administration (frequent small doses) and the fact that 
nicotine intake is "voluntary1 and based on the positive reinforcing effects of the 
drug. The technique is therefore frequently used for studying tobacco 
dependence and evaluating potential anti-smoking medications (Rose & 
Corrigall 1997).
The ability to perceive and identify the subjective effects of a drug is considered 
important in addiction, as it encourages the development of drug-seeking 
behaviour and directs it towards one substance rather than another. It is widely 
believed that humans abuse psychoactive drugs in order to obtain their 
characteristic subjective effects (Stolerman & Shoaib 1991).
Like many addictive drugs, nicotine also has potent, aversive, unpleasant 
effects, with many smokers experiencing noxious effects such as nausea, 
coughing and dizziness on their initial exposure to tobacco. However, with 
repeated exposure to the drug, tolerance to these aversive effects develops 
(Laviolette & van der Kooy 2004). Aversive stimulus effects of nicotine are often 
examined using conditioned taste aversion procedures (see section 4.4), where 
rats learn to avoid a flavoured solution when its consumption is previously 
paired with administration of nicotine (Kumar et al 1983, Iwamoto & Williamson 
1984). Aversive effects have been implicated in the regulation of nicotine intake, 
and may play a role in setting an upper limit to the amount consumed (Shoaib et 
al 2003).
Behavioural sensitisation to the effects of nicotine 
Neurochemical aspects: Nicotine has the ability to enhance basal neuronal 
firing and/or basal transmitter release in the mesolimbic dopamine pathway, as 
do other drugs of abuse (Andreoli et al 2003). Adaptations occurring in brain 
reward circuits as a result of excessive stimulation are thought to contribute to 
the development of the compulsive drug use, which characterises addiction. 
Upregulation of nAChRs and sensitisation of dopamine release in the striatum 
are two examples of adaptations occurring in the brain as a consequence of 
prolonged exposure to nicotine, which are discussed in more detail in Chapters 
2 & 3.
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Environmental context: Environmental or contextual stimuli can become 
associated with the effects of nicotine if exposure to the drug is repeatedly 
paired with such “conditioned stimuli” (Bevins & Palmatier 2003). Over time 
these conditioned stimuli can come to control responses related to drug 
seeking, withdrawal, and dependence.
In animals pre-treated with nicotine, sensitisation to the effects of a subsequent 
nicotine challenge on locomotor activity (see section 4.2) and nucleus 
accumbens dopamine release has been observed. However, this sensitisation 
appears to be more pronounced in animals that were repeatedly administered 
the drug in the testing environment during nicotine pre-treatment, suggestive of 
an emerging association between the conditioned stimulus (context) and drug 
effects (Walter & Kuschinsky 1989, Reid et al 1996, Bevins et al 2001). Stimuli 
associated with nicotine self-administration have also been shown to reinstate 
nicotine seeking in rats (Liu et al 2006).
Such associative learning is thought to resemble the strong associations 
smokers develop between environmental cues associated with the act of 
smoking and the reinforcing effects of nicotine (Stolerman & Shoaib 1991, Geier 
et al 2000, Laviolette & van der Kooy 2004). Such smoking-related 
environmental stimuli, including the sight, smell and taste of cigarettes, contexts 
in which smoking occurred, or behaviours that frequently accompanied smoking 
(handling a cigarette, for example), have been implicated as an important factor 
in triggering relapse in abstinent tobacco smokers (Balfour et al 2000, Caggiula 
et al 2001, Liu et al 2006).
Effects of nicotine abstinence/withdrawal
Positive reinforcement plays a major role in the acquisition and routine 
maintenance of nicotine self-administration, both in smokers and in animal 
models. During nicotine withdrawal, for example during a quit attempt in 
smokers, a nicotine abstinence syndrome develops, with typical symptoms 
including irritability, anxiety, depression, difficulty concentrating, and craving for 
tobacco (Malin 2001). An equivalent nicotine abstinence syndrome has also 
been studied in rodents rendered nicotine-dependent by means of continuous 
nicotine infusion; abstinence is induced by termination of the infusion 
(spontaneous abstinence) or through the administration of a nicotinic
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antagonist, such as mecamylamine (mecamylamine-precipitated withdrawal, 
see section 4.5). The resulting symptoms of nicotine withdrawal can be 
alleviated by administration of nicotine. This mirrors the human situation, where 
smoking serves as a "negative reinforcer" by providing relief from the aversive 
state, which explains why the desire to alleviate the discomforts of tobacco 
withdrawal is the most commonly cited reason for relapse during a smoking quit 
attempt (Malin 2001).
Nicotine replacement therapy (NRT) reduces the severity of withdrawal 
symptoms and cravings by providing a continuous low-dose infusion of nicotine. 
It can approximately double the success rate of a quit attempt, and is the most 
commonly used medication for smoking cessation (Schneider et al 2001, 
Hughes 2003, Foulds et al 2004). However, even with NRT, the majority of quit 
attempts are still unsuccessful. The anti-cotinine vaccine studied in this thesis is 
aimed at making NRT more effective by removing or reducing any cotinine- 
mediated antagonism of nicotine's actions.
In this chapter we studied the effects of anti-cotinine vaccination on a wide 
variety of behavioural effects of nicotine. In an attempt to cover as many 
aspects of nicotine addiction and smoking cessation as possible, we utilised 
animal models of drug-taking, drug-seeking, and drug-withdrawal behaviour, as 
well as examining locomotor depressant/stimulant properties of nicotine, its 
reinforcing and subjective stimulus effects, and the role of environmental stimuli 
on nicotine-induced behavioural measures.
4.2 Effects of anti-cotinine vaccination on nicotine-induced &
conditioned locomotor activity
4.2.1 Introduction
Effects of acute nicotine on locomotor activity
In experimentally naive rats, systemic nicotine administration produces a 
decrease followed by an increase in locomotor activity in a dose-dependent 
manner (Clarke & Kumar 1983, Ksir et al 1987, Walter & Kuschinsky 1989, 
Bevins et al 2001, Bevins & Palmatier 2003). Both the initial reduction and the 
increase in locomotor activity are blocked by administration of the centrally
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active, non-selective nicotinic antagonist mecamylamine in a dose-related 
manner (Clarke & Kumar 1983, Walter & Kuschinsky 1989).
Dopaminergic reward pathways (see Chapter 1) appear to play a major role in 
the effects of nicotine on locomotor activity: administration of nicotine directly 
into the VTA has been shown to enhance locomotor activity in rats, as well as 
increasing accumbal dopamine release, whereas injection directly into the NAcc 
also increased accumbal dopamine output, but had no effect on locomotion 
(Ferrari et al 2001). Further evidence for the involvement of dopaminergic 
pathways in nicotine-induced locomotor activity comes from lesion studies, 
which have found that lesions of mesolimbic DA neurons attenuate the 
locomotor stimulant properties of nicotine (Benwell & Balfour 1992, Louis & 
Clarke 1998).
Effects of chronic nicotine on locomotor activity 
Chronic nicotine treatment produces tolerance to the initial locomotor 
depressant effects and sensitisation to the subsequent locomotor stimulatory 
effects of nicotine in rats (Clarke & Kumar 1983, Ksir et al 1987, Clarke et al 
1988, Walter & Kuschinsky 1989, Vezina et al 1992, Shoaib & Stolerman 1992, 
Whiteaker et al 1995, Reid et al 1996, Bevins et al 2001), with tolerance to the 
depressant effects persisting for at least 3 weeks (Clarke & Kumar 1983). 
Sensitisation to the locomotor stimulant effects of nicotine can be observed after 
as few as 5 days of nicotine pre-treatment (Ksir et al 1985 & 1987, Reid et al 
1996), and is dose-dependent. The locomotor response to a 0.2 mg/kg 
challenge dose of nicotine did not differ from saline controls in rats pre-treated 
with 0.1 mg/kg/day nicotine for 5 days, but groups pre-treated with higher doses 
showed increased stimulation of locomotor activity in response to the same test 
dose. Pre-treatment with 0.2 mg/kg for the same time period shifted the bell­
shaped dose-response curve to a nicotine challenge (0.1 -  1.6 mg/kg) upwards, 
so that greater stimulation was observed at each test dose after nicotine 
exposure, compared to baseline activity in response to the test dose measured 
prior to the 5 day pre-treatment (Ksir et al 1987). The enhanced locomotor 
activity resulting from 5 days of nicotine administration (0.2 mg/kg) was even 
observed after 7 days of withdrawal, but had returned to saline levels after 21 
days (Ksir et al 1985). Sensitisation to the locomotor stimulant effect of an acute
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nicotine challenge (0.2 mg/kg) was also seen after subcutaneous infusion of 
nicotine (1.5 mg/kg/day) by osmotic minipump for up to 14 days (Fung & Lau 
1988).
Effects of conditioning on nicotine-induced locomotor activity 
This sensitisation to a nicotine challenge observed in nicotine-treated rats in 
terms of both locomotor activity and nucleus accumbens dopamine release, 
appears to be more pronounced in rats that are conditioned to the testing 
environment during nicotine pre-treatment (Walter & Kuschinsky 1989, Reid et 
al 1996, Bevins et al 2001). Pavlovian conditioning is thought to be involved in 
this process, where rats are placed in a distinct environment reliably paired with 
nicotine administration (Bevins et al 2005). The context alone (no nicotine 
during testing) comes to evoke an increase in activity relative to controls, which 
is thought to reflect a learned association between the context and the 
psychomotor stimulant effects of nicotine. Walter & Kuschinsky (1989) found 
evidence for nicotine-conditioned locomotor activity after 6 pairings of a distinct 
context with nicotine (0.6 mg/kg) administration, as did Reid and colleagues 
(Reid et al 1996). Bevins and colleagues (Bevins et al 2001) showed a 
significant conditioning effect after 8 conditioning trials with daily 0.6 and 1.2 
mg/kg nicotine (tartrate) injections (highest dose equivalent to -0 .4  mg/kg 
base). They did not, however, see a significant effect of conditioning in their 
lowest nicotine treatment group (0.3 mg/kg tartrate).
Smokers have also been observed to develop strong associations between 
environmental cues associated with smoking and the reinforcing effects of 
nicotine (Stolerman & Shoaib 1991, Geier et al 2000, Laviolette & van der Kooy 
2004). Such smoking-related environmental stimuli might include the sight, 
smell and taste of cigarettes, a context in which smoking frequently occurred, or 
other behaviours that frequently accompanied smoking. These environmental 
cues have been implicated as an important factor in triggering relapse in 
abstinent tobacco smokers (Balfour et al 2000, Caggiula et al 2001, Liu et al 
2006).
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As with other psychomotor stimulant drugs, such as cocaine, nicotine 
administration induces an increase in locomotor activity in rodents, which is 
enhanced by conditioning to the test environment. Such locomotor conditioning 
experiments can act as a preclinical model for associative learning processes in 
human smokers (Bevins et al 2005), and provide a useful starting point for 
determining the effect of anti-cotinine vaccination on behavioural effects 
induced by nicotine.
We therefore studied the effects of acute and chronic nicotine administration on 
locomotor activity, as well as the role of environmental stimuli in the expression 
of these behavioural effects, and examined the impact of anti-cotinine 
vaccination on nicotine-induced responses.
Trials 1 - 3  were carried out at Bath University, while Trials 4 & 5 were 
performed at the University of Newcastle-upon-Tyne (see table in section
2.3.2.3 for details of which experiments were part of which trial).
4.2.2 Methods
4.2.2.1 Apparatus & data collection
Bath apparatus
Spontaneous activity of individual rats was measured using an in-house 
locomotor activity monitoring system consisting of 24 clear Perspex cages (40 
cm (long) x 24 cm (wide) x 20 cm (high)) and cage surrounds containing 
infrared photocell beam monitors. Any movement of the rats interrupted the 
photo beams, which was detected and recorded by a PC. Locomotor activity 
counts were collected at 5 min intervals.
Newcastle apparatus
Spontaneous activity of individual rats was measured using infrared photocell 
beam monitors (Multi-Varimax, Columbus Instruments, Columbus, U.S.) and 4 
experimental boxes, with box dimensions of 40 cm (long) x 40 cm (wide) x 30 
cm (high). Any movement of the rats interrupted the photo beams, which was 
detected and recorded by a PC. Locomotor activity counts were collected at 10 
min intervals.
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4.2.2.2 Conditioned locomotor activity after 4-day nicotine treatment 
-  un-vaccinated pre-trial
Twenty four unvaccinated male Sprague-Dawley rats were used to examine 
locomotor activity induced by acute administration of nicotine or saline. The 
locomotor activity cages were also used as conditioning compartments. These 
experiments were undertaken at Bath University.
Rats were allocated to one of 4 treatment conditions (n = 6 per group): 2 paired 
groups (nicotine & saline), and 2 unpaired groups (nicotine & saline). During the 
conditioning phase, rats were injected with either saline or nicotine (0.5 mg/kg, 
s.c.) and then immediately placed in a locomotor activity cage (paired 
environment). Control, unconditioned animals received saline or nicotine (0.5 
mg/kg, s.c.) in their home cages, 3 h before being placed into the locomotor 
activity cages (unpaired environment). Locomotor activity was monitored for 45 
min and recorded in 5 min time bins. All animals were acclimatised to the 
locomotor activity room for 30 min before starting the session. This was 
repeated once a day for 4 days.
The test phase was conducted as the conditioning phase, except that all rats 
were given a saline injection, including those that had received nicotine during 
the conditioning phase. Thus, during the test phase, the locomotor activity was 
induced by saline or nicotine-associated cues only. All experiments were carried 
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4.2.2.3 Conditioned locomotor activity after 4-day nicotine treatment 
-  vaccinated pre-trial
Thirty vaccinated male Sprague-Dawley rats from the adjuvant optimisation 
experiments (Trial 1, Bath Uni; see section 2.3.2.3.1) were used for this 
preliminary assessment of the effect of vaccination on locomotor activity 
induced by acute nicotine administration.
Rats were allocated to one of 4 groups: 2 groups were vaccinated with TT- 
CotSH, and 2 with TT-Cysteine (n = 8 for the nicotine groups, n = 7 for the 
saline groups). Locomotor activity under the paired condition was examined as 
described in section 4.2.2.2, so all rats received their injections just prior to 
being placed in the test cages for locomotor activity measurement. All 
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4.2.2.4 Conditioned locomotor activity after 4-day nicotine treatment
Ninety six vaccinated male Sprague-Dawley rats (Trial 2, Bath Uni; see section 
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Locomotor activity induced by acute nicotine or saline was examined as 
described above (see section 4.2.2.2). However, although this set of 
experiments was also carried out during the rats' light phase, this time the room 
containing the locomotor equipment was not lit.
On the final day (test day), results for one run were lost due to the computer 
crashing whilst recording. This resulted in a group size of n = 9 for the test day, 
instead of n = 12.
4.2.2.5 Conditioned locomotor activity over 12-day nicotine treatment
The protocol for these experiments was based on a paper by Kosowski and 
Liljequist (2005), with minor alterations. Forty eight vaccinated male Sprague- 
Dawley rats (Trial 3, Bath Uni; section 2.3.2.3.3J were allocated one of 4 
treatment conditions (n = 12 per group): 2 groups vaccinated with TT-CotSH 
(saline vs nicotine), and 2 groups vaccinated with TT-Cysteine (saline vs 
nicotine).
Rats were injected subcutaneously with saline (1 ml/kg) and immediately placed 
in a locomotor activity cage for 30 min. Rats were then given an injection of 
either saline or nicotine (0.5 mg/kg, s.c.) and returned to their locomotor activity 
cage for a further 60 min. Locomotor activity was recorded throughout the 90 
min sessions in 5 min time bins. This was done once daily for 12 days. 
Unfortunately, data for 4 saline rats could not be obtained due to malfunctioning 
locomotor cages, resulting in slightly lower numbers for the saline groups (n =
12 for nicotine groups, n = 10 for saline groups). These rats were however 
included in the experiment (even if locomotor data was not being generated), in 
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4.2.2.6 Locomotor activity induced by acute nicotine administration
After completion of the conditioned taste aversion experiments at the University 
of Newcastle (see section 4.4), the 32 vaccinated male hooded Lister rats (16 
vaccinated with TT-CotSH, 16 with TT-Cysteine) were housed in their original 
groups of 4 again, and their locomotor activity in response to acute injections of 
saline and nicotine examined.
Every second day, rats were injected subcutaneously with saline, 0.1 mg/kg 
nicotine, or 0.4 mg/kg nicotine, and immediately placed in a locomotor activity 
box. Drug treatments were administered in a randomised order, with 48 hours 
between individual treatments to allow any residual drug to be fully metabolised 
and excreted before the next session. Each animal was tested once in each 
condition. Locomotor activity was recorded in 10 min time bins for 90 min under 
each condition.
4.2.2.7 Data analysis
Data are presented as means (± S.E.M), and expressed as distance travelled in 
discrete units per 5 or 10 min intervals, or as the area under the curve (AUC) for 
a given period of time. Data were analysed using ANOVA (two-way or three- 
way, depending on the experiment) with repeated measures as needed, and 
followed by Bonferroni's post hoc analysis.
4.2.3 Results
4.2.3.1 Effects of pairing of drug and environment on locomotor
activity after 4-day nicotine treatment -  un-vaccinated pre­
trial
Initially we studied a small cohort on unvaccinated rats to establish testing 
procedures and examine effects of treatment, as well as pairing of treatment 
with the test, on nicotine-induced responses. The results of this pre-trial are 
illustrated in Figure 4.1. The raw data for each day and the area under the curve 
for each 45 min session (AUC45) were analysed using a two-way ANOVA (with 
repeated measures for the raw data), followed by Bonferroni's post-hoc 
analysis.
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Locomotor activity in all groups decreased gradually over the course of each 45 
min session, which was reflected in a significant effect of time (p < 0.0001) 
throughout the 5-day experiment. Both nicotine treatment and pairing of nicotine 
administration with the test environment resulted in an increase in locomotor 
activity:
Acute administration of nicotine (0.5 mg/kg, s.c.) initially resulted in a slight 
reduction of locomotor activity (see Figure 4.1 A), which was more marked in 
rats whose injections were paired with the locomotor test cage. The analysis for 
day 1 revealed only effects of time x pairing (F(time x pairing)efi6o = 3.074, p = 
0.0030) and time x treatment (F(time x treatment)a,i6o = 7.261, p < 0.0001).
Over the following days (see Figure 4.1 B - D), an increase in locomotor activity 
was observed in the paired nicotine group, which became more pronounced 
from one day to the next. This effect was even observed, though to a much 
lesser extent, on day 5 (see Figure 4.1 E), when all groups were injected with 
saline to test for conditioning effects. The initial increase in activity found in the 
paired saline group was not as robust or as long lasting as that seen in 
response to nicotine administration.
These observations were reflected in the results of the statistical analysis: on 
day 2 (see Figure 4.1 B), a significant main effect of pairing appeared 
(F(pairing)i,2o = 21.154, p = 0.0002), which persisted until day 5. A significant 
main effect of pairing x treatment was seen on day 3 (F(pairing x treatment^>2o 
= 6.686, p = 0.0177; see Figure 4.1 C), which was still present on day 4 (see 
Figure 4.1 D), when a significant effect of treatment was also observed 
(F(treatment)ii2o = 18.358, p = 0.0004). Neither of the latter effects was seen on 
day 5 (see Figure 4.1 E).
Similar results were obtained when examining the area under the curve for each 
day: there were no significant main effects on day 1, whereas significant main 
effects of pairing, pairing x treatment, and treatment were observed on days 2 -  
5, 3 -  4, and day 4, respectively (see Figure 4.1 F).
Having observed a significant increase in locomotor activity as a result of 
pairing nicotine injections with the test environment, we studied the effect of 
anti-cotinine vaccination on nicotine-induced hyperlocomotion.
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F) Area under the curve for each 45 min session (AUC45); *p<0.05, ***p<0.001, 
****p<0.0001 (Day 5: significant effect of treatment, but not treatment x pairing) 
Unvaccinated rats were administered nicotine (0.5 mg/kg, s.c.) or saline for 4 days, 
either in the locomotor activity cage (paired) immediately before, or in their homecage 
(unpaired) 3 h prior to measurement of locomotor activity for 45 min. On day 5 all rats 
were injected with saline to test for conditioning effects. Movement was detected by 
means of infrared beams in the cage surround.
Data presented are mean ± S.E.M, n = 6 per group.
4.2.3.2 Effects of vaccination on locomotor response after 4-day 
nicotine treatment -  vaccinated pre-trial
For the second pre-trial we utilised the remaining vaccinated animals from Trial 
1 (see section 2.3.2.3.1), in order to focus on the effects of anti-cotinine 
vaccination on nicotine-induced locomotor responses. Data analysis was 
performed as described in section 4.2.3.1, and the results are illustrated in 
Figure 4.2.
Again, locomotor activity in all groups decreased gradually over the course of 
each 45 min session (see Figure 4.2 A - D), and the effect of time was highly 
significant throughout (p < 0.0001). Nicotine-induced locomotor hyperactivity 
was observed from day 2 onwards, with a significant effect of treatment (saline 
vs nicotine) appearing on day 2 and persisting until day 4 (p < 0.0001 
throughout). There was no significant effect of treatment x vaccination (see 
Figure 4.2 A - E), however, on day 5 (see Figure 4.2 E) a significant effect of 
vaccination (control vs active) alone was observed (F( vaccination^ j26 = 4.935, p 
= 0.0352).
The analysis of the area under the curve over 45 min yielded similar results 
(see Figure 4.2 F), with no significant effects on day 1, a significant main effect 
of treatment (p < 0.0001) on days 2 - 4 ,  and a small but significant main effect 
of vaccination on day 5 (F(vaccination)ii26 = 4.721, p = 0.0391).
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Figure 4.2: Effects of vaccination on nicotine-induced locomotor activity
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vaccination (control vs active) between nicotine-treated groups: fp<0.05, ffp<0.01; 
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***p<0.001
-159-
Chapter 4 -  Behavioural measures of nicotine dependence
Immunised rats were administered nicotine (0.5 mg/kg, s.c.) or saline for 4 days, in the 
locomotor activity cage immediately before measurement of locomotor activity for 45 
min. On day 5 all rats were injected with saline to test for conditioning effects. 
Movement was detected by means of infrared beams in the cage surround.
Data presented are mean ± S.E.M, n = 8 (nicotine) or 7 (saline) per group.
4.2.3.3 Effects of pairing and vaccination on locomotor activity after 
4-day nicotine treatment
For the full trial we divided the 96 rats, immunised with either TT-Cysteine or 
TT-CotSH, into 8 groups to examine not just the effect of vaccination against 
cotinine, but also pairing of the nicotine/saline treatment with the test 
environment.
Differences between groups were greatest in the first 15 min, so the area under 
the curve for the first 15 min (AUC15) was analysed by three-way ANOVA, 
followed by Bonferroni's post-hoc analysis.
Locomotor activity in all groups decreased gradually over the course of each 30 
min session (see Figure 4.3 A), and the main effect of time was highly 
significant throughout (p < 0.0001). Both nicotine treatment and pairing of the 
test environment with nicotine administration resulted in enhanced locomotor 
activity, whilst vaccination against cotinine displayed a tendency to further 
increase activity levels:
Examining the AUC15 (see Figure 4.3 B - F), significant interactions of 
vaccination, treatment and pairing (F(vaccination x treatment x pairing)^ = 
7.804, p = 0.0065), and treatment with pairing (F(treatment x pairing)i>84 =
6.670, p = 0.0115) were found on day 1. Main effects of treatment 
(F(treatment)ii84 = 5.616, p = 0.0201) and pairing (F(pairing)ii84 = 12.443, p = 
0.0007) appeared on day 2 and persisted until day 4, and a significant 
interaction of treatment with pairing was also observed on days 3 & 4 (F(pairing 
x treatment^ ,84 = 14.365, p = 0.0003 and F(pairing x treatm ent)^ = 10.418, p = 
0.0018, respectively). The effect of pairing remained significant on day 5 
(F(pairing)i,84 = 6.619, p = 0.0125) and the treatment effect was very close to 
significant (p = 0.0506). A three-way interaction on day 3 was also close to 
significant (F(vaccination x treatment x pairing)ii84 = 3.852, p = 0.0530), and in 
addition, a significant main effect of vaccination was observed on day 4 
(F(vaccination)i,84 = 4.324, p = 0.0406).
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Figure 4.3: Effects o f pairing and vaccination on nicotine-induced locomotor
activity
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Vaccinated rats were administered nicotine (0.5 mg/kg, s.c.) or saline for 4 days, either 
in the locomotor activity cage (paired) immediately before, or in their homecage 
(unpaired) 3 h prior to measurement of locomotor activity for 30 min. On day 5 all rats 
were injected with saline to test for conditioning effects. Movement was detected by 
means of infrared beams in the cage surround.
Data shown are area under the curve for the first 15 min (AUC15), mean ± S.E.M, 
n - 1 2  (A-E) or 9(F) per group; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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4.2.3.4 Effects of vaccination on locomotor activity over 12-day
nicotine treatment
Having looked at the effects of sub-chronic nicotine administration (daily 
nicotine injections for 4 days, followed by saline on the testing day, see above), 
we chose to study the effects of longer-term daily injections of nicotine (for 12 
days) to assess whether more prolonged exposure to nicotine would result in a 
greater increase in locomotor activity and a more significant conditioning effect 
of environmental cues.
The sum of activity (distance travelled) per day over the 12-day period for the 
pre-treatment and post-treatment phases is illustrated in Figures 4.4 A and B, 
respectively, and was analysed using a two-way ANOVA with repeated 
measures, and Bonferroni's post-hoc test. The area under the curve (AUC) for 
each group over the 12-day period was also plotted for both pre-treatment and 
post-treatment phases (see Figure 4.4 C), and analysed by two-way ANOVA 
and Bonferroni's post-hoc analysis.
Each day, the locomotor activity in all groups gradually declined over the course 
of the pre-treatment phase (data not shown). A reduction in locomotor activity 
levels was also observed from one day to the next until a plateau was reached 
around day 3 (see Figure 4.4 A). This effect was greater in the groups receiving 
nicotine during the treatment phase, than in those receiving saline 
(F(treatment)ii4o = 14.508, p = 0.0005). Examination of the area under the curve 
for each group (see Figure 4.4 C) revealed a significant effect of drug treatment 
(F(drug)i,4o = 17.858, p = 0.0001). The effect of time was also highly significant 
throughout (p < 0.0001).
Over the course of the post-treatment phase, locomotor activity in the groups 
injected with saline again decreased over time (each day), whilst in the groups 
that had received nicotine injections, activity increased over the initial 15 min 
post-injection until a plateau was reached, usually around 20 -  30 min (data not 
shown). Levels of overall activity in the saline-treated groups remained relatively 
constant over the 12-day experiment, whereas activity of nicotine-treated 
groups gradually increased from day to day (see Figure 4.4 B). This resulted in 
a highly significant main effect of treatment (F(treatment)i,4o = 227.637, p < 
0.0001) over the 12 day period, which was repeated in the comparison of AUC
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(F(treatment)i,4o = 217.461, p < 0.0001; see Figure 4.4 C). The effect of time 
was also highly significant throughout (p < 0 .0001).
Figure 4.4: Effect o f vaccination on locomotor activity over 12-day nicotine
treatment
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P r e - t r e a t m e n t P o s t - t r e a t m e n t
1 2 3 4  5 6 7 8 9 10 11 12
Time (Day)
A) Locomotor activity during the pre­
treatment phase over the 12-day 
experiment
B) Locomotor activity during the 60 min 
post-treatment phase over the 12-day 
experiment 
Treatment effect (saline vs nicotine) 
between rats immunised against 
cotinine: *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
Treatment effect (saline vs nicotine) between rats immunised with TT-Cysteine: 
+p<0.05, ++p<0.01, +++p<0.001, ++++p<0.0001; Vaccination effect (active vs control) 
between nicotine-treated rats: $ p<0.05 
C) Area under the curve (AUC) for A & B; *p<0.05, **p<0.01, ****p<0.0001 
Vaccinated rats were injected with saline (1 mi/kg, s.c.) and placed in a locomotor 
activity cage for 30 min (pre-treatment phase). They were then given another injection 
of either nicotine (0.5 mg/kg, s.c.) or saline, and locomotor activity measured for a 
further 60 min (post-treatment phase). This procedure was repeated for 12 days. 
Movement was detected by means of infrared beams in the cage surround.
Data presented are mean ± S. E.M, n = 12 (nicotine) or 10 (saline) per group.
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Vaccination against cotinine tended to further increase nicotine-induced 
locomotor activity; however, a significant effect of vaccination was only found 
(post-treatment) on day 6 (F(vaccination)ii4o = 4.703, p = 0.0361) and a trend 
towards a vaccination effect was also observed on day 4 post-treatment 
(F(vaccination)ii40 = 3.637, p = 0.0637). In addition, a significant interaction 
between time and vaccination was seen post-treatment on day 4 (F(time x 
vaccination)iii44o = 2.058, p = 0.0221), and on day 12 (post-treatment) the 3- 
way interaction between time, vaccination and treatment was also very nearly 
significant (F(time x vaccination x treatment^ii44o = 1.809, p = 0.0503).
4.2.3.5 Effects of vaccination on locomotor activity induced by acute 
nicotine administration
To complement the experiments looking at the effects of chronic and sub­
chronic nicotine exposure (see above), the effects of vaccination on the acute 
response to saline and nicotine administration (0.1 & 0.4 mg/kg, s.c.) were 
examined over a 90 min period.
The raw data for each day were analysed using a two-way ANOVA with 
repeated measures, followed by Bonferroni's post-hoc analysis. In addition, the 
area under the curve for 1 - 30, 31 - 60, and 61 - 90 min (AUC30, AUC60 and 
AUC90, respectively) were also compared by two-way ANOVA with Bonferroni's 
post-hoc tests.
A main effect of treatment (F(treatment)2l9o = 5.109, p = 0.0079) was seen when 
examining the raw data (see Figure 4.5 A), along with a highly significant effect 
of time (p < 0.0001). The treatment effect was also apparent upon analysis of 
the AUC data (see Figure 4.5 B - D), but decreased in significance over time 
(F(treatment)2,9o = 24.974, p < 0.0001, F(treatment)2,9o = 8.446, p = 0.0004 and 
F(treatment)2,9o = 5.828, p = 0.0042, for AUC30, AUC60 and AUC90, 
respectively).
Administration of the higher nicotine dose (0.4 mg/kg) produced an initial 
depression, followed by an increase in locomotor activity, whereas the lower 
dose (0.1 mg/kg) had no initial depressant effect on activity levels and resulted 
in a more rapid increase in locomotor activity. No significant effects of 
vaccination were observed during these experiments.
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Figure 4.5: Effect o f vaccination on locomotor activity induced by acute nicotine
administration
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A) Locomotor activity over the 90 min measurement period; B) Area under the curve 
for the first 30 min (AUC30); C) Area under the curve for 31-60 min (AUC60); D) Area 
under the curve for 61-90 min (AUC90)
Immunised rats were injected with nicotine (0.4 or 0.1 mg/kg, s.c.) or saline, and 
locomotor activity recorded for 90 min. Movement was detected by means of infrared
beams in the cage surround.
Data presented are mean ± S.E.M, n = 16 per group; *p<0.05, **p<0.01, ***p<0.001
4.2.4 Discussion
In this section we examined nicotine-induced changes in locomotor activity in 
rats, using a variety of nicotine treatment regimes, as well as studying the 
effects of conditioning to the test environment on these responses.
Effects of short intermittent nicotine exposure on locomotor activity
Initially we utilised a 5-day treatment schedule, consisting of 4 days of nicotine
or saline treatment, followed by a test day for conditioning effects. Using this
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treatment schedule we observed a progressive increase in nicotine-induced 
hyperlocomotion over the 4-day treatment period, consistent with previous 
findings (Benwell & Balfour 1992, Reid et al 1996, Bevins et al 2001). This 
enhancement of locomotor activity was more significant and was observed 
earlier in rats whose nicotine administration was paired with the test 
environment (see Figures 4.1 & 4.3), which is in agreement with other studies 
(Reid et al 1996, Bevins et al 2001).
In addition, the nicotine-induced hyperlocomotion was more pronounced and 
appeared sooner in the paired group vaccinated against cotinine, than in the 
paired group vaccinated with TT-Cysteine (see Figure 4.3). Together with the 
significant 3-way interaction on day 3 and the vaccination effect on day 4, this 
was an indication that the anti-cotinine vaccine might be increasing nicotine- 
induced locomotor activity.
There are a number of possible explanations for the absence of significant 
effects on the test day of the full experiment (see section 4.2.3.3). It is possible 
that the anti-cotinine antibody titres in the vaccinated groups were too low to 
have had a noticeable effect on nicotine-induced behaviour. This is especially 
likely in the vaccinated pre-trial (see section 4.2.3.2), as rats in this experiment 
(“Adjuvant X/Y/Z” groups) had anti-cotinine antibody titres of around 1:2000 
(see section 2.3.3.3 & Figure 2.4), whereas in the full experiment (see section 
4.2.3.3), where a trend towards a vaccine effect was detected, titres were closer 
to 1:7500 (see Figure 2.10 & section 2.3.3.3).
Another possibility is that the stimuli associated with the test environment may 
not have been sufficient to produce a conditioned response, although the fact 
that we detected a significant pairing effect in our first pre-trial (see section
4.2.3.1 & Figure 4.1) suggests this was not the case. Hakan and Ksir (1985) 
observed that even after 9 days of nicotine administration (0.2 mg/kg) 
associated with visual and auditory cues, a challenge with saline and cues 
alone on day 10 produced locomotor activity levels very similar to saline pre­
treated rats and significantly lower than the response to nicotine and cues on 
the previous and the following day. Bevins and colleagues (Bevins et al 2001) 
on the other hand, showed a significant conditioning effect after 8 conditioning 
trials with daily 0.6 and 1.2 mg/kg nicotine (bitartrate) injections. They did not, 
however, see a significant effect of conditioning in their lowest nicotine
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treatment group (0.3 mg/kg), so it is possible that the lack of conditioning 
observed by Hakan and Ksir could have been due to an insufficient dose. This 
is less likely to be the case for our studies, as our dose of 0.5 mg/kg (base) is 
not that dissimilar to the 1.2 mg/kg nicotine tartrate dose (equivalent to ~0.4 
mg/kg nicotine base) used by Bevins (Bevins et al 2001).
Finally, the 4-day nicotine pre-treatment might not have been long enough to 
produce a measurable conditioning effect on locomotor activity in the absence 
of nicotine on day 5. Bevins et al (2001) used an 8-trial conditioning procedure, 
observing a significant conditioning effect on day 9. However, conditioning 
effects have also previously been observed after only 5 days of nicotine 
pretreatment (Ksir et al 1987, Walter & Kuschinsky 1989, Reid et al 1996).
The choice of a 4-day pre-treatment experimental design was based on advice 
from Christian Heidbreder (GSK), whose group had used this schedule routinely 
and observed reliable nicotine-induced hyperlocomotion on the test day 
(personal communication). Such a difference between laboratories in terms of 
results might have been due to a number of factors, such as rat strain 
(Sprague-Dawleys vs Lister Hooded), housing conditions (group vs single), or 
the size of the locomotor activity boxes. The rats used by the GSK group were 
also significantly younger and smaller/lighter than ours, as they did not undergo 
~3 months of vaccinations prior to the experiment, which might also have 
impacted on their locomotor activity responses.
Effects of 12-dav intermittent nicotine exposure on locomotor activity 
In order to address the possibility that the lack of conditioned hyperlocomotion 
on day 5 might have been due to the relatively short nicotine treatment period, 
we looked at the effects of a 12-day treatment schedule on nicotine-induced 
locomotor activity. Rather than using a longer version of our previous schedule, 
we chose a paradigm used by Kosowski and Liljequist (2005) because it 
allowed us to look at conditioning effects as well as nicotine effects in the same 
subjects. This meant we could use a simpler experimental design requiring 
fewer groups, and therefore fewer animals. To control for injection effects, we 
modified the design slightly, to include a saline injection at the beginning of the 
30 min pre-treatment phase (as suggested by Kosowski & Liljequist in their 
discussion).
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We observed that repeated pairing of nicotine (0.5 mg/ kg, s.c.) with the testing 
environment elicited nicotine-conditioned hypolocomotion in the pre-treatment 
phase over the 12-day period (see Figure 4.4), in contrast with the increase in 
locomotor activity observed by Kosowski & Liljequist (2005). The progressive 
increase in locomotor activity observed in response to nicotine administration 
was, however, consistent with the results obtained by Kosowski and Liljequist, 
as well as previous studies (Benwell & Balfour 1992, Reid et al 1996), and was 
highly significant over the entire 12-day period. Nisell and colleagues have also 
shown a substantial increase in nicotine-induced hyperlocomotion, as well as an 
enhancement of DA release from the PFC and NAcc, in rats pretreated with 
nicotine, using the same dose of nicotine (0.5 mg/kg) and length of treatment 
(12 days; Nisell et al 1996).
There was a general tendency towards slightly higher activity levels (post­
treatment) in the group vaccinated against cotinine, compared to controls, 
however this was not significant. Again this relatively slight effect may have 
been due to low anti-cotinine antibody titres, since those achieved in this Trial 
(-1:3,000) were approximately half as high as those obtained in the previous 
Trial (-1:7,500; see Figure 2.10 & section 2.3.3.3).
Effects of acute nicotine administration on locomotor activity 
Finally, we examined the acute effects of different doses of nicotine on the 
locomotor activity of rats over a 90 min period. Administration of 0.4 mg/kg 
nicotine resulted in an initial depressant effect on locomotor activity, followed by 
an increase, which is consistent with previous studies (Clarke & Kumar 1983, 
Walter & Kuschinsky 1989, Bevins et al 2001, Bevins & Palmatier 2003). The 
0.1 mg/kg dose had no initial depressant effect on activity levels, and resulted in 
a more rapid increase in locomotor activity. Bevins et al (2001) observed similar 
dose-dependent effects, with a decrease in locomotor activity after 
administration of 1.2 mg/kg (bitartrate; equivalent to -0 .4  mg/kg base), but not 
0.3 or 0.6 mg/kg.
We did not observe any effects of vaccination, which is likely to be due to the 
low titres (-1:800) achieved in this Trial (see Figure 2.10 & section 2.3.3.3). This 
was a result of the mislabelling of vials containing a fresh batch of conjugates
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for vaccination (see section 2.3.2.3.4) and the consequent vaccination of control 
animals with active vaccine and vice-versa (see section 2.3.2.3.6).
Effects of immunisation on locomotor activity
Passive immunisation against nicotine has been shown to block the locomotor 
stimulant effect of an acute dose (0.28 mg/kg, s.c.) of nicotine (Pentel et al 
2000). This is thought to be the result of nicotine-specific antibodies binding the 
drug molecules and preventing them from crossing the blood-brain-barrier and 
acting on nAChRs. Furthermore, both vaccination and passive immunisation 
have been shown to attenuate the locomotor stimulant effects of nicotine in rats 
after repeated exposure to nicotine and, in the case of passive immunisation, in 
a dose-dependent fashion (Carrera et al 2004).
According to the premise for the cotinine vaccine approach, vaccination of rats 
against cotinine would be expected to enhance nicotine-induced stimulation of 
locomotor activity, due to cotinine-specific antibodies retaining cotinine in the 
bloodstream and preventing it from antagonising the effects of nicotine. 
However, we did not detect any robust effects of vaccination against cotinine on 
locomotor activity levels. This may be a result of the relatively low anti-cotinine 
antibody titres generally achieved in the vaccinated rats. On the other hand, 
some encouraging signs of a vaccination effect were observed in the locomotor 
experiments conducted as part of Trial 2, in which the highest anti-cotinine 
antibody titres were obtained (see Figure 2.10 & section 2.3.3.3). In this study 
there was evidence of a possible enhancement of nicotine-induced locomotor 
activity as a consequence of vaccination against cotinine (see section 4.2.3.3); 
however, no clear correlation between antibody titre and locomotor activity (on 
day 4) was found (data not shown), possibly due to the large variability in terms 
of antibody levels within each group. If the number of subjects per group had 
been greater and higher antibody titres had been achieved, this might have 
resulted in a more significant impact on locomotor activity levels.
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4.3 Effects of anti-cotinine vaccination on intravenous self­
administration of nicotine
4.3.1 Introduction
In smokers, nicotine self-administration appears to be motivated by both 
positive and negative reinforcement. Negative reinforcement refers to the relief 
of nicotine withdrawal symptoms, including nervousness, restlessness, 
irritability, anxiety, and impaired concentration and cognitive function, whereas 
positive reinforcing effects include relaxation, reduced stress, enhanced 
vigilance, and improved cognitive function and mood. Humans have been 
shown to like and self-administer oral, nasal, and intravenous nicotine, and the 
associated reinforcing effects and self-administration behaviour can be blocked 
by pretreatment with the nicotinic antagonist mecamylamine (Benowitz 1996, 
Rose & Corrigall 1997, Caggiula et al 2001).
Self-administration studies have shown that many drugs considered to be 
addictive in humans can serve as positive reinforcers for laboratory animals, 
including amphetamine, cocaine, morphine, heroin, phencyclidine and nicotine 
(Stolerman & Shoaib 1991). Just as a large portion of the human population is 
drawn to tobacco use on a daily basis, rodents will self-administer nicotine (i.v.) 
when the opportunity is presented in the laboratory (Rose & Corrigall 1997, 
Caggiula et al 2001, Mansvelder & McGehee 2002). One of the primary 
advantages of the self-administration model is its resemblance to real-life drug- 
taking behaviour in humans, both in terms of the repeated intake of small doses 
of nicotine, but also in the voluntary nature of the nicotine administration.
In rodent self-administration studies (see Figure 4.6), the drug is obtained 
through a chronically indwelling catheter (implanted intravenously during brief 
surgical anaesthesia), and serves to reinforce behaviour (usually lever-pressing 
or nose-poking). Access to the drug is generally restricted so that animals must 
respond a certain number of times or within a certain time in order to receive a 
drug infusion. A time-out period after each infusion serves to minimise the risk 
of adverse and toxic effects, such as seizures, as a result of cumulative actions 
of repeated doses (Rose & Corrigall 1997).
Animal self-administration models can differ in several ways, such as whether 
the schedule of access to the drug is continuous or limited and intermittent, 
whether animals are maintained on free feeding or restricted feeding schedules,
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and whether animals receive prior operant training and/or drug exposure before 
the first self-administration session. Reliable self-administration of nicotine has 
been reported under all of the above conditions. Limited, intermittent access 
(such as 1 - 2 h per day) appears to result in more rapid acquisition and higher, 
more stable rates of drug-maintained behaviour (Goldberg et al 1983, 
Henningfield & Goldberg 1983). On the other hand, continuous access is 
generally a better model for chronic, continuous drug exposure or patterns of 
administration (Donny et al 1998).
Figure 4.6: Intravenous self-administration apparatus







infusion pump via an 
intravenous cannula.
Presses on the active lever 
result in an infusion of 
nicotine. A second lever (not 
pictured) is inactive, ie 
responses on that lever are 
recorded but have no 
programmed consequence.
(from Stolerman 1992)
Self-administration behaviour in rats can be extinguished by substituting saline 
for nicotine, or by pre-treatment of animals with the nicotinic antagonists 
mecamylamine or DH|3E by subcutaneous injection (Corrigall & Coen 1989, 
Shoaib et al 1997, Watkins et al 1999). Infusion of DHpE into the VTA prior to 
the start of the nicotine self-administration session also results in a significant 
decrease in the number of nicotine infusions taken, but does not affect 
responding for food or cocaine. However, the same dose infused into the NAcc 
is without effect on nicotine self-administration (Corrigall et al 1994). 
Furthermore, nicotine self-administration is attenuated in (32 knockout mice, 
providing additional evidence for the involvement of (32* nAChRs in nicotine 
reinforcement (Picciotto et al 1998). A marked reduction in self-administration of 
nicotine can also be observed when the mesolimbic DA system is lesioned by 
injecting 6-OHDA into the NAcc (Corrigall et al 1992), but also when rats are 
administered selective D1 and D2 dopamine receptor antagonists (Corrigall &
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Coen 1991), suggesting that DA transmission plays a key role in mediating 
nicotine self-administration behaviour. Exposing rats to nicotine prior to 
experimental sessions (either by injections or by chronic subcutaneous infusion 
via an osmotic minipump) has also been shown to dose-dependently reduce 
responding (Corrigall & Coen 1989, LeSage et al 2002).
Although somewhat invasive, intravenous self-administration techniques have 
the advantage of eliminating the influence of non-pharmacological factors, such 
as the taste of drug solutions, on drug intake. Also, there is only a very small 
delay between lever-pressing responses and delivery of the drug (i.e. 
immediate reward), which facilitates learning of the required behaviour. Drug- 
taking behaviour can be sustained over long periods of time, and dose- 
response as well as control data can be obtained from the same subject. In 
addition, various parameters of addiction can be studied, from acquisition and 
maintenance of drug-taking behaviour to withdrawal effects and reinstatement 
by nicotine and/or associated cues. Self-administration techniques are therefore 
considered to be one of the most direct and best-established methods for 
assessing the positively reinforcing effects of addictive drugs (Stolerman & 
Shoaib 1991). For this reason, we chose to examine the effects of vaccination 
against cotinine on intravenous self-administration of nicotine in rats.
Initially we discussed two schedule options for our experiments:
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With option 1, rats would not be implanted with a catheter until the vaccination 
schedule had been completed. This would allow for monitoring of titres, and 
possible exclusion of rats with a low immune response prior to catheterisation. 
Although with this timeline it would be possible to examine the effects of 
vaccination on the acquisition of self-administration, this would not accurately 
reflect the proposed application in smokers, where vaccination would be used to 
support cessation.
Option 2 on the other hand, mirrors a smoker's cessation attempt more closely, 
as vaccinations would not take place until self-administration behaviour had 
been established. The main drawback with this option is the length of time the 
intravenous catheters would have to remain patent (~5 - 6 months) in order to 
complete all phases of the experiment.
After considering both options, and bearing in mind that the vaccine was 
designed to assist with smoking cessation, we decided to pursue option 2, as it 
mimicked the human situation (smokers attempting to quit) more closely, and 
would potentially enable us to examine the effects of anti-cotinine vaccination 




Male hooded Lister rats (Harlan UK) initially weighing 200 - 250 g were 
acclimatised to the animal house for approximately one week before surgery 
and had access to food and water ad libitum.
4.3.2.2 Apparatus
Standard operant chambers (Med-Associates, Vt., USA), consisting of a 
Plexiglas enclosure with one house light, two levers, one tether and fluid swivel, 
were used. One lever was defined as active and presses on this lever resulted 
in fluid infusions and extinction of the house light for 20 s; presses on the other 
lever were recorded but had no programmed consequences. Catheters were 
connected to an infusion pump (Razal; MED-Associates, Ind., USA) with a 
syringe containing nicotine solution (saline during extinction and reinstatement).
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The operant chambers were controlled by computer, using the MED-Associates 
MEC-PC software package.
4.3.2.3 Surgery and recovery
Under surgical anaesthesia (mixture of medetomidine 0.3 mg/kg and ketamine 
70 mg/kg, i.p.), a chronic Silastic catheter was implanted into the external 
jugular vein and tunnelled subcutaneously by Dr Shoaib as described previously 
(Shoaib et al 1997). The catheter was then externalised via a head mount (by 
me). Daily flushing with 0.9 % physiological saline containing Baytril 
(enrofloxacin; 0.16 mg/kg per day) and heparin (30U/ml) maintained the 
patency of the intravenous catheter.
Rats were housed individually post-operatively until they had regained their pre­
operative weights. They were then housed in pairs for the duration of the self- 
administration experiments.
4.3.2.4 Acquisition
In 1 h limited access sessions, rats were given the opportunity to lever-press for 
intravenous infusions of nicotine (0.03 mg/kg per infusion) as described 
previously (Shoaib et al 1997). A stimulus light was utilised to signal the 
availability of nicotine, which was turned off for 20 s during the time-out period 
after an infusion. Initially each press on the active lever resulted in a nicotine 
infusion (fixed ratio 1, FR-1). Once rats showed response accuracy with at least 
80 % of the responses on the active lever and with stable intake of nicotine (± 2 
infusions) over 2 days, the number of responses required to produce an infusion 
was increased progressively to 2 and finally 3 lever presses (FR-3).
4.3.2.5 Vaccination during stable maintenance
Vaccinations began once a rat exhibited stable levels of nicotine self­
administration under a FR-3 schedule of reinforcement (less than 30 % 
variability from the mean number of infusions self-administered over three 
sessions). Animals were vaccinated with TT-CotSH or TT-Cysteine according to 
the schedule described in Chapter 2 (see section 2.2.3.4). Self-administration 
sessions continued throughout the vaccination period, except for the 
vaccination days. Upon completing the course of vaccinations, rats were again
- 1 7 4 -
Chapter 4 -  Behavioural measures of nicotine dependence
required to reach stable levels of nicotine self-administration before progressing 
to the extinction phase.
4.3.2.6 Extinction
During the extinction phase of the experiment, presses on the active lever were 
recorded, but had no programmed consequences. As well as removing the 
nicotine infusion (infusion lines were connected to a saline-filled syringe), the 
cues predicting the onset of nicotine infusion were also eliminated: infusion 
pumps were turned off, and the stimulus light was left on for the entire session 
(time-out period not used).
4.3.2.7 Reinstatement tests
Once lever-pressing behaviour had been extinguished (3 days of £ 20 % of 
stable maintenance baseline), rats were challenged with systemically 
administered nicotine (0.05, 0.1, or 0.2 mg/kg) and no cues, or saline (s.c.) plus 
cues associated with pressing the active lever (pump noise on, stimulus light 
switching off), in a randomised order. Active lever presses were recorded 
throughout; they either had no programmed consequences (nicotine test), or 
triggered cues (see above; saline test). After each challenge, rats were again 
required to reach extinction criteria prior to the next reinstatement test.
4.3.2.8 Data Analysis
During the maintenance phase, responses over the 10 sessions following each 
vaccination were compared using ANOVA with repeated measures, followed by 
Bonferroni’s post-hoc test where required. Response rates on the active lever 
on reinstatement test days were compared to the mean response levels over 
the preceding 3 extinction days (baseline) by means of unpaired t-tests.
4.3.3 Results
4.3.3.1 Surgery and recovery
Surgery was performed on a total of 58 male hooded Lister rats. Recovery rates 
were generally good, with most rats regaining their pre-operative weight within a 
week of surgery, and infection as a result of surgery was rare. Of an initial 37 
animals that were catheterised, only one was culled because of infection post­
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surgery. In order to replace rats excluded over the course of the acquisition 
period due to blocked catheters and/or lack of acquisition of self-administration 
behaviour, a further 21 animals were implanted with catheters (2 were culled 
post-surgery due to a blocked catheter and infection, respectively). In all, a total 
of 55 rats proceeded to the acquisition phase.
4.3.3.2 Acquisition
Acquisition of nicotine self-administration behaviour is summarised in Figure 
4.7. Response rates on the inactive lever were very low throughout the 
experiments. Initially acquisition rates were good, and some rats progressed 
from FR1 to FR2 and then FR3 relatively quickly. However, levels of self­
administration behaviour were soon found to be inconsistent from session to 
session in the majority of animals. In an attempt to stabilise responding rates, 
rats were switched from daily sessions to sessions every second day 
(approximately around session 40). This appeared to improve rates of 
responding to a certain extent; however it also meant that data acquisition was 
very much slower.
As other studies have only measured self-administration behaviour for 2 -  6 
weeks (Shoaib et al 1997 & 2003, Donny et al 1998, Caggiula et al 2001, Liu et 
al 2006), and we were unsure how long the catheters were likely to remain 
patent, we switched back to daily sessions, in the hope that rats that had 
acquired self-administration behaviour would be able to maintain it with more 
frequent sessions. Several animals that had satisfied stability criteria were able 
to progress to the next stage of the experiment. The remaining rats still showed 
highly variable rates of lever pressing, and most were therefore not able to 
move on to the vaccination phase.
The variability of the response rate resulted in a high rate of attrition, and 
consequently, of the 55 rats that entered the experiment, only 18 satisfied the 
criteria for stable maintenance. Figure 4.7 only shows the data for these 18 
animals. Some rats acquired the nicotine self-administration behaviour a lot 
faster than others, and progressed to the next phase of the experiment 
whenever they had reached stability. The graph shows the first 70 sessions, 
during which most of the 18 rats satisfied stability criteria; in the interest of 
clarity, the data for the additional sessions for the remaining animals is not
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depicted, as the decreasing sample number resulted in greatly increased error 
bars. (The last rat to complete acquisition and move into the vaccination phase 
required -60 sessions in addition to those shown in Figure 4.7.)
Figure 4.7: Acquisition of nicotine self-administration behaviour
In 1 h limited access 
sessions, rats were given 
the opportunity to lever- 
press for intravenous 
infusions of nicotine (0.03 
mg/kg per infusion) on an 
FR-1 schedule of 
reinforcement. This was 
increased to FR-2 and then 
FR-3, response accuracy 
permitting, until stable 
response rates were 
achieved under FR-3.
Data shown are mean ± S. E.M for the 18 animals that completed the acquisition phase 
(n decreases over time) for the first 70 sessions (see section 4.3.3.2).
4.3.3.3 Effects of vaccination on stable maintenance
Rats that had satisfied criteria for stable maintenance (see section 4.3.2.4) were 
given 5 vaccinations of TT-CotSH or TT-Cysteine over a -3-month period 
indicated by black arrows in Figures 4.9 A -  C. The grey arrow indicates the 
start of the extinction period. In the interest of clarity, mean responses during 
the first 10 sessions after each vaccination are shown; rats completed varying 
numbers of sessions during the inter-vaccination periods, which resulted in 
large error bars towards the end of each period.
Lever-pressing response rates during the vaccination phase remained rather 
variable between sessions (see Figure 4.9 A), although the rats vaccinated 
against cotinine generally had higher response levels on the active lever (and 
therefore more infusions (see Figure 4.9 B)), than those vaccinated with control 
vaccine. There was a significant effect of vaccination (see Figure 4.8) on active 
lever presses and infusions over the 10 sessions following the 4th 
(F(vaccination)1i113 = 15.450, p=0.0001 and F(vaccination)it1i3 = 15.661,
70
Active lever presses 
Infusions
Inactive lever presses
0 10 20 30 40 50 60 70
Session
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p=0.0001) and 5th immunisations (^vaccination)^ 17 28.117, p<0.0001 and 
F(vaccination)i,ii7 28.388, p<0.0001). However vaccinated rats also showed 
elevated levels of responding on the inactive lever (see Figure 4.8 & 4.9 C), 
compared to control vaccinated rats, indicative of a general increase in activity.
Figure 4.8: Significant effects of vaccination on maintenance of nicotine self-
administration
After vaccination No. Sessions
Active Lever 4th: F(vacc)i,n3 = 15.450 (p = 0.0001) 3-5 & 8 (p < 0.05)
5th: F(vacc)i,117 = 28.117 (p < 0.0001) 9 (p < 0.01)
Infusions 4th: F(vacc)i,ii3 = 15.661 (p = 0.0001) 3-5 & 8 (p < 0.05)
5th: F(vacc)i,n7 = 28.388 (p < 0.0001) 9 (p < 0.01)
Inactive Lever 1 st: F(vacc)i,i48 = 4.423 (p < 0.05) -/-
2nd: F(vacc)ii134 = 7.462 (p < 0.01) 1 (p < 0.05)
3rd: F(vacc)i,i48 = 6.969 (p < 0 .01) -/-
4th: F(vacc)i,n3 = 24.523 (p < 0.0001) 8 (p < 0.05)
5th: F(vacc)i,n7 = 9.910 (p < 0.01) -/-
Rats were vaccinated on 5 occasions during the maintenance phase (see section 
4.3.2.5). Responses over 10 sessions following each vaccination were analysed by 
one-way ANOVA with repeated measures.
Although all 18 rats that entered the vaccination phase completed the schedule 
of vaccinations, the results presented for this phase are those for only 15 
individuals. The 3 rats excluded from the analysis were lost during the 
subsequent withdrawal and reinstatement phases due to blocked catheters; 
however their lever-pressing responses during the vaccination phase were 
extremely variable, especially in the latter stages of this phase, presumably due 
to a blockage gradually developing in the catheter. As it was practically 
impossible to determine exactly at which point the development of the blocked 
catheter started to impact on lever-pressing behaviour, their data for this phase 
were excluded as too unreliable.
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Figure 4.9: Effects o f anti-cotinine vaccination on maintenance and extinction of
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Once response rates were stable 
under FR-3, rats were immunised 
with TT-CotSH or TT-Cysteine 
according to the schedule described 
in Chapter 2 (see section 2.2.3.4). 
Self-administration continued throughout the immunisation period, except on injection 
days. After the final immunisation, rats were again required to reach stable levels of 
responding for 3 days before progressing to the extinction phase. During extinction, 
responses on the active lever were recorded, but had no programmed consequences. 
As well as removing the nicotine infusion, cues predicting the onset of nicotine infusion 
were also eliminated (infusion pumps turned off, stimulus light left on for the entire
session).
Data shown are mean ± S. E. M (n = 7-8 per group). The number of sessions between 
vaccinations varied among rats, resulting in large error bars for later time points; for the 
sake of clarity 10 sessions immediately after each vaccination (black arrows) and 13 
sessions following initiation of extinction (grey arrow) are shown.
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4.3.3.4 Extinction of self-administration behaviour
Once rats had completed the series of vaccinations and again fulfilled stable 
maintenance criteria (see section 4.3.2.4J, lever-pressing responses on the 
active lever were extinguished by removing the nicotine-reinforcement (grey 
arrow in Figures 4.9 A -  C indicates initiation of extinction), as well as the cues 
associated with nicotine administration (see section 4.3.2.6). As mentioned 
above, 3 rats were lost during this phase and the subsequent one, leaving 15 
rats that completed the entire experiment.
Extinction was observed to be similar in both groups of rats, with active lever 
response rates decreasing to a level similar to the response rate on the inactive 
lever (see Figures 4.9 A -  C).
4.3.3.5 Reinstatement of nicotine-seeking behaviour by nicotine and 
associated cues
Reinstatement tests were carried out in the remaining 15 rats: nicotine-induced 
reinstatement was examined by injecting nicotine (0.05 -  0.2 mg/kg, s.c.) just 
prior to the self-administration session (no cues or nicotine infusions), whilst 
cue-induced reinstatement was explored by injecting saline and presenting only 
the cues (auditory & visual) associated with nicotine infusion (again no nicotine 
infusions).
Due to the mislabelling of vials containing a fresh batch of conjugates for 
vaccination (see section 2.3.2.3.4), several rats were mis-vaccinated. As a 
consequence, several "control" rats started to develop anti-cotinine antibody 
titres, whilst the titres in some rats in the "active" vaccine group did not increase 
as anticipated (see Figure 2.8 & section 2.3.3.3J. Rats were assigned to an 
overall active or control group, depending on whether they had raised sustained 
anti-cotinine antibody titres or not (see section 2.3.3.3). It is these groups that 
the comparisons below refer to.
In rats vaccinated with control vaccine (TT-Cysteine), response levels during 
the reinstatement sessions (see Figures 4.10 A -  D) were significantly greater 
compared to the baseline response levels of the same group at all nicotine 
doses tested (p<0.05 for 0.05 -  0.1 mg/kg and p<0.01 for 0.2 mg/kg), as well as 
with cues alone (p<0.001). In the group vaccinated against cotinine (TT-CotSH), 
a significant reinstatement of lever-pressing behaviour (compared to the
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baseline of this group) was only observed at the 0.05 and 0.2 mg/kg nicotine 
doses (p<0.05).
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A) Cue-induced reinstatement; B-D) Nicotine-induced reinstatement 
Once lever-pressing behaviour had been extinguished, rats were challenged with (A) 
saline (s.c.) plus cues associated with nicotine infusion (pump noise on, house-light off) 
or (B,C,D) nicotine (0.05, 0.1, or 0.2 mg/kg) with no cues, in a randomised order. 
During these sessions active lever presses were again recorded but had no 
programmed consequences. After each challenge, rats were again required to reach 
extinction criteria prior to the next reinstatement test.
Data shown are mean ± S.E.M, n = 6-8 per group; Test day response significantly 
different from mean baseline (3 days before): Control vaccine: fp<0.05, np<0.01, 
fttp<0.001; Active vaccine: *p<0.05
When comparing the levels of active lever responding during reinstatement 
tests, no significant differences were observed between rats vaccinated against
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cotinine and those vaccinated with control vaccine. Cue-induced response 
levels (see Figure 4.10 A) were similar to those elicited by the lowest nicotine 
dose (see Figure 4.10 B). At the highest dose tested (see Figure 4.10 D), the 
active vaccine group showed slightly higher levels of responding on the active 
lever than the animals vaccinated with TT-Cysteine, however this was not 
significant.
4.3.4 Discussion
Overall, the length of time required for rats to complete all phases of the self­
administration experiments was much greater than anticipated, which was 
mainly due to the extremely slow acquisition of nicotine self-administration 
behaviour. This naturally had an impact on catheter patency, and the majority of 
rats were lost due to a failure to acquire lever pressing responses or the 
development of a block in the intravenous catheter. Nevertheless, upon 
completion of the experiments, several rats still had patent catheters -  some 8- 
9 months after surgery -  which was really quite remarkable.
Acquisition of nicotine self-administration
Intra-venous infusion of nicotine has been found to serve as a reinforcer of self­
administration behaviour in rats, dogs and monkeys (Goldberg et al 1983). 
Acquisition of nicotine self-administration can be influenced by the dose of 
nicotine infused, with self-administration observed with doses of 0.03 - 0.06 
mg/kg/infusion, but not 0.01 mg/kg/infusion, but the feeding schedule used also 
appears to play a role (Donny et al 1998). Food shaping (i.e. initially training 
rats to lever-press for food before switching to nicotine) has been shown to 
influence the speed of acquisition of nicotine self-administration, and appears to 
result in higher levels of responding for nicotine in rats maintained at relatively 
low body weights (Corrigall & Coen 1989, Donny et al 1995 & 1998) compared 
to free-feeding subjects (Shoaib et al 1997). However, neither weight restriction 
nor food deprivation is necessary to establish self-administration behaviour 
(Donny et al 1998). We did not use food shaping to establish lever-pressing 
behaviour, as we wanted to study the ability of nicotine to elicit self­
administration (ie nicotine-seeking) behaviour without the prior association of 
the lever with a food reward.
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The slow acquisition of nicotine self-administration observed in our study 
contrasts with previous reports of rats acquiring lever pressing behaviour for 
nicotine infusions in the space of approximately 1 4 - 4 0  sessions (Shoaib et al 
1997 & 2003, Donny et al 1998, Caggiula et al 2001, Liu et al 2006). Studies by 
various groups have demonstrated reliable acquisition of self-administration 
with a nicotine dose of 0.03 mg/kg/infusion (Shoaib et al 1997, Donny et al 
1998, Watkins et al 1999, Liu et al 2006); however, our animals did not appear 
to self-administer nicotine as readily. Cox et al (1984) observed that a reduction 
of the nicotine dose delivered with each infusion (0.03 to 0.003 mg/kg/infusion) 
resulted in a differential increase in active lever responses relative to 
responding on the inactive lever. We therefore attempted to increase the level 
of responses on the active lever and speed up the acquisition rate by switching 
the nicotine infusion dose from 0.03 to 0.015 mg/kg/infusion. After 2 days, 
having observed no effect on response rates, we reverted back to the 
established 0.03 mg/kg/infusion dose.
Sustained self-administration may result from a combination of heightened 
positive reinforcement early in the session, due to resensitisation of nAChRs 
over the 23-h abstinence period, and the need to reduce withdrawal by 
desensitising the overactive cholinergic system (Caggiula et al 2001).
Consistent with this idea, the first cigarette of the day has been reported to 
posses enhanced reinforcing effects (Fagerstrom & Schneider 1989). We 
reduced the frequency of self-administration sessions from daily to every other 
day, effectively increasing the length of the abstinence period, and observed 
greater and more stable levels of responding as a result. This could have been 
due to rats being effectively "withdrawn" in between sessions as detailed above, 
however this seems unlikely as self-administration sessions only lasted 1 h and 
infusion rates were often not very high. Also, Watkins et al (1999) have reported 
that rats self-administering nicotine in 1 h daily sessions do not appear to be 
dependent on nicotine 24 h later, as indicated by the absence of somatic 
behavioural signs of withdrawal after a subcutaneous injection of 
mecamylamine. As less frequent self-administration sessions also meant that 
data acquisition was very much slower, we reverted back to daily sessions after 
a couple of weeks, since our planned experiments were comparatively lengthy
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and we did not know how long the intravenous catheters were likely to remain 
patent.
Other possible factors that might have played a role in the lack of acquisition of 
nicotine self-administration behaviour include the rat strain used, and the time of 
day at which the experiments took place. Due to other ongoing studies 
unrelated to this thesis, the equipment used for the self-administration 
experiments could not be accessed until ~2pm (lights on 0700 -  1900 h). The 
time of day at which various research groups performed their self-administration 
studies does not appear to be well documented, however, one group report 
using 5 h sessions commencing at 9 am (Lynch & Carroll 1999). A 
chronobiological effect might therefore be at least partly responsible for the 
problems we experienced in terms of lack of acquisition of lever-pressing 
behaviour and variability of response rates.
The ability to acquire nicotine self-administration behaviour also appears to be 
partly dependent on genetic background. Shoaib et al (1997) explored this issue 
in an experiment comparing 4 different strains of laboratory rat: two outbred 
strains (Sprague-Dawley (SD) & Long-Evans (LE)) and two inbred strains 
(Lewis & Fisher (F344)). They observed that the outbred strains acquired the 
self-administration behaviour, whereas the two inbred strains failed to do so. 
These findings are supported by other studies, showing that SD (Donny et al 
1995, Tessari et al 1995) and LE rats (Corrigall & Coen 1989) self-administer 
nicotine, while Fisher rats do not (Dworkin et al 1993). However, Wistar (Lynch 
& Carroll 1999, Watkins et al 1999), Holtzman (LeSage et al 2002) and hooded 
Lister rats (Shoaib et al 2003), which we were using, have also been shown to 
reliably self-administer nicotine.
Maintenance and extinction of nicotine self-administration behaviour 
Response rates during the stable maintenance and vaccination phase of the 
experiment remained rather variable from one day to the next, but viewed over 
a longer period of time they were comparatively stable. Shoaib et al (2003) also 
observed relatively stable levels of responding over a -4 0  session maintenance 
period.
We had originally intended to establish a dose-response curve for nicotine once 
rats had completed the vaccination schedule, by varying the concentration of
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the nicotine solution infused, but had to abandon this plan due to the length of 
time taken for rats to progress through the acquisition phase, as well as the day 
to day variability of response rates. Several laboratories have previously 
reported obtaining a bell-shaped dose-response curve when dose per infusion 
was varied (0.002 - 0.12 mg/kg/infusion), with a maximum response around 
0.01 - 0.03 mg/kg/infusion (Corrigall & Coen 1989, Shoaib et al 1997, Watkins 
et al 1999). This dose-response curve was observed to be relatively flat, as 
animals appeared to only partially compensate for the change in dose (Corrigall 
& Coen 1989, Donny et al 1995, Tessari et al 1995, Watkins et al 1999). In 
contrast, when cocaine doses were manipulated, animals compensated for the 
change in dose to obtain a relatively constant level of intake (Lynch & Carroll 
1999).
When saline was substituted for nicotine and nicotine-associated cues were 
removed, responding on the active lever markedly reduced over approximately
6 - 1 7  sessions, which is similar to the 12-session period reported previously 
(Caggiula et al 2001, Liu et al 2006). Withdrawal of nicotine, or its 
pharmacological blockade, typically results in significant decreases in self­
administration but not complete cessation of operant responding (Rose & 
Corrigall 1997, Shoaib & Stolerman 1999, Di Chiara 2000, Caggiula et al 2001). 
This may reflect a shift in the control of self-administration behaviour from the 
motivational effects of nicotine to a more automatic response, whereby stimuli 
conditioned to the drug trigger self-administration behaviour, which is relatively 
independent of the drug (Di Chiara 2000).
Reinstatement of nicotine self-administration
Smoking-related environmental stimuli have been implicated as an important 
factor in triggering relapse in abstinent tobacco smokers (Balfour et al 2000, 
Caggiula et al 2001, Liu et al 2006). In a study on briefly abstinent smokers, 
Rose and colleagues (Rose et al 2000) observed that cues alone (smoking of a 
de-nicotinised cigarette) increased smoking satisfaction to the same degree as 
smoking a nicotine-containing cigarette, but intravenous nicotine administration 
did not influence satisfaction. However, the reduction in craving due to smoking 
the de-nicotinised cigarette was greater in combination with intravenous nicotine
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administration, so that both together produced a reduction in craving equal to 
that of smoking a regular nicotine-containing cigarette.
In animal self-administration experiments, the infusion of nicotine is typically 
paired with contextual stimuli such as lights (Corrigall & Coen 1989, Watkins et 
al 1999, Caggiula et al 2001, Liu et al 2006), and presentation of these 
contextual stimuli appears to promote nicotine taking and nicotine seeking 
responses. Rats have been observed to spontaneously recover previously 
extinguished behaviour upon re-exposure to the nicotine self-administration 
context after being maintained in their home cages for 21 days (Shaham et al 
1997). Reintroduction of nicotine-paired stimuli after extinction also results in 
increased responses on the active lever (Caggiula et al 2001, LeSage et al 
2004, Liu et al 2006).
In agreement with these findings, we observed a significant reinstatement effect 
of nicotine-associated cues in the group vaccinated with TT-Cysteine.
Significant reinstatement was also seen in this group following administration of 
various priming doses of nicotine, with a slightly larger effect at the highest 
dose. The group vaccinated against cotinine also demonstrated significant 
reinstatement in response to nicotine, but only at the highest and lowest doses 
used. Nicotine-induced reinstatement of nicotine self-administration behaviour 
does not appear to be as robust as that induced by nicotine-associated cues 
alone. While some studies have reported the reinstatement of previously 
extinguished nicotine self-administration behaviour by priming injections of 
nicotine in rats (Chiamulera et al 1996, Shaham et al 1997), LeSage and 
colleagues (LeSage et al 2004) observed that nicotine alone generally failed to 
reinstate nicotine self-administration, but that a significant reinstatement was 
achieved in combination with nicotine-associated cues. Similar results were 
obtained by Caggiula et al (2001), although this group utilised intravenous 
nicotine infusion, rather than priming injections, to test for nicotine-induced 
reinstatement (i.e. reacquisition).
Effects of vaccination on nicotine self-administration in rats 
Vaccination against nicotine has been shown to affect the acquisition of nicotine 
(but not cocaine) self-administration behaviour under a 23-h access schedule, 
with vaccinated rats earning 38 % fewer infusions during the last week of a 3-
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week training period (LeSage et al 2005). The percentage of rats meeting 
acquisition criteria was also lower in the vaccinated group than in the controls 
(36 % versus 70 %), but this was not statistically significant. Vaccination of rats 
during the maintenance phase did not affect nicotine self-administration until 
after the fourth dose, when the number of infusions obtained was significantly 
reduced (by -57  %) in vaccinated rats compared to controls (LeSage et al 
2005). The delayed onset of the effect was thought to be due to the slow 
development of antibody levels. Food-maintained responding was unaffected by 
anti-nicotine vaccination. Finally, while control rats exhibited a significant 
increase in responding in reinstatement tests following a low priming dose of 
nicotine, rats vaccinated against nicotine (during the extinction phase) did not, 
indicating that vaccination blocked the ability of a low dose of nicotine to 
reinstate nicotine self-administration behaviour (Lindblom et al 2002).
Towards the beginning of this trial, a new batch of cotinine derivative (CotSH) 
was synthesised, and fresh conjugates were produced (see sections 2.3.2.1.1 & 
2.3.2.1.2). Unfortunately, vials containing the new conjugates for vaccination 
were mislabelled prior to their arrival in Newcastle. As a result of this error, 
several control rats were vaccinated with active vaccine and vice-versa, which 
resulted in relatively low anti-cotinine titres ( -1 :400) in the active group (more 
than 10-fold lower than those achieved with anti-nicotine vaccination in the 
studies mentioned above), as well as a small degree of anti-cotinine antibody 
production in the control animals (see Figure 2.9 & section 2.3.3.3).
Anti-cotinine vaccination did appear to increase lever-pressing rates, and some 
significant differences were observed between the vaccinated and control 
groups during the maintenance phase of the experiments, despite the overall 
variability in responding over time. Correlations between the number of 
responses on the active lever during reinstatement tests and the final titres of 
rats in the active group were examined to see if there was a trend towards 
increased lever pressing with higher titres, but interactions were found to be 
very weak (r2 = 0.0449 (cues), r2 = 0.0258 (0.05 mg/kg nicotine), r2 = 0.2259 
(0.1 mg/kg nicotine), and r2 = 0.1683 (0.2 mg/kg nicotine)). This was at least 
partly due to the low number of subjects (n = 6) in the active group, which 
reached this late phase of the experiment.
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4.4 Effects of anti-cotinine vaccination on conditioned taste
aversion
4.4.1 Introduction
Nicotine is known to induce feelings of pleasure and reward in humans and 
other species. But like many other addictive drugs, it also has potent, aversive, 
unpleasant effects. Many people experience noxious effects such as nausea, 
coughs and dizziness on their initial experience with tobacco, which are 
attributed to nicotine, however, tolerance to the aversive effects of nicotine 
develops with repeated exposure. Although the precise neurobiological 
mechanism(s) underlying this tolerance to nicotine aversion are not known, its 
occurrence suggests that chronic nicotine exposure might induce functional 
alteration(s) in the neural systems mediating the aversive and/or rewarding 
effects of nicotine (Laviolette & van der Kooy 2004).
In rats, the aversive effects of nicotine appear to be dependent on direct 
stimulation of DA neurons in the mesolimbic pathway (see Chapter 1), whereas 
indirect stimulation of DA release via GABAergic / glutamatergic mechanisms 
may be implicated in mediating the motivational effects of nicotine, such as 
nicotine self-administration (Laviolette & van der Kooy 2004). This may be 
explained, at least in part, by differences between behavioural models: in 
nicotine self-administration drug delivery is contingent upon a behavioural 
response (lever-pressing), whilst in conditioned place preference/aversion tasks 
nicotine is administered non-contingently (Wonnacott et al 2005).
The aversive effects of nicotine have been implicated in the regulation of drug 
intake, perhaps by setting an upper limit to the amount consumed (Shoaib et al 
2003). Aversive stimulus effects of nicotine are often examined using the 
conditioned taste aversion (CTA) procedure (Laviolette & van der Kooy 2004). 
CTA is believed to tap directly into the aversive properties of a drug and takes 
advantage of the fact that animals appear able to associate specific tastes with 
aversive states. By pairing a given drug with a particular taste, animals learn to 
avoid this taste, as the unpleasant effects of the drug become associated with it 
(Kumar et al 1983, Iwamoto & Williamson 1984). On the other hand, a taste that 
is paired with the injection of vehicle is not avoided when the animal is given a 
choice between the two flavours (see Figure 4.11).
- 1 8 8 -
Chapter 4 -  Behavioural measures of nicotine dependence
\ Drug 4 4 *  VehicleV >, •
Figure 4.11: Conditioned taste aversion procedure
On conditioning days, rats are given 
access to one of two flavoured solutions, 
followed by administration of drug or 
vehicle. Following several training sessions 
with each injection-flavour pairing, rats are 
given access to both flavoured solutions at 
the same time in a test session (2-bottle 
choice test). The amount of each solution 
consumed is measured, with a mean score 
significantly lower than 50 % indicating a 
conditioned taste aversion to the drug- 
paired solution, (from Laviolette & van der 
Kooy 2004)
Pavlovian conditioning appears to play a role in the development of the 
association between a flavoured solution (conditioned stimulus) and drug 
effects (unconditioned stimulus) (Bevins & Palmatier 2003). In taste avoidance 
and place conditioning preparations, drug pre-exposure is thought to alter an 
affective process (e.g. aversive or appetitive effect of nicotine), which in turn 
becomes associated with the conditioned stimulus (flavour). Several studies 
have used nicotine as a drug stimulus in this task and have reported that, like 
many other addictive drugs, it produces potent aversive effects (Shoaib et al 
2000 & 2002, Laviolette & van der Kooy 2003, Pescatore et al 2005). Such 
reports, as well as studies using self-administration or conditioned place 
preference/aversion (CPP/A) procedures, have provided further evidence of the 
dual nature of the motivational effects of nicotine in animals, consistent with the 
reported aversive and rewarding psychological effects of nicotine in humans 
(Laviolette & van der Kooy 2004).
Nicotine conditioned taste aversion (CTA) has been observed in rats utilising a 
one-bottle test CTA procedure, where the drug is paired with only one flavoured 
solution, and saline is paired with water (Pescatore et al 2005). However, with 
this set-up there is a risk that any aversion observed might be due to a dislike of 
the flavour the drug was paired with, rather than the effects of the drug itself. 
With the two-bottle procedure (Shoaib et al 2000 & 2002), a selective avoidance 
of the drug-paired flavour indicates that the aversion is a function of the
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association of the taste with the effects of nicotine, rather than a generalised 
unconditioned suppression due to preference of one flavour over another 
(Pescatore et al 2005).
Smokers appear to subconsciously titrate their nicotine intake to achieve a 
desired blood concentration, taking deeper and longer inhalations if they are 
switched to a cigarette brand with a low nicotine yield, and limiting their nicotine 
intake through more shallow inhalations when smoking a higher-yield brand 
(Russell et al 1980, West et al 1984). The existence of this upper limit of 
nicotine intake in order to achieve a given blood nicotine concentration could be 
an indication of possible aversive effects of nicotine above a certain level. 
Removing or reducing cotinine-mediated antagonism of nicotine's actions by 
means of vaccination against cotinine could lead to a reduction in the number of 
cigarettes smoked per day in current smokers, which might assist in a reduce- 
to-quit approach to smoking cessation. However, it could also help to enhance 
the efficacy of NRT at relieving nicotine withdrawal symptoms in those trying to 
quit the habit. Here we examine the effects of anti-cotinine vaccination on the 
development of aversion to a nicotine-paired solution in rats, using a two-bottle 
conditioned taste aversion procedure.
4.4.2 Methods
4.4.2.1 Animals & apparatus
Male hooded Lister rats (Harlan, UK), 6 - 7  weeks old, were housed in groups of 
4 for the duration of the vaccination process with access to food and water ad 
libitum. Prior to the conditioned taste aversion experiments, rats were housed 
individually and acclimatised to these conditions for one week.
In preparation for the conditioned taste aversion experiments on vaccinated 
animals, two small pre-trials were undertaken to establish the nicotine test 
doses to be used in the experiments on vaccinated rats. For the unvaccinated 
pre-trials, rats ( 6 - 7  weeks old) were acclimatised to the animal unit for a week, 
before being housed individually for another week prior to the start of the 
experiments.
Rats were weighed on a daily basis throughout the time they were housed 
individually, in order to monitor their weight and condition and determine 
injection volumes.
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All conditioned taste aversion experiments were carried out in the rats’ home 
cages, using 50 ml graduated conical tubes (instead of the usual drinking 
bottles) and rubber stops with drinking spouts to facilitate accurate 
measurement of fluid intake. Three sets of tubes were used: one for each 
flavoured solution, and another set for water.
4.4.2.2 Conditioned taste aversion (CTA) procedures
Once rats had been housed individually for a week, their access to water was 
restricted to 1 h per day ( 1 - 2  p.m.). Rats were adapted to this regime for 7 
days, before any presentation of the flavoured solutions.
Then, during the hour in which the rats had previously had access to water, one 
of two flavoured solutions (sodium saccharin 0.1 % or sodium chloride 0.9 %) 
was presented for 15 min on every second day. (On the days in between, rats 
were given access to water for 1 h as during the training period.) The two 
flavoured solutions were presented alternately, thus each flavour was presented 
to a given rat every fourth day. Immediately after the tubes containing the 
flavoured solutions were removed, the rats were injected with either nicotine 
(0.05, 0.1, 0.2 or 0.4 mg/kg, s.c.) or saline (flavour-injection pairing) and 
returned to the home cage. For half of the rats, one flavour was consistently 
paired with nicotine, whereas the other flavour was paired with vehicle. These 
arrangements were reversed in the remaining rats to balance out effects due to 
inherent palatability of the flavours. The order of nicotine and saline injections 
was also counterbalanced.
An additional 15 ml of water (10 ml for the smaller animals used in the pre-trials) 
was presented 3 - 4 h after removing the flavoured solutions on conditioning 
days, in order to prevent dehydration and weight loss. Each rat was given two 
drug and two saline conditioning sessions (4 of each for the CTA experiments 
on vaccinated rats).
2 days after completing the conditioning sessions, rats were subjected to a two- 
stimulus test, consisting of simultaneous presentation of both nicotine-and 
saline-paired flavoured solutions for 15 min. The next day, the test was 
repeated with the positions of the two stimuli (flavours) reversed, in order to 
balance for side preferences.
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4.4.2.3 Data analysis
The percentage of nicotine-paired flavoured solution consumed during the two- 
bottle tests was subjected to arc-sine transformation to normalise the 
distribution. To test for a significant CTA for each group, t-tests were carried out 
to determine whether the means differed significantly from 50 %. A mean score 
near to 50 % wouid indicate that the drug did not produce conditioned taste 
aversion or preference.
4.4.3 Results
4.4.3.1 Optimisation of nicotine dose (pre-trials)
Two pre-trials were conducted to establish the nicotine doses to be used in the 
experiments on the vaccinated animals. Nicotine was tested at doses of 0.1, 0.2 
and 0.4 mg/kg (s.c.), with each group of rats being assigned one dose.
During conditioning sessions, rats were alternately given access to one of two 
flavoured solutions: one paired with an injection of nicotine, and the other paired 
with saline, as described in the methods. After 2 conditioning sessions for each 
solution, rats were given access to both flavoured solutions simultaneously 
(without injections) to test for conditioned taste aversion.
Rats were trained to drink water during a daily 1 h access session, and 
consumed on average around 16 ml/day in the first pre-trial, and around 13 
ml/day in the second pre-trial (data not shown). Once the conditioning sessions 
(flavoured solutions paired with injections) began, this decreased to 13 ml/day 
and 9 ml/day, respectively.
During the first set of conditioning sessions (i.e. first exposure to the flavoured 
solutions), rats showed no preference/aversion: consumption of nicotine- and 
saline-paired solutions was very similar, with rats in the first pre-trial (see 
Figures 4.12 A & B) drinking -14  ml, and those in the second pre-trial (see 
Figures 4.12 C & D) drinking ~9 ml. In the first pre-trial, the 0.1 mg/kg dose of 
nicotine did not produce a CTA (p = 0.0673), despite a trend in that direction, 
whereas at the 0.4 mg/kg dose a significant CTA was observed (p = 0.0007; 
see Figures 4.12 A & B). We therefore conducted the second pre-trial with a 
lower dose of nicotine, which produced similar results (see Figures 4.12 C & D), 
however, this time rats exhibited significant CTA at both nicotine doses (0.1 and 
0.2 mg/kg) tested (p = 0.0484 and p = 0.0153, respectively).
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A & B) Pre-trial 1: CTA produced by 0.1 and 0.4 mg/kg nicotine; C & D) Pre-trial 2: CTA 
produced by 0.1 and 0.2 mg/kg nicotine 
Two flavoured solutions were presented alternately, with each rat receiving its assigned 
dose of nicotine (0.1, 0.2 or 0.4 mg/kg, s.c.), or saline, immediately after removing the 
flavoured solutions, and then being returned to their home cage. Flavour-drug pairings 
were counterbalanced to balance out effects of palatability of the two flavours. The 
order of nicotine and saline injections was also counterbalanced. An additional 10 ml of 
water was presented 3-4 h after removing the flavoured solutions on conditioning days, 
to prevent dehydration and weight loss. Each rat was given two drug and two saline 
conditioning sessions prior to the two-bottle choice tests (see section 4.4.2.2).
Data shown are mean ± S.E.M, n - 4  per group; *p<0.05, ***p<0.001 (Significant 
difference in fluid intake from 50 %)
4.4.3.2 Effect of vaccination on CTA
Conditioning sessions were conducted as described above (see section 
4.4.3.1); rats were exposed to each solution/injection pairing on four occasions
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to maximise conditioning effects with the low nicotine doses used. Based on the 
results of the pre-trials, we examined doses of 0.1 and 0.05 mg/kg nicotine.
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N i c o t i n e - p a i r e d  s o l u t i o n
0
1 2 3 4 T e s t
CTA produced by 0.05 mg/kg nicotine in control (A; TT-Cysteine) and immunised (B; 
TT-CotSH) groups; CTA produced by 0.1 mg/kg nicotine in control (C; TT-Cysteine) 
and immunised (D; TT-CotSH) groups; Data shown are mean ± S. E. M, n = 6-8 per 
group; ****p<0.0001 (Significant difference in fluid intake from 50 %)
Two flavoured solutions were presented alternately, with each rat receiving its assigned 
dose of nicotine (0.05 or 0.1 mg/kg, s.c.), or saline, immediately after removing the 
flavoured solutions, and then being returned to their home cage. Flavour-drug pairings 
were counterbalanced, as was the order of nicotine and saline injections. An additional 
15 ml of water was presented 3-4 h after removing the flavoured solutions on 
conditioning days, to prevent dehydration and weight loss. Each rat was given 4 drug 
and 4 saline conditioning sessions prior to the two-bottle choice tests.
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Water consumption during the initial training averaged around 16 ml/day, which 
decreased to approximately 9 ml/day once conditioning sessions were initiated 
(data not shown). In the first conditioning session, the consumption of both 
nicotine- and saline-paired solutions was very similar at around 14 ml. Over the 
course of the 4 conditioning sessions, consumption of the nicotine-paired 
solution gradually decreased from one session to the next (see Figure 4.13). In 
the two-bottle choice tests, all groups demonstrated a highly significant 
conditioned taste aversion (p < 0.0001), despite the low concentrations of 
nicotine used in these experiments.
Vaccination against cotinine did not appear to affect the magnitude of the 
conditioned taste aversion to nicotine observed at either of the doses tested.
4.4.4 Discussion
Over the course of a week, rats were trained to drink their daily fluid intake 
within a 1-hour period. The development of conditioned taste aversion to 
flavoured solutions paired with injections of saline / nicotine over a range of 
doses was then examined in two pre-trials, before the effect of anti-cotinine 
vaccination on nicotine conditioned taste aversion were studied in a larger trial.
Fluid consumption
The variation in water consumption between trials is likely to be due to 
differences in the age and size of the animals. All rats on the drink deprivation 
schedule were closely monitored for weight loss and signs of dehydration, 
neither of which were observed. Animals tended to lose a couple of grams of 
body weight as a result of the initial change from 24-h to 1-h access to water, 
however they rapidly adjusted to the new access schedule and usually regained 
the weight initially lost by the end of the experiment.
Although weight differences within each trial were marginal, the rats used in the 
second pre-trial were several weeks younger than those used in the first pre­
trial, and consequently slightly smaller (250 -  300 g versus 300 -  350 g), which 
could explain why their required daily intake of water was a little lower.
However, there appears to be an upper limit to daily fluid requirement, since the 
vaccinated rats, which were approximately 3 months older and also heavier
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(450 -  550 g) than those used in the first pre-trial, did not drink noticeably more 
water during their training period.
Water consumption decreased by several millilitres once conditioning sessions 
started. Several hours after each conditioning session, rats were given access 
to a limited ration of water overnight (10 ml in the pre-trials, 15 ml for the 
vaccinated animals). The consumption of this overnight ration the night before 
the next 1-h water access session was likely to be responsible for the slight 
reduction in the amount of water drunk on the days in between conditioning 
sessions.
Conditioned taste aversion to nicotine
Pairing of nicotine administration (0.2 -  0.4 mg/kg, s.c.) with the consumption of 
a flavoured solution has been shown to produce a significant conditioned taste 
aversion in rats (Shoaib et al 2000), using the two-bottle choice test procedure. 
Similar results have also been obtained using mice (Gommans et al 2000). Our 
results are in agreement with these findings (see Figure 4.12) and show that the 
conditioned taste aversion resulting from the association of the taste of a 
flavoured solution with an injection of nicotine can be seen even with very low 
doses of nicotine (0.05 -  0.1 mg/kg; see Figures 4.12 & 4.13). The effect was 
especially strong when the number of conditioning sessions prior to the two- 
bottle choice tests was increased (see Figure 4.13).
Pre-treatment with DHpE (0.5 - 5.0 mg/kg, s.c.) 30 min prior to nicotine 
administration fails to block nicotine (0.4 mg/kg, s.c.) conditioned taste aversion 
(Shoaib et al 2000). Co-administration of DHpE (5.0 mg/kg, s.c.) together with 
nicotine (0.2 - 0.4 mg/kg, s.c.) on the other hand, prevented the development of 
conditioned taste aversion. This observed short-lasting competitive antagonism 
by DHpE suggests that aversive effects of nicotine may be mediated, at least in 
part, by a4p2* nAChRs (Shoaib et al 2000).
Mice have also been shown to display a strong conditioned taste aversion to 
nicotine, which has been shown to be DHpE-sensitive in this species too 
(Gommans et al 2000). Further evidence for the involvement of a4p2 nAChRs 
in mediating conditioned taste aversion comes from studies using knockout 
mice. Mice lacking the p2 nAChR subunit show a strong reduction in nicotine- 
induced conditioned taste aversion compared to wild-type controls, indicating
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that p2* nAChRs are involved in mediating the aversive effects of nicotine 
(Shoaib et al 2002).
Conditioned taste aversion studies rely on systemic nicotine administration, 
which also targets peripheral nAChRs. The activation of such receptors has the 
potential to produce noxious and toxic effects, leading to the expression of 
conditioned taste aversion. The same problem occurs with intra-venous self­
administration procedures, and high concentrations of intravenously 
administered nicotine have been observed to produce aversive effects as a 
result (Rose & Corrigall 1997). However, infusion of nicotine directly into the 
VTA (to exclude peripheral effects) also appears to produce both aversive and 
rewarding effects, depending on the concentration of nicotine administered 
(Laviolette & van der Kooy 2003). Examining the effects of nicotine infusion into 
various brain regions, Shoaib and Stolerman (1995) found that conditioned 
taste aversion was produced by bilateral nicotine administration directly into the 
nucleus accumbens, and that this effect was blocked in rats pre-treated with the 
nicotinic antagonist mecamylamine. Infusion of nicotine directly into the VTA, 
striatum, hippocampus and several other brain regions, on the other hand, 
failed to produce CTA. It therefore appears that the aversive effects produced 
by systemically administered nicotine may be mediated at least in part through 
nicotinic receptors located in the NAcc (Shoaib & Stolerman 1995).
Effects of anti-cotinine vaccination
By reducing cotinine-mediated antagonism of nicotinic effects, anti-cotinine 
vaccination should enhance the efficacy of NRT and increase the chances of a 
quit attempt being successful. Unfortunately, in this study anti-cotinine 
vaccination did not appear to result in an enhancement of the conditioned taste 
aversion to nicotine observed, compared with control-vaccinated rats (see 
Figure 4.13). However, it is very likely that the lack of a vaccination effect was 
due to the low anti-cotinine antibody titres achieved in this Trial (~1:800; see 
Figure 2.10, section 2.3.3.3J as a result of the mislabelling of vials containing 
the conjugates (see section 2.3.2.3.4), and the consequent mis-vaccination of 
rats.
As far as I am aware, none of the studies into anti-nicotine vaccines have 
examined effects on conditioned taste aversion, but titres achieved in other
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behavioural studies showing effects of nicotine vaccines (Pentel et al 2000, 
Lindblom et al 2002, LeSage et al 2005) have been much higher (> 1:10,000) 
than those obtained here. The experiment therefore needs to be repeated in 
rats with higher titres of anti-cotinine antibodies in order to be able to assess the 
impact of such antibodies on the development of conditioned taste aversion to 
nicotine.
4.5 Effects of anti-cotinine vaccination on mecamylamine-
precipitated withdrawal
4.5.1 Introduction
Chronic tobacco use generally results in a state of "physical dependence", 
where termination of drug administration results in an abstinence syndrome, 
comprising symptoms such as irritability, anxiety, depression, increased hunger, 
restlessness, difficulty concentrating, sleep disturbances, weight gain, 
decreased heart rate and craving for tobacco (Malin 2001). By relieving these 
symptoms, smoking acts as a "negative reinforcer", and has been implicated in 
the relapse of many smokers during a quit attempt. So, whilst positive 
reinforcement is the main factor in the acquisition and routine maintenance of 
the smoking habit, the abstinence syndrome and the ability of renewed smoking 
to provide negative reinforcement can play an important role during a cessation 
attempt (Malin 2001).
Development of a preclinical model to assess nicotine withdrawal 
Malin and colleagues have developed a preclinical model of nicotine abstinence 
syndrome in the rat (Malin et al 1992), in which dependence is induced through 
continuous subcutaneous infusion of nicotine (1.05 or 3.15 mg/kg/day free 
base) via an osmotic minipump for 7 days, and abstinence can be initiated by 
terminating the infusion through pump removal. The result is an abstinence 
syndrome involving a pattern of behaviours resembling opiate abstinence in the 
rat (Malin et al 1992).
In order to quantify the severity of nicotine withdrawal, the number of 
occurrences of each sign is scored against a standard checklist of abstinence 
signs included teeth chattering, chewing, gasping, writhing, head shakes, body
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shakes, tremors (particularly cheek tremors), ptosis and miscellaneous less 
frequent signs. The subject's overall abstinence score is defined as the number 
of signs cumulated across all categories (Malin et al 1992). The group termed 
these behavioural abstinence signs "somatic abstinence signs" to distinguish 
them from other behavioural changes, such as changes in trained or 
conditioned behaviour, but suggested that the term "somatic behavioural signs" 
might be more appropriate since some signs (such as vacuous chewing or a 
wet dog shake) were not so much changes in somatic state as an actual 
somatically expressed behaviour coordinated by the CNS (Malin 2001).
The procedure appears to be a relatively robust model of nicotine dependence, 
with evidence from several groups indicating that the observed abstinence 
behaviours are the result of a period of nicotinic receptor overstimulation 
followed by reduced nicotinic stimulation.
- Abstinence scores are greater following nicotine infusion than saline infusion, 
and increased with nicotine dose (Malin et al 1992, Hildebrand et al 1997).
The amount of nicotine typically infused (1-3 mg/kg/day free base) did not 
appear to debilitate the rats during the infusion period in terms of locomotor 
activity, open-field behavioural observations, weight gain, food consumption or 
operant performance for food reward (Malin 2001).
- Significantly more abstinence signs are observed at 16 h after the end of drug 
infusion (by pump removal) than before infusion, during infusion or following a 
subsequent recovery period (Malin et al 1992).
- Nicotine abstinence can be potently and promptly reversed by injection of 0.4 
mg/kg nicotine (Malin et al 1992).
- Administration of a nicotinic antagonist such as dihydro-p-erythroidine 
(Epping-Jordan et al 1998, Malin et al 1998), mecamylamine (Malin et al 1994, 
Hildebrand et al 1997), hexamethonium (Malin et al 1997) or chlorisondamine 
(Hildebrand et al 1997) also promptly precipitated the abstinence syndrome. 
Injection of mecamylamine or chlorisondamine even appeared to result in a 
larger increase in the abstinence score than termination of nicotine infusion by 
pump removal (Hildebrand et al 1997).
Nicotine replacement therapy (NRT) primarily improves cessation efforts by 
reducing the severity of withdrawal symptoms and cravings occurring as a
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consequence of nicotine abstinence. It provides an alternative source of 
nicotine, avoiding exposure to various other carcinogenic components 
contained in cigarette smoke, and is the most commonly used medication for 
smoking cessation (Schneider et al 2001, Hughes 2003, Foulds et al 2004). The 
anti-cotinine vaccine is designed to make NRT more effective by removing or 
reducing any cotinine-mediated antagonism of nicotine's actions by initiating the 
production of cotinine-specific antibodies, which bind the metabolite and prevent 
it from crossing the blood-brain-barrier. We therefore used this animal model of 
nicotine withdrawal to examine the effects of anti-cotinine vaccination on the 
expression of a nicotine abstinence syndrome in nicotine-dependent rats.
4.5.2 Methods
4.5.2.1 Animals & apparatus
As a result of the mislabelling of vials containing fresh conjugate solutions for 
vaccination (see section 2.3.2.3.4), the "control" vaccinated rats had developed 
some (low) anti-CotSH antibody titres (see Figure 2.9 & section 2.3.3.3). We 
therefore decided to only use rats with the lowest (for "control" groups) and 
highest titres (for "vaccinated" groups) for the experiment.
Experiments were performed in the same set-up as the locomotor experiments 
(see Newcastle apparatus 4.2.2.1), with locomotor activity recorded as 
described. In addition to scoring somatic signs during the experiment (see
4.5.2.3), each box/rat was also filmed during the test using video cameras and a 
video recorder, and the tapes stored as a record and backup. The use of a split 
screen allowed all four boxes to be filmed simultaneously.
4.5.2.2 Minipump implantation
Rats were anaesthetised with isofluorane, and an incision made on one flank. 
After creating a skin pocket by means of blunt dissection, rats were implanted 
with a 2ML1 Alzet osmotic minipump filled with nicotine solution (to deliver 3.16 
mg/kg/day nicotine base in physiological saline), which was administered as a
7-day continuous infusion, rendering the animal nicotine-dependent. Control 
animals were implanted with a “blank” (a piece of plastic of similar size, shape & 
weight as a minipump). The incision was closed using wound clips.
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4.5.2.3 Behavioural observations
On day 7, each rat was injected subcutaneously with 1 ml/kg saline, placed in a 
locomotor activity box, and observed for 30 min. Rats were then challenged with 
mecamylamine HCI (Sigma) by subcutaneous injection (1 mg/kg), and observed 
for a further 60 min.
Rats were observed one at a time for 1 min periods (4 rats per run, so each was 
observed for 1 min every 4 min). Behaviours were scored against a checklist of 
behavioural signs associated with nicotine abstinence (developed and validated 
by Malin et al 1992). Categories included body and head shakes, cheek 
tremors, teeth chatters and chews, scratches, ptosis, eye blinks, foot and 
genital licks, and miscellaneous less frequent signs (yawns, escape attempts, 
gasps and writhes). Ptosis was scored no more frequently than once each 
minute (i.e. present/absent), and all other signs were scored as number of 
observed behaviour per minute, with any continuous behaviour (scratching, foot 
licking, tremors etc) counted no more than once every 15 sec. All sessions were 
captured on video (VHS) as backup.
In addition to the behavioural observations, the rats’ locomotor activity was also 
monitored throughout the 90 min session (using the apparatus described in 
section 4.2.2.1).
At the end of these experiments rats were terminally anaesthetised and 
perfused with PBS (see section 3.2.2.2.2), and brain tissues used for 
radioligand binding and determination of blood and brain nicotine and cotinine 
levels (see Chapter 3).
4.5.2.5 Data analysis
Locomotor activity was recorded at 10 min intervals over the entire 90 min 
measurement period, and then summarised to give total activity in the baseline 
(1 - 30 min) and post-mecamylamine phase (31 - 90 min), respectively. A two- 
way AN OVA with factors vaccination (control vs active) and treatment (blank vs 
nicotine) was performed, followed by Bonferroni's post-hoc analysis.
Behavioural signs were scored as above (see section 4.5.2.3); they are 
presented as either total abstinence score (sum of all behaviours scored in a 
given period of time) or as scores for individual signs. Analysis of total scores 
(baseline, post-mec & post-mec minus baseline) and scores for individual signs
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Locomotor activity measurements were divided into baseline activity (30 min 
prior to mecamylamine administration) and post-mecamylamine activity (60 
min).
Baseline locomotor activity declined steadily over the course of the 
measurement period (data not shown). Activity levels (distance travelled) over 
the baseline period in the control groups (-4,000 (TT-Cysteine); ~4,500 (TT- 
CotSH); see Figure 4.14 A) were comparable to those of the control groups 
(-4,500 (TT-Cysteine), 4,800 (TT-CotSH)) in the first 30 min of the experiments 
on the effects of acute nicotine administration (see section 4.1 & Figure 4.5 B). 
Activity in the TT-Cysteine vaccinated group receiving a chronic nicotine 
infusion (-4,500) was similar to both of the control groups, whereas the 
nicotine-treated group immunised with TT-CotSH (-3,500) had much lower 
activity levels, which were more like the high-dose (0.4 mg/kg) nicotine groups 
in the acute nicotine administration study (-3,000 (TT-Cysteine); -3,400 (TT- 
CotSH)). The difference in activity levels between the saline- and nicotine- 
treated TT-CotSH groups in this study was significant (p = 0.0199; see Figure 
4.14 A), resulting in an overall significant interaction of vaccination and 
treatment (F(vaccination x treatm ent)^ = 5.023, p = 0.0345).
Activity levels continued to decline over time after mecamylamine administration 
(data not shown). No significant differences between any of the groups were 
observed (see Figure 4.14 A), although there was still a trend towards lower 
locomotor activity in the nicotine-treated, compared to the saline-treated TT- 
CotSH group; however, this was not significant (p = 0.5643).
Total abstinence score
Rats were observed during both the baseline and post-mecamylamine periods, 
and behaviours were scored against a checklist of behavioural signs associated 
with nicotine abstinence. The total abstinence scores (sum of all behaviours 
scored over each period) are shown in Figure 4.14 B.
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Figure 4.14: Effects of anti-cotinine vaccination on the occurrence o f somatic 
behavioural signs during mecamylamine-precipitated nicotine withdrawal
6 0 0 0 C o n t r o l /B la n k
C o n t r o l /N ic o t in e
A c t iv e /B la n k
A c tiv e /N ic o t in e
3 0 0 0
p=0.0512
C o n t r o l / B l a n k  
C o n t r o l / N i c o t i n e  
A c t iv e /B la n k  
A c t iv e /N ic o t in e
B a s e l i n e P o s t - M e c P o s t - M e c  - B a s e l i n e
Chews Eye Blinks Head Shakes Ptosis
A) Locomotor activity pre- and post- 
mecamylamine administration 
B) Overall abstinence score (total 
signs)
C) Scores for individual somatic 
behavioural abstinence signs (Scores 
shown are post-mecamylamine 
scores minus baseline, except for 
ptosis, which was not observed prior 
to mecamylamine administration in 
any of the groups)
Rats were implanted subcutaneously with either osmotic minipums delivering 3.16 
mg/kg/day nicotine (base) for 7 days or a "blank" (mock minipump). On day 8, rats 
were given an injection of saline and placed in locomotor activity boxes for 30 min, 
where behavioural signs were observed and scored.
They were then injected with 1 mg/kg mecamylamine (s.c.) and returned to the activity 
boxes and scored for behavioural signs for a further 60 min.
The number of occurrences of each sign was recorded, and the subject's overall 
abstinence score (total score) defined as the number of signs cumulated across all 
categories in a given period of time (e.g. post-mecamylamine administration).
Data presented are mean ± S.E.M, n = 6-8 per group; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
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Baseline scores: No differences were observed between groups in terms of 
baseline abstinence scores, i.e. prior to mecamylamine administration (see 
Figure 4.14 B).
Post-mecamylamine scores: Despite the low anti-CotSH antibody titres 
achieved in this trial (~800), due to the mislabelling of the fresh batch of 
conjugates and subsequent mis-vaccination of rats (see sections 2.3.2.3.4 &
2.3.3.3), total scores were higher in the nicotine-treated group vaccinated 
against cotinine than in the nicotine-treated TT-Cysteine group. Analysis of the 
post-mecamylamine total scores revealed a significant main effect of 
vaccination (F(vaccination)i,24 = 6.421, p = 0.0182), and a highly significant 
main effect of treatment (F(treatment)i,24 = 49.732, p < 0.0001). Post-hoc test 
showed significantly increased scores for nicotine pre-treated rats compared to 
the corresponding controls, with a greater difference between the TT-CotSH 
groups than the groups vaccinated with TT-Cysteine (p < 0.01 and p < 0.0001 
for control and active vaccine groups, respectively). The difference between the 
two nicotine-treated groups, however, was not significant (p = 0.0832; see 
Figure 1.14 B).
Post-mecamylamine minus baseline: Both the treatment and vaccination effects 
were still seen when the baseline scores were subtracted from the post- 
mecamylamine scores (F(vaccination)i>24 = 7.190, p = 0.0131 and 
F(treatment)i,24 = 41.585, p < 0.0001). Post-hoc test showed significantly 
increased scores for nicotine pre-treated rats (see Figure 4.14 B) compared to 
those implanted with a blank (p < 0.01 and p < 0.001 for control and active 
vaccine groups, respectively); again the difference was greater between the two 
TT-CotSH vaccinated groups. The increase in somatic behavioural abstinence 
signs in nicotine-treated rats vaccinated against cotinine, compared to those 
receiving control vaccine, was also very nearly significant (p = 0.0512).
Individual somatic signs
The scores for the four signs that accounted for the majority of the total 
abstinence score (89.5 - 99.8%) are shown in Figure 4.14 C. The remaining 
abstinence signs occurred quite rarely in any of the groups.
Chews: In the "chews" category, significant main effects of vaccination and 
treatment were observed (F(vaccination)ii24 = 9.648, p = 0.0048 and
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F(treatment)ii24 = 34.198, p < 0.0001). Post-hoc analysis revealed significant 
increases in the number of chews in nicotine-treated rats compared to their 
control group (p < 0.01 (TT-Cysteine); p < 0.001 (TT-CotSH)). The difference 
was again greater in the group vaccinated against cotinine, and a significant 
increase in chews was also observed in the nicotine-treated TT-CotSH, 
compared to the nicotine-treated TT-Cysteine group (p < 0.05).
Eye blinks: A treatment effect was again observed (F(treatment)i,24 = 13.991, p 
= 0.0010). Although the number of eye blinks observed was increased in both 
nicotine-treated groups, compared to their controls, the difference was only 
significant in the TT-Cysteine vaccinated groups (p < 0.01).
Head shakes: For "head shakes" a main effect of treatment was also observed 
(F(treatment)ii24 = 12.259, p = 0.0018), but this time the increase in scores was 
only significant in the TT-CotSH vaccinated groups (p < 0.01).
Ptosis: Ptosis was only observed after mecamylamine administration, but a 
significant main effect of treatment was observed for this abstinence sign, too 
(F(treatment)i,24 = 23.725, p < 0.0001). The post-hoc analysis revealed 
significant increases in both nicotine-treated groups, compared to their control 
groups, with a greater increase in the TT-Cysteine group (p < 0.01), compared 
to the group vaccinated against cotinine (p < 0.05).
4.5.4 Discussion
Comparison between the rat model of nicotine abstinence syndrome and 
withdrawal in human smokers
There are obvious differences between this rat model and the clinical situation 
experienced by smokers. For reasons of practicality, the period of nicotine 
exposure is shortened to 1-2 weeks, compared with years of smoking. To 
compensate for this, the rate of nicotine exposure is quite high. At the 1 
mg/kg/day rate, the amount of nicotine administered is comparable to the 
amount ingested by a 70 kg smoker smoking three packs of average-yield 
cigarettes per day, whereas at the 3 mg/kg/day rate, the amount administered is 
comparable to that ingested by a 5 pack/day smoker of high-yield cigarettes 
(Malin 2001).
Another difference is the continuous and subcutaneous drug administration in 
the laboratory model, compared to the intermittent administration by inhalation
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in smoking. However, it is well established that many heavy smokers "titrate" 
their smoking consumption to maintain relatively stable levels of serum nicotine 
during waking hours (Malin 2001).
A further important point to bear in mind is that rats generally have much higher 
metabolic and drug clearance rates than humans. Blood nicotine concentration 
can therefore provide a more meaningful basis of comparison: a blood nicotine 
concentration of 40 ng/ml has been measured in rats infused with ~3 mg/kg/day 
nicotine for 7 days (Malin 2001), as well as in rats infused with 4 mg/kg/day for 
14 days (Sanderson et al 1993). This is virtually identical to the concentration 
maintained by human subjects smoking 30 high-yield cigarettes per day during 
waking hours (Benowitz et al 1982).
Characteristics of the nicotine abstinence syndrome in rats 
Several groups have observed decreased locomotor activity as a result of 
nicotine withdrawal in rats previously infused with nicotine (~3 mg/kg/day, free 
base) for 7 (Hildebrand et al 1997) or 14 days (Fung et al 1996) compared to 
saline-infused animals, when using pump removal (spontaneous withdrawal) to 
initiate nicotine abstinence. However, when withdrawal was induced by injection 
of a nicotinic antagonist (mecamylamine or chlorisondamine), Hildebrand and 
colleagues did not see a decrease in locomotor activity in nicotine-treated rats, 
compared to those pre-treated with saline (Hildebrand et al 1997). This is also 
in agreement with our results, as we observed no significant effect of 
mecamylamine on locomotor activity.
Administration of mecamylamine did, however, induce a withdrawal syndrome 
in all groups, which emerged gradually, with only few signs detected in the first 
5 min after the injection, in agreement with Hildebrand et al (1997). A high dose 
of mecamylamine (5 mg/kg) has previously been reported to induce a pseudo­
abstinence syndrome in nicotine naive rats, suggesting that blockade of 
endogenous nAChR stimulation might produce abstinence-like signs (Malin et al 
1994). Hildebrand et al (1997) also found that their saline control group showed 
a trend towards an increase in overall signs at a dose of 1 mg/kg 
mecamylamine, and in control rats in our experiment, this effect was significant 
compared to baseline.
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The increase in overall abstinence signs observed was significantly greater in 
the groups receiving a subcutaneous nicotine infusion, compared to controls. 
Malin and colleagues observed that nicotine-infused rats administered 
mecamylamine displayed significantly more gasps/writhes, teeth chatter/chews, 
shakes/tremors and ptosis than controls (Malin et al 1994). Although we saw 
hardly any gasps/writhes, we did detect significant increases in chews, 
headshakes and ptosis in nicotine-infused rats, in agreement with this group's 
findings.
Hildebrand and colleagues noted that the abstinence syndrome precipitated by 
chlorisondamine was characterised only by a significant increase in teeth 
chatter and overall signs (Hildebrand et al 1997). Thus, it differed slightly from 
that precipitated by mecamylamine, as well as from the abstinence syndrome 
elicited through termination of nicotine infusion by removal of the osmotic pump. 
They concluded that this was likely to be due to mecamylamine acting centrally 
as well as peripherally, whereas chlorisondamine was only acting peripherally at 
the dose used in this study, although, at higher doses, chlorisondamine has 
also been shown to have central effects (El-Bizri & Clarke 1994a&b, Engberg & 
Hajos 1994).
Several research groups have modified or extended this model of nicotine 
withdrawal by measuring emotional/motivational changes associated with 
nicotine abstinence such as conditioned place aversion (Suzuki et al 1996), 
intracranial self-stimulation (ICSS) thresholds (Epping-Jordan et al 1998) and 
the startle response (Helton et al 1993). While mecamylamine produced place 
aversion in chronically nicotine-treated, but not in sham-operated rats (Suzuki et 
al 1996), it did not lead to place aversion after acute injection of nicotine (0.2 - 
0.8 mg/kg). It therefore seems likely that the mecamylamine-precipitated place 
aversion as a result of chronic nicotine treatment reflects physical dependence 
on nicotine, i.e. a withdrawal sign. During nicotine withdrawal, significant 
increases were seen in the amplitude of the acoustic startle response for 4 
days. Again, administration of 0.4 mg/kg nicotine (i.p.) prior to testing attenuated 
the increased reactivity observed during nicotine withdrawal (Helton et al 1993). 
Nicotine withdrawal induced by removal of osmotic pumps or DH0E 
administration in dependent rats also resulted in a significant decrease in brain
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reward function for four days, as measured by elevations in brain reward 
thresholds (Epping-Jordan et al 1998).
Effects of vaccination on nicotine abstinence syndrome in rats 
Administration of nicotine has been shown to alleviate the abstinence 
syndrome, decreasing the behavioural signs of withdrawal. However, in rats 
passively immunised with serum containing nicotine-specific antibodies, acute 
nicotine administration failed to reduce signs of withdrawal (Malin et al 2001). 
This is thought to be due to the antibodies binding nicotine and retaining it in the 
blood, and the authors suggested this might reduce the likelihood of relapse in 
abstinent smokers by rendering tobacco use less effective in relieving 
withdrawal. On the other hand, it might also lead to increased nicotine 
consumption in an attempt to overcome the effects of the anti-nicotine 
antibodies.
Vaccination against cotinine should reduce cotinine-mediated antagonism of 
nicotine’s actions by binding cotinine and sequestering it in the bloodstream, 
thus preventing it from crossing the blood-brain-barrier. This is supported by the 
increases in total abstinence scores in nicotine-treated animals, which were 
greater in the TT-CotSH vaccinated group, than in the control vaccine group, to 
the extent that the difference was very nearly significant once baseline scores 
had been subtracted (see Figure 4.14 B). The significantly greater "chews" 
score in the nicotine-treated TT-CotSH, compared to the nicotine-treated TT- 
Cysteine group, provides further evidence that the anti-cotinine vaccine 
removed cotinine-mediated antagonism of nicotine (see Figure 4.14 C).
Anti-cotinine vaccination is aimed at making NRT more effective via the 
reduction of cotinine-mediated antagonism of nicotine's actions. This should 
increase the efficacy of NRT, enabling a quitter to remain abstinent from 
smoking tobacco whilst using less NRT (or a formulation containing a lower 
dose of nicotine) to alleviate the symptoms of nicotine withdrawal. As an added 
benefit, the exposure of the quitter to various carcinogens contained in tobacco 
smoke would also be reduced as a result.
Unfortunately, the anti-cotinine antibody titres achieved in this Trial were very 
low (~1:800; see Figure 2.10) as a result of the mislabelling of conjugates and
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the resulting mis-vaccination of control animals with active vaccine and vice- 
versa (see section 2.3.3.3). Consequently all rats in the "control" group raised 
some (low) anti-CotSH titres. By giving an extra large dose (5 times the usual 
concentration) of the old conjugates as a final booster injection, we were able to 
restore the active and control groups to a certain extent (see section 2.3.3.3 & 
Figure 2.9); however, the titres in the active group were not very high.
We therefore picked the rats with the highest and lowest anti-CotSH antibody 
titres, respectively, to use for the TT-CotSH/active vaccine and TT- 
Cysteine/control vaccine groups in this set of experiments. This arrangement 
was not ideal, but it allowed us to proceed with the experiment. The question 
remains, whether some of the vaccination effects observed might have been 
greater if higher anti-cotinine antibody titres had been achieved in the active 
vaccine groups and the control vaccine groups had never been exposed to the 
immunogen.
4.6 Chapter conclusions
The in vivo experiments conducted as part of this thesis were used to study a 
variety of factors and behaviours involved in the acquisition and maintenance of 
nicotine addiction and smoking behaviour, and also to examine several aspects 
of nicotine withdrawal experienced during a quit attempt, as well as the effects 
of vaccination against cotinine on all of the above.
The ability of nicotine to act as a positive reinforcer plays a major part in the 
acquisition and maintenance of nicotine-taking behaviour. Despite procedural 
differences (cigarette smoking versus intra-venous infusion), studies of nicotine 
self-administration in humans and animals have reported similar responses in 
terms of self-administration behaviour (Rose & Corrigall 1997). Our findings are 
in general agreement with previous studies, and show that rats are able to 
acquire and maintain nicotine self-administration over a relatively long period of 
time (see Figures 4.7 & 4.9). Both human and animal studies of nicotine self- 
administration show a relatively flat bell-shaped dose-response curve for 
nicotine, with maximal rates or responding occurring at intermediate nicotine 
doses. Nicotine supplementation via non-contingent nicotine administration
- 2 0 9 -
Chapter 4 -  Behavioural measures of nicotine dependence
suppresses nicotine self-administration behaviour in both animal models and 
human cigarette smokers, and administration of nicotinic antagonists also 
reduces responding, although human studies tended to observe a transient 
increase in smoking, which is thought to represent an attempt to compensate 
for nicotinic receptor blockade (Rose & Corrigall 1997).
The genetic background of an individual also appears to be an important factor 
determining the acquisition and strength of nicotine addiction, and responses to 
nicotine in several behavioural tasks have been shown to vary considerably 
between rat strains (Pescatore et al 2005). While Shoaib et al (1997) found that 
Sprague-Dawley (SD) and Long Evans (LE) rats (outbred strains) acquired self­
administration in 2-hour daily sessions, and (inbred) Lewis (LEW) and Fisher 
(F344) strains failed to acquire nicotine self-administration under these 
conditions, Brower et al (2002) observed that LEW rats self-administered 
nicotine more readily than F344 or Holtzman rats, using a 23-h unlimited access 
setup. In the latter study, the LEW rats were also seen to be more likely to 
continue self-administration in the face of increasing work requirements and 
decreasing drug reinforcement (Brower et al 2002).
Pavlovian conditioning processes have also been implicated in the control of 
drug seeking and drug taking behaviours, as well as relapse following treatment 
for the abuse (Bevins et al 2001). Thus repeated pairing of the psychoactive 
effects of nicotine (unconditioned stimulus) with cues serving as conditioned 
stimuli is thought to result in such cues acquiring the ability to control behaviour, 
even in the absence of nicotine. In smokers, such cues might include throat 
stimulation, taste/odour of cigarettes, discrete objects associated with smoking 
(cigarette pack, matches/lighter, ashtray), as well as situational (contextual) 
cues like a bar, living room, smoking area, or vehicle (Rose & Corrigall 1997, 
Lazev et al 1999, Bevins et al 2001).
Conditioned locomotor sensitisation is often used to examine the behavioural 
processes involved in Pavlovian conditioning with nicotine, and several groups 
have demonstrated that the increase in locomotor activity observed with 
repeated nicotine administration is enhanced when drug injections are paired 
with a distinct context, and can even be induced by context alone (Walter & 
Kuschinsky 1989, Reid et al 1996, Bevins et al 2001). We were able to confirm
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that repeated administration of nicotine resulted in an enhancement of the 
hyperlocomotion observed after acute administration, and that the effect was 
more pronounced in the animals that had received their nicotine injections in the 
testing environment (see Figures 4.1 & 4.3). However, after only four pairings of 
drug administration with the context, the environmental stimuli alone only 
induced an increase in activity compared to their unpaired controls, but 
locomotor activity of the nicotine-treated group was not significantly greater than 
that of the saline-treated animals (see Figure 4.1).
Environmental stimuli associated with availability and subjective actions of 
nicotine are thought to play an important role in relapse to tobacco smoking in 
abstinent smokers (Caggiula et al 2001, LeSage et al 2004, Liu et al 2006). 
Clinical studies have demonstrated that smoking-related cues produce an 
enhanced desire to smoke and increase the rate, intensity and time of smoking 
(Mucha et al 1998, Lazev et al 1999). In fact, smoking de-nicotinised cigarettes 
(i.e. cues alone) produced an equal amount of smoke intake and similar levels 
of satisfaction compared to nicotine-containing cigarettes (i.e. cues plus 
nicotine; Butschky et al 1995, Gross et al 1997, Rose et al 2000).
In agreement with previous studies (Shaham et al 1997, Caggiula et al 2001, 
LeSage et al 2004, Liu et al 2006), we were able to confirm that cues previously 
associated with nicotine administration are able to induce reinstatement of 
nicotine-seeking (lever-pressing) behaviour to a similar degree as priming 
doses of nicotine (Chiamulera et al 1996, Shaham et al 1997), following 
extinction of self-administration behaviour (see Figure 4.10).
These animal studies support clinical observations that smoking-related cues 
enhance the desire to smoke. Tobacco smoking (or nicotine self-administration) 
is particularly effective in establishing or even magnifying the incentive 
properties of accompanying environmental stimuli (Balfour et al 2000, Caggiula 
et al 2001). Indeed, environmental stimuli associated with nicotine intake 
appear to play a more important role in maintaining nicotine self-administration 
and tobacco smoking, than is the case for other drugs of abuse (Balfour et al 
2000).
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The ability of a drug to exert discriminable subjective effects is central to the 
maintenance of addiction, and plays a major part in encouraging the 
development of drug-seeking behaviour by directing it towards one substance 
rather than another. Humans are thought to abuse psychoactive drugs in order 
to obtain their characteristic subjective effects, and a variety of paradigms are 
used to study the ability of animals to identify the subjective effects of a drug. 
Frequently such subjective drug effects become associated with a given 
environment (conditioned place preference / aversion) or, in the case of 
conditioned taste aversion, with the taste of a flavoured solution.
Both rats and mice have been shown to display conditioned taste aversion to a 
flavoured solution previously paired with nicotine administration (Shoaib et al 
2000, Gommans et al 2000, Shoaib et al 2002). Our findings were in agreement 
with these studies, and we observed that rats displayed significant conditioned 
taste aversion even when relatively low doses of nicotine were used during 
conditioning sessions (see Figures 4.12 & 4.13).
Conditioned taste aversion relies on the ability of nicotine to act as an aversive 
stimulus. It has been suggested that such aversive effects might be implicated 
in regulating drug intake and could be important in setting an upper limit to the 
amount of drug consumed (Shoab et al 2003, Laviolette & van der Kooy 2004).
As well as providing positive reinforcement, nicotine has also been shown to act 
as a negative reinforcer by relieving the aversive withdrawal state experienced 
by smokers upon abstinence. This explains why the desire to relieve the 
discomforts of tobacco withdrawal is the most commonly cited reason for 
smokers to relapse during a quit attempt. So, whilst positive reinforcement 
appears to control acquisition and routine maintenance of the smoking habit, 
the abstinence syndrome and the ability of renewed smoking to provide 
negative reinforcement, are central to the failure of many smoking cessation 
attempts (Malin 2001).
A nicotine abstinence syndrome has also been characterised in rats (Malin et al 
1994, Fung et al 1996, Hildebrand et al 1997), after rendering the animals 
nicotine-dependent by means of chronic subcutaneous infusion of nicotine. 
Using mecamylamine to precipitate the abstinence syndrome, we were able to 
demonstrate that rats pre-treated with nicotine exhibited significantly greater
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abstinence scores than controls (see Figures 4.14 B & C), in agreement with 
the above studies.
Nicotine replacement therapy (NRT) is the most widely used medication for 
smoking cessation, and can roughly double the likelihood of success of a quit 
attempt. However, the slow continuous delivery of nicotine from NRT means 
that it is not as effective at relieving withdrawal symptoms as a cigarette, which 
can deliver a high dose of nicotine to the brain almost immediately. As a result, 
the majority of abstinent smokers still relapse during a cessation attempt and it 
is essential to improve the efficacy of NRT in order to provide better relief from 
the symptoms of nicotine withdrawal.
Vaccination against nicotine is being explored as a means of reducing the ability 
of smoking to provide negative reinforcement, by inducing the production of 
anti-nicotine antibodies, which prevent the drug molecules from crossing the 
blood-brain-barrier (LeSage et al 2006). However, the resulting lack of relief 
from withdrawal symptoms could lead to smokers trying to overcome the effect 
of the vaccine by increasing nicotine intake. A further disadvantage is that NRT 
would also be rendered ineffective, leading to a significant reduction in the 
possible treatment options available to an abstinent smoker.
Several of the anti-nicotine vaccines currently under development have been 
shown to affect a variety of behavioural parameters in preclinical studies in rats, 
similar to the ones carried out as part of this thesis (LeSage et al 2006). These 
studies obtained much greater antibody titres (£ 1 :1 0 ,0 0 0 ) than those achieved 
in our studies, at least in part through the use of the relatively aggressive 
Freund's adjuvant, compared to the GSK adjuvant we used (see section 1.7.3). 
Also, some studies employed passive immunisation, utilising a higher dose and 
antibody affinity than had been previously achieved in rats by vaccination; this 
may have further exaggerated the likely efficacy of these vaccines (LeSage et al 
2006).
In contrast to the anti-nicotine vaccines, the proposed anti-cotinine vaccine is 
designed to make NRT more effective. The antibodies raised in response to 
vaccination with this vaccine should bind cotinine, the main metabolite of 
nicotine, retaining it in the blood stream. Preventing cotinine from crossing the
- 2 1 3 -
Chapter 4 -  Behavioural measures of nicotine dependence
blood-brain-barrier should reduce its antagonism of nicotine's effects, increasing 
the ability of NRT to relieve withdrawal symptoms in abstinent smokers. It could 
also be used to help smokers, who are not yet ready to quit, to reduce the 
number of cigarettes smoked per day, thereby decreasing their exposure to the 
many harmful chemicals contained in cigarette smoke and allowing them to 
gradually wean themselves off the habit.
Initially we used the existing stock of cotinine derivative to produce conjugates; 
however, as the antibody titres obtained in the first three trials were 
comparatively low and appeared to be decreasing from one Trial to the next 
(see Figure 2.10), we had another batch of CotSH made. Unfortunately, the 
vials containing TT-CotSH (active vaccine) and TT-Cysteine (control vaccine) 
were mislabelled during the production of the conjugates for vaccination. As 
vaccinations with the old conjugates had already commenced (due to time 
constraints), this lead to rats being immunised with the wrong conjugates (see 
section 2.3.3.3), and resulted in the "control group" developing (low) anti- 
cotinine titres, and the "active group" not developing further anti-bodies. The 
end result was a control group that was no longer a pure control group, and a 
vaccinated group that had very low titres. This meant that differences observed 
between control and active vaccine groups were not as large as they might 
have been, had greater antibody levels been achieved.
Despite the low titres achieved in the later trials, noticeable trends were 
observed in a number of the behavioural experiments:
- Locomotor activity: nicotine-induced hyperlocomotion was more 
pronounced and appeared sooner in the paired group vaccinated against 
cotinine, than in the paired group vaccinated with TT-Cysteine (see 
Figure 4.3). A significant 3-way interaction (pairing x treatment x 
vaccination) on day 3 and a main effect of vaccination on day 4, provide 
further evidence that the anti-cotinine vaccine might be increasing 
nicotine-induced locomotor activity.
- Intravenous self-administration: animals vaccinated against cotinine 
tended to have slightly higher response levels on the active lever, and 
therefore more infusions (see Figures 4.9 A & B), than those vaccinated
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with control vaccine. In the reinstatement test, the active vaccine group 
showed slightly higher levels of responding on the active lever than the 
animals vaccinated with TT-Cysteine at the highest dose tested (see 
Figure 4.10 D).
- Mecamylamine-precipitated nicotine withdrawal: Significant main effects 
of vaccination were found in the post-mecamylamine total abstinence 
scores, both before and after subtraction of baseline scores, as well as in 
the “chews” category. The increase in total abstinence signs (post-mec 
minus baseline) in rats vaccinated against cotinine, compared to those 
receiving control vaccine, was very nearly significant (p = 0.0512), and in 
the “chews” category this difference reached significance.
It seems likely that, if higher anti-cotinine antibody titres could be achieved, the 
trends observed might well become significant effects of vaccination.
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Conclusions and future perspective
5.1 Is there a need for a vaccine targeting cotinine?
Cigarette smoking is the single largest cause of preventable death and disease, 
and many of the 1 .2  billion smokers worldwide will die prematurely as a result of 
their habit (Foulds et al 2004). Cessation can greatly improve health prospects, 
yet of the ~50% of smokers who attempt to quit each year, only a fraction (<5%) 
succeed, despite the use of smoking cessation aids, such as bupropion and 
NRT products (see Chapter 1). Current pharmacotherapy options are clearly not 
effective enough, as the majority of abstinent smokers still relapse. Helping 
smokers to quit has become a public health priority, and more efficacious 
cessation aids are therefore required, if this is to be achieved. Ideally, these 
should reduce the reinforcing properties of nicotine, but also provide some relief 
from withdrawal symptoms, one of the main causes of relapse in abstinent 
smokers.
Several anti-nicotine vaccines are being developed; these aim to break the 
cycle of withdrawal and reinforcement by preventing nicotine from acting at 
nAChRs. Nicotine-specific antibodies raised in response to vaccination bind 
nicotine molecules, thus stopping them from entering the brain. In abstinent 
smokers, this would reduce the ability of a cigarette to relieve withdrawal 
symptoms in the event of a relapse, thereby decreasing nicotine-mediated 
reinforcement of smoking. However, it would also render all NRT products 
ineffective since they act by delivering low levels of nicotine to alleviate the 
symptoms of nicotine withdrawal (see Chapter 1). This led to the proposal to 
target cotinine, the main metabolite of nicotine, in an immunotherapy approach 
to smoking cessation.
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Since the start of the project, nicotine vaccines have progressed from Phase I 
studies in healthy non-smokers to Phase II studies in smokers. In vaccinated 
smokers who achieved high anti-nicotine titres, quit rates were approximately 
doubled; however, when those with lower titres were included in the analysis, 
there was no significant difference, compared to placebo (Cytos Media Release 
2005). Varenicline, a partial agonist at nAChRs, was launched approximately a 
year ago as a new smoking cessation treatment (see Chapter 1). However, quit 
rates appear to be similar to those achieved with NRT, and there have recently 
been some concerns over the safety of varenicline in some patient groups 
(Freedman 2007, Kohen & Kremen 2007). There is therefore clearly still a need 
for a more effective treatment for nicotine dependence.
5.2 Target validation -  interaction of cotinine with nAChRs
Cotinine has been reported to have weak agonist activity at nAChRs, inducing 
dopamine release from rat brain preparations, albeit at 1 0 0 0 -fold higher 
concentrations than nicotine (Dwoskin et al 1999, Pashmi 2004). Our results 
showing cotinine-induced striatal DA release are in agreement with these 
findings (see section 2.2). Cotinine-mediated DA release is attenuated by 
mecamylamine, and pre-treatment with cotinine inhibits nicotine-induced DA 
release from rat striatal minces (Pashmi 2004). This suggests that cotinine is 
acting at nAChRs, and that antagonism of nicotine’s actions is likely to be due 
to desensitisation of nAChRs by cotinine. Removal of cotinine-mediated 
antagonism of nicotine’s actions by targeting cotinine with specific antibodies 
should therefore enhance the efficacy of NRT.
Further examination of the ability of nicotinic antagonists to block cotinine- 
mediated DA release could help to elucidate the nAChR subtypes involved. The 
actions of cotinine, and interactions between nicotine and cotinine, modulating 
DA release could be further explored using behavioural models:
-T o  extend the findings in striatal minces, microdialysis techniques could be 
employed to characterise cotinine-induced dopamine release in vivo, as well as 
the effects of cotinine on DA release in response to nicotine administration. Pre­
treatment with (i.v.) cotinine has previously been observed to dose-dependently
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inhibit nicotine-evoked DA release in this paradigm (Sziraki et al 1999); however 
it remains to be determined whether cotinine administered directly into the brain 
via a microdialysis probe would have the same effect. The effects of nAChR 
antagonists on cotinine-mediated DA release also do not appear to have been 
evaluated.
- Possible reinforcing effects of cotinine might be examined by means of 
intravenous self-administration. A variety of species have been found to self- 
administer nicotine intravenously (Goldberg et al 1981, Risner & Goldberg 
1983, Corrigall & Coen 1989, Donny et al 1995 & 1998, Shoaib et al 1997).
Rats also appear to self-administer nornicotine (Bardo et al 1999); however, 
intravenous self-administration of cotinine does not appear to have been 
attempted.
- The preclinical model of nicotine abstinence syndrome described in section
4.5.1 of this thesis could be used to examine the effects of cotinine on nicotine 
abstinence syndrome: after initiation of spontaneous abstinence (removal of 
osmotic pumps), the effect of cotinine administration on withdrawal could be 
studied. If its agonist activity at nAChRs is sufficiently strong, cotinine should 
alleviate the abstinence syndrome to an extent, though it is unlikely to be as 
effective as nicotine. However, if its primary effect is desensitisation it would 
have no effect or might exacerbate the syndrome. Co-administration of cotinine 
after initiating withdrawal could determine whether the ability of nicotine to 
alleviate withdrawal symptoms was reduced in the presence of cotinine.
- There have also been reports of somatic behavioural abstinence signs in mice 
after prolonged nicotine exposure (Isola et al 1999, Damaj 2003). Although (32* 
nAChRs appear to be involved in the regulation of nicotine self-administration 
(Besson et al 2006), administration of mecamylamine in (32 knockout mice has 
been shown to trigger comparable withdrawal signs as in wild-type mice, 
whereas mice null for the (34 nAChR subunit display significantly milder somatic 
symptoms (Salas et al 2004). This raises the possibility of using knockout or 
other genetically engineered mouse strains to ascertain which nAChR subtypes 
are likely to be involved in cotinine-mediated effects.
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5.3 Immune response to vaccination against cotinine
The aim of vaccination against cotinine is to raise cotinine-specific antibodies, 
which bind cotinine and prevent it from entering the brain and interacting with 
nAChRs. Achieving a high anti-cotinine antibody titre is therefore essential to 
determine vaccine efficacy.
The titres achieved varied with trial and some were very low (see section
2.3.3.3 & Figure 2.10), partly due to the mislabelling of the fresh conjugates 
used in Trials 4 & 5 (see section 2.3.2.3.4). However, even in the early trials, 
titres were not as high as those achieved in comparable anti-nicotine vaccine 
studies (Hieda et al 1997, de Villiers et al 2004, Satoskar et al 2003). Titres 
measured in these studies regularly exceeded 1 :1 0 ,0 0 0 , which is due, at least 
in part, to the use of the rather aggressive Freund's adjuvant to stimulate the 
immune response of vaccinated animals.
As explained in section 2.4, we chose to use a GSK proprietary adjuvant, 
developed with a view towards future use in humans, rather than Freund's 
adjuvant, which is too aggressive to be used in clinical studies. By using 
Freund's adjuvant, anti-cotinine titres in future preclinical experiments might be 
increased to a level sufficient to observe reliable effects of vaccination. 
Preclinical studies of nicotine vaccines have used Freund’s adjuvant to achieve 
high antibody titres; however, this may have raised unrealistic expectations 
about the level of immune response that might be expected in clinical studies, 
where Freund’s adjuvant cannot be used. Initial clinical trials of anti-nicotine 
vaccines have shown that antibody titres vary considerably between individuals 
(LeSage et al 2006).
Another strategy for increasing antibody titres would be to increase the dose of 
conjugate (TT-CotSH) administered with each vaccination. In the studies 
presented in this thesis, we used a dose of 5 pg TT-CotSH per vaccination. This 
was based on a comparison of 3 doses (1, 5 & 25 pg) previously carried out by 
Pashmi (Pashmi 2004). Upon closely re-examining the data from this dose- 
comparison study, we found that the range of titres achieved for each dose and 
the low number of animals in each group (n = 5), did not justify the conclusion 
that the medium dose was optimal (see section 2.3.4). However, Pashmi did
- 220 -
Chapter 5 -  Conclusions and future perspective
observe that even the highest TT-CotSH dose, which was 5 times greater than 
that used in our studies, appeared to be well tolerated. It is therefore unlikely 
that an increase in vaccine dose administered with each injection would impact 
negatively on the safety profile of the anti-cotinine vaccine.
Pre-clinical studies on anti-nicotine vaccines have tended to utilise doses of 
25pg of immunogen per vaccination (Hieda et al 1997, 1999 & 2000, Keyler et 
al 1999, Tuncok et al 2001, Satoskar et al 2003, LeSage et al 2005), with some 
even giving doses of up to 250 pg (Lindblom et al 2002, Carrera et al 2004), 
and have achieved much greater titres (see above). Increasing the dose of TT- 
CotSH administered with each vaccination might therefore be a relatively simple 
measure to increase anti-cotinine antibody titres.
In addition to studying the levels of anti-CotSH antibodies raised, we also set 
out to characterise the immune response to the conjugate vaccines (TT- 
CotSH/TT-Cysteine) further:
We determined titres of antibodies specific for the tetanus toxoid portion of both 
conjugates, in order to obtain a more detailed picture of the overall magnitude of 
the immune response. As expected, the levels of anti-TT antibodies were much 
greater (~10-fold) than those measured for anti-CotSH antibodies, due to the 
much greater immunogenicity and size of tetanus toxoid.
Pashmi had previously observed that, whilst anti-CotSH antibodies recognised 
cotinine, they did not interact with any of the other nicotine metabolites 
examined, with the exception of a small degree of cross-reactivity for 
norcotinine, a very minor metabolite of nicotine with no known pharmacological 
activity (Pashmi 2004). Using competitive ELISA techniques, we confirmed the 
specificity of the anti-CotSH antibodies for cotinine (see section 2.3).
Further characterisation of the immune response to anti-cotinine vaccination is 
likely to be advantageous. Several studies on anti-nicotine vaccines have 
determined the affinity of the nicotine-specific antibodies raised (Pentel et al 
2000, Maurer et al 2005). As the affinity of an antibody determines the strength 
with which it binds its antigen, it would be desirable to measure this for the anti- 
cotinine antibodies, too. Knowledge of the isotype of the antibodies raised, and 
whether this changes over the course of the vaccination schedule, would help to
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further characterise the immune response to anti-cotinine vaccination. There 
are several methods for determining the affinity of monoclonal antibodies or 
estimating the mean affinity of polyclonal antibodies; several groups studying 
anti-nicotine vaccines have used competitive radioimmunoassay methods to 
determine the affinity of the antibodies produced (Muller 1983). Unfortunately, 
we were unable to perform these experiments in addition to those described in 
this thesis, due to time constraints.
5.4 Effects of anti-cotinine vaccination on measures of nicotine
dependence
In order for anti-cotinine vaccination to be a credible smoking cessation 
strategy, the cotinine-specific antibodies raised in response to immunisation 
with TT-CotSH need to have a measurable effect on parameters of nicotine 
dependence. We therefore performed the following studies:
In vitro: we examined whether the presence of anti-cotinine antibodies affected 
nicotine and cotinine distribution to blood and brain, or the upregulation 
of nAChRs observed following chronic nicotine exposure.
In vivo: we utilised a variety of behavioural models to explore the effects of anti- 
cotinine vaccination on aversive and reinforcing effects of nicotine and 
conditioned stimuli, and to examine whether vaccination against 
cotinine affects the severity of nicotine withdrawal syndrome.
5.4.1 Distribution of nicotine & cotinine
Vaccination against cotinine produces cotinine-specific antibodies (see above 
and Chapter 2), which circulate in the bloodstream and bind cotinine, preventing 
it from entering the brain and antagonising nicotine's actions. In vaccinated 
animals, plasma cotinine levels should therefore increase, whilst brain levels 
are expected to decrease, compared to controls.
We observed a significant increase in plasma cotinine concentrations in TT- 
CotSH vaccinated rats, compared to controls (see Figure 3.2); brain levels, 
however, were similar to those found in rats vaccinated with TT-Cysteine. This 
could have been due to contamination of brain samples with minor traces of 
blood during dissection. Perfusion of rats prior to taking the brain clearly
- 222 -
Chapter 5 -  Conclusions and future perspective
reduced such contamination; by comparison, unperfused rats had brain cotinine 
levels that were significantly higher than those in the control group (compare 
Figures 3.1 & 3.2). Nicotine distribution was not affected, providing further 
evidence of the specificity of the anti-cotinine antibodies.
Preclinical studies have also demonstrated the ability of anti-nicotine vaccines 
to affect nicotine distribution: brain nicotine concentrations were significantly 
reduced, whilst serum nicotine levels were significantly increased (Hieda et al 
1997, Pentel et al 2000, Keyler et al 2005, Cerny et al 2002, de Villiers 2004, 
Satoskar et al 2003, Carrera et al 2004). The magnitude of these effects on 
nicotine distribution was greatest in rats with the highest antibody titres and 
therefore the greatest capacity to bind nicotine (Keyler et al 1999).
The modulation of nicotine distribution was also dependent on the dose of 
nicotine administered; with higher doses the reduction in brain nicotine was not 
quite as large as with smaller doses (Carerra et al 2004). When nicotine was 
given repeatedly or as a chronic infusion, immunisation had comparatively little 
effect on the accumulation of nicotine in the brain (Keyler et al 1999, Hieda et al
2 0 0 0 ); however, the peak level of nicotine produced by each individual dose 
was still substantially reduced (LeSage et al 2006).
Similar effects are likely to be observed after anti-cotinine vaccination, with 
cotinine bound by antibodies and retained in the bloodstream until it is 
metabolised further (see Chapter 1) and eventually excreted. Brain cotinine 
levels should therefore be reduced as a result of vaccination, even during 
continuous exposure to nicotine, such as might occur with NRT, thereby 
decreasing any cotinine-mediated antagonism and improving the efficacy of 
NRT.
As explained above and in Chapter 2, the antibody titres achieved in our study 
were much lower than those measured in the nicotine vaccine studies; this 
would have had an impact on the ability of anti-cotinine vaccination to modulate 
cotinine distribution. It therefore seems likely that more significant effects would 
be observed, provided higher antibodies were achieved.
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5.4.2 Upregulation of nAChRs
Chronic nicotine administration has been shown to result in upregulation of 
nAChRs in animals (Wonnacott 1990, Flores et al 1992, Rowell & Li 1997). 
There have also been reports of receptor upregulation in the brains of human 
smokers, compared to non-smokers (Benwell et al 1988, Breese et al 1997, 
Perry et al 1999). Our radioligand binding experiments showed an increase in 
[3H]epibatidine binding levels in brain homogenates from rats chronically 
infused with nicotine for 7 days (see Figure 3.5), but not in those given daily 
nicotine injections for up to 15 days (see Figures 3.3 & 3.4).
The mechanism of receptor upregulation is still unclear; however, several 
theories have been put forward: chronic nicotine might increase receptor 
assembly or decrease receptor degradation and turnover (Darsow et al 2005, 
Nashmi et al 2003, Wang et al 1998, Peng et al 1994). Alternatively, it might 
induce a conformational switch to a more easily activated high-affinity receptor 
(Buisson & Bertrand 2001, Vallejo et al 2005), or facilitate the assembly of 
subunits into pentamers (Kuryatov et al 2005, Harkness & Millar 2002). Sallette 
and colleagues have suggested that intracellular binding of nicotine favours the 
maturation of nAChRs in the endoplasmatic reticulum (ER) of the secretory 
pathway, leading to upregulation (Sallette et al 2005). Receptor activation and 
signal transduction via Ca2+ signalling do not appear to be necessary, as the 
competitive antagonist DHpE also appears to upregulate nAChRs; however, 
binding of nicotine to nAChR subunits/receptors is likely to be required (Nashmi 
& Lester 2007).
Cotinine is unlikely to contribute to upregulation via nAChR binding, as it has a 
much lower affinity; however, it might impair nicotine-mediated upregulation by 
competing for binding sites. Anti-cotinine vaccination was therefore expected to 
further increase [3H]epibatidine binding levels, compared to controls, by 
reducing cotinine-mediated antagonism of nicotine; however, no effect was 
observed (see Figure 3.5). The titres achieved in this trial were very low due to 
the mislabelling of vaccine conjugates (see section 2.3.2.3.4), which could 
explain the absence of a vaccine effect.
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This hypothesis could be examined by repeating the radioligand binding 
experiments in rats with sufficiently high levels of anti-cotinine antibodies. Any 
observed upregulation of nAChRs after nicotine administration could then be 
further characterised using additional radioligands to determine the effect on a 
variety of nAChR subtypes, possibly in combination with autoradiography 
techniques to explore the localisation of upregulated receptor populations. Rats 
could also be implanted with minipumps filled with cotinine instead of nicotine, 
to assess whether cotinine alone can upregulate binding sites.
5.4.3 Locomotor activity
Chronic nicotine treatment has also been shown to lead to behavioural 
sensitisation; locomotor activity is increased as a result of nicotine 
administration, and this hyperlocomotion is enhanced by repeated exposure 
(Clarke & Kumar 1983, Ksir et al 1987, Clarke et al 1988, Walter & Kuschinsky 
1989, Vezina et al 1992, Shoaib & Stolerman 1992, Whiteaker et al 1995), 
which we were able to confirm (see Figure 4.3).
We also examined the effect of pairing the test environment with the actions of 
nicotine, and found that this association further increased nicotine-induced 
hyperlocomotion (see Figure 4.3), in agreement with observations previously 
made by several other groups (Walter & Kuschinsky 1989, Reid et al 1996, 
Bevins et al 2001). Environmental stimuli are thought to play an important role 
in smoking behaviour, and smokers often experience difficulties in maintaining 
abstinence due to the reinforcing effects of such stimuli, even in the absence of 
nicotine (Balfour et al 2000, Caggiula et al 2001, Liu et al 2006).
Passive immunisation against nicotine has been shown to block the locomotor 
stimulant effects of a single dose of nicotine (Pentel et al 2000), and both 
vaccination and passive immunisation appear to attenuate the locomotor 
sensitisation resulting from repeated nicotine exposure (Carerra et al 2004). We 
therefore studied the effects of vaccination against cotinine on locomotor activity 
induced by acute and repeated nicotine administration.
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By removing cotinine-mediated antagonism of nicotine’s actions, anti-cotinine 
vaccination should enhance nicotine-induced locomotor activity. We observed a 
trend towards increased locomotor activity over repeated nicotine exposure in 
TT-CotSH vaccinated rats, with nicotine-induced hyperlocomotion occurring 
earlier and to a greater degree than in controls (see Figure 4.3). As antibody 
titres in these trials were not as high as those achieved in the anti-nicotine 
vaccine studies mentioned above (see section 2.3.4), it is conceivable that 
vaccine effects that are currently trends might become significant, provided 
sufficiently high levels of anti-cotinine antibodies were achieved.
As well as re-examining the effects of anti-cotinine vaccination in rats with 
higher antibody titres, the use of microdialysis techniques in conscious freely 
moving rats could be considered. Such techniques would allow the 
simultaneous measurement of locomotor activity and in vivo DA release in 
immunised and control rats, which would complement the in vitro DA release 
measurements carried out as part of this study (see Chapter 2).
5.4.4 Intravenous self-administration
The positive reinforcement exerted by nicotine plays an important part in the 
development of nicotine dependence, as well as the failure of many smoking 
cessation attempts (Stolerman & Shoaib 1991, Rose & Corrigall 1997). Several 
species have been shown to self-administer nicotine (Goldberg et al 1981, 
Risner & Goldberg 1983, Corrigall & Coen 1989, Donny et al 1995 & 1998, 
Shoaib et al 1997), and the paradigm is therefore considered a relatively 
accurate preclinical model of nicotine dependence; it has the advantage of 
nicotine intake occurring as a series of small doses, controlled by the animal, 
rather than the experimenter, which mimics human smoking behaviour. The 
effects of anti-cotinine vaccination on the reinforcing properties of nicotine and 
conditioned stimuli associated with nicotine delivery were therefore examined 
using intravenous self-administration.
Anti-nicotine vaccination has been shown to reduce the percentage of rats 
meeting acquisition criteria, as well as decreasing response levels in rats 
vaccinated after acquisition of the behaviour (LeSage et al 2005). Vaccination
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against nicotine also blocked the ability of nicotine to reinstate nicotine self- 
administration behaviour (Lindblom et al 2 0 0 2 ).
In the experiments described in Chapter 4, rats acquired nicotine-taking 
behaviour (see Figure 4.7), albeit over a comparatively long period of time, and 
continued to self-administer the drug for several months. During this time they 
underwent a series of vaccinations with TT-CotSH or TT-Cysteine (see Figure 
4.9). This was expected to result in increased levels of lever-pressing on the 
active lever in vaccinated rats, since anti-cotinine antibodies should remove 
cotinine-mediated inhibition of nicotine’s actions. We observed some significant 
increases in active lever responses and infusions obtained in rats vaccinated 
against cotinine, despite the variability of response rates (see Figure 4.9). 
However, anti-cotinine vaccination did not appear to affect responding on the 
active lever during reinstatement induced by either cues alone, or an injection of 
nicotine (see Figure 4.10), although there was a tendency for immunised rats to 
exhibit higher levels of responding at the largest nicotine dose tested.
It is regrettable that the success of these experiments was compromised by the 
mislabelling of the new batch of conjugate vaccines (see section 2.3.2.3.4). This 
is especially unfortunate as the patency of the catheters over an extended 
period of time had originally been our main concern, and we found we were 
able to maintain patent catheters in our animals for up to 9 months in some 
individuals. This was most likely due to a combination of Dr Shoaib’s surgical 
skills, the flushing of all catheters both before and after each session, and the 
inclusion of a small amount of heparin in the flushing solution.
Due to the low antibody titres achieved as a result of the labelling error, it is not 
possible to rule out a more significant effect of anti-cotinine vaccination on 
aspects of nicotine self-administration behaviour. The effects of vaccination 
against cotinine on nicotine self-administration should therefore be re-examined 
once immunisation parameters have been further optimised and sufficient 
antibody titres can be achieved. The same technique could also be used, as 
described in section 5.1, to determine whether cotinine is self-administered in 
rats.
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5.4.5 Conditioned taste aversion
As well as having positive reinforcing actions, nicotine can also have aversive 
effects, which are thought to limit the amount self-administered by animals and 
smokers (Shoaib et al 2003). We used the two-bottle model of conditioned taste 
aversion to determine the effects of anti-cotinine vaccination on the 
development of taste aversion to a flavoured solution reliably paired with 
nicotine administration, as has been shown in non-vaccinated animals.
We were able to demonstrate the development of conditioned taste aversion 
(see Figures 4.12 & 4.13), even with low nicotine doses; this is in agreement 
with previous observations (Shoaib et al 2000 & 2002, Gommans et al 2000). 
However, no clear effect of vaccination was observed (see Figure 4.13); this is 
likely to be due to the low titres achieved in these animals as a result of the 
mislabelling of conjugates (see section 2.3.2.3.4).
Once high enough anti-cotinine antibody levels have been achieved, 
conditioned taste aversion to nicotine should therefore be re-examined, to 
determine whether an effect of anti-cotinine vaccination might have been 
missed in this trial due to the low levels of cotinine-specific antibodies. Aversive 
effects of nicotine might be enhanced by vaccination against cotinine, which 
should help to limit nicotine intake and encourage smokers to attempt to quit by 
gradually reducing the number of cigarettes smoked.
5.4.6 Mecamylamine-precipitated nicotine withdrawal syndrome
In dependent individuals, abstinence from nicotine precipitates a withdrawal 
syndrome, characterised by craving for nicotine, difficulty concentrating, 
depressed mood, irritability, etc. The desire to relieve the unpleasant symptoms 
of nicotine withdrawal is believed to be the reason high numbers of smokers 
relapse during a quit attempt (Malin 2001, Shiftman et al 2004).
A nicotine abstinence syndrome has also been characterised in rats (Malin et al 
1992), as described in section 4.5.1. Animals were rendered nicotine dependent 
by chronic infusion, and behavioural somatic signs of abstinence scored 
following termination of nicotine exposure, either by removal of osmotic pumps 
or administration of nicotinic antagonists (Malin et al 1992,1994,1997 & 1998,
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Hildebrand et al 1997, Epping-Jordan et al 1998). Abstinence scores measured 
were significantly higher in nicotine-treated rats, compared to controls, and our 
results are in agreement with these findings (see Figure 4.14).
We also examined the effect of vaccination against cotinine on the severity of 
the nicotine abstinence syndrome in rats. As anticipated, abstinence scores 
were generally higher in vaccinated animals, due to the removal of cotinine- 
mediated antagonism of nicotine by the cotinine-specific antibodies. In the 
“chews” category, the increase observed was significant (see Figure 4.14 C); 
furthermore, the increase in terms of total abstinence signs observed in 
vaccinated rats, compared to controls, was just short of significance (see Figure 
4.14 B). Since anti-cotinine antibody titres achieved in this trial were very low as 
a result of the mislabelling of conjugate vials (see section 2.3.2.3.4), it seems 
likely that the effects of vaccination observed could be significant in animals 
with higher cotinine-specific antibodies.
Smokers experiencing withdrawal during a quit attempt often relapse because 
the nicotine obtained from a cigarette alleviates the withdrawal symptoms (Wise 
1996, Malin 2001). NRT was developed to promote cessation by providing an 
alternative and less reinforcing source of nicotine; these products also do not 
contain the tar and carcinogens present in tobacco smoke, and are less 
reinforcing (see Chapter 1).
The impact of passive immunisation against nicotine on the ability of nicotine to 
relieve withdrawal symptoms has been studied, using the nicotine abstinence 
model described above. In rats injected with nicotine-specific antibodies, 
nicotine failed to reduce signs of withdrawal compared to controls (Malin et al
2001). Although this could reduce the likelihood of relapse by rendering tobacco 
use less effective in relieving withdrawal, it would also rule out the use of NRT, 
one of the main categories of smoking cessation products, in patients 
vaccinated against nicotine.
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Anti-cotinine vaccination, on the other hand, is designed to increase the efficacy 
of NRT by removing cotinine-mediated antagonism of nicotine’s actions. This 
hypothesis could be examined by studying the effects of vaccination against 
cotinine on the ability of nicotine to relieve symptoms of nicotine abstinence in 
rats.
The fraction of a nicotine dose converted to cotinine is much lower in rats (27%) 
than in humans (70%; Hieda et al 1997). Therefore, provided sufficient anti- 
cotinine antibody titres can be achieved, vaccination against cotinine has the 
potential to result in more significant effects in humans, compared to rats, 
making NRT much more effective and thus enabling more smokers to quit.
5.5 Possible concerns related to the clinical application of
immunotherapy for nicotine dependence
A number of immunotherapy strategies targeting drugs of abuse are being 
developed, and some of these vaccines are already being evaluated in clinical 
trials (see Chapter 1). This section summarises some of the problems potential 
"anti-addiction" vaccines must address before they can become standard 
therapeutic options for the treatment of drug dependence. We discuss clinical 
issues specific to anti-nicotine vaccines, and explore some of the ethical 
dilemmas associated with "anti-addiction" vaccines generally, and those 
targeting nicotine dependence in particular.
5.5.1 Issues concerning anti-addiction immunotherapy generally
Conventional pharmacotherapies often act at targets such as receptors or 
transporter molecules, which can be widely distributed and are often involved in 
the control/modulation of normal physiological responses. The resulting side 
effects may affect the safety profile and limit the indications for which the 
medicine is licensed (e.g. methadone). In contrast, strategies based on 
vaccination are expected to have a relatively good safety profile, as the specific 
antibodies produced react directly with the drug of abuse, preventing drug 
molecules from interacting with their targets (Kosten & Owens 2005, LeSage et 
al 2006).
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This comparative specificity of immunotherapy could also allow the approach to 
be used in combination with already existing pharmacotherapy options (LeSage 
et al 2006). The anti-cotinine vaccine, for example, might be used concurrently 
with NRT, and is hypothesised to improve the efficacy of NRT by removing 
cotinine-mediated antagonistic effects.
One of the major challenges for vaccination, as preclinical work, such as that 
presented in this thesis, and initial clinical trials have highlighted, is the lack of 
control over the titres of drug-specific antibodies achieved (Le Houezec 2005, 
LeSage et al 2006). In order to address this issue, booster injections are likely 
to be required at regular intervals throughout the treatment period. However, 
even if booster injections were needed every couple of months, as has been 
suggested (Hatsukami et al 2005, Le Houezec 2005), this dosing regimen is still 
minimal compared to other pharmacotherapies, where daily administration of 
drugs is required, which is likely to impact positively on patient compliance, 
leading to a greater percentage of patients completing a course of treatment.
Due to the inherent nature of the immune response, the onset of vaccine effects 
is likely to be slow (weeks -  months), especially in comparison with other 
pharmacotherapy options. A course of vaccination would therefore need to be 
initiated several months before a quit attempt was planned, in order to ensure 
maximum efficacy of the treatment (Kosten & Owens 2005).
Whilst vaccination has the advantage of potentially providing long-term 
protection, passive immunisation results in more immediate effects. However, 
there are also a number of disadvantages: production of monoclonal antibodies 
for passive immunisation would greatly increase the expense of treatment 
(Kosten & Owens 2005, LeSage et al 2006). Use of polyclonal antibodies 
seems unlikely, as only limited quantities can be generated and there are risks 
of serum sickness associated with the administration of foreign proteins to 
humans, as well as the danger of potential transmission of animal viruses 
(Kosten & Owens 2005). Also, the protection provided by passive immunisation 
would only endure until the administered antibodies were cleared from the host 
system, which would necessitate more frequent dosing in order to maintain 
titres. On the other hand, in immune compromised individuals, such as cancer
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patients, who are unable to mount an immune response of sufficient magnitude 
in response to vaccination, passive immunisation could provide the required 
antibody titres for successful immunotherapy (Kosten & Owens 2005).
Both active and passive immunisation strategies could be used in pregnant 
women to reduce potential harm to the unborn child and assist the mother with 
a quit attempt (Kosten & Owens 2005, Keyler et al 2003 & 2005). Furthermore, 
it is conceivable that the use of active and passive immunisation might be 
combined: antibodies administered by means of passive immunisation could 
provide initial protection whilst titres of antibodies raised as a result of 
vaccination were still relatively low (Kosten & Owens 2005, LeSage et al 2006).
5.5.2 Issues relating to immunotherapy strategies for the treatment
of nicotine dependence
Whilst a number of anti-nicotine vaccines are being developed for the treatment 
of nicotine dependence, this approach could be problematic:
Vaccinated smokers might attempt to overcome the blockade of nicotine's 
actions mediated by the anti-nicotine antibodies through a compensatory 
increase in their nicotine intake, thereby reducing the ability of vaccination to 
break the cycle of positive reinforcement and dependence. An increase in 
cigarettes smoked would also expose smokers to elevated levels of tar and 
other carcinogens in tobacco smoke (see Chapter 1), leading to an elevated risk 
of cancer and other smoking-related diseases (Kosten & Owens 2005). Clinical 
trials have not found evidence of compensatory smoking occurring (Hatsukami 
et al 2005); however, the trials conducted so far have been comparatively small, 
and it remains to be seen whether these observations hold true in larger 
cohorts.
Furthermore there is a possibility that inhibition of nicotine's actions by nicotine- 
specific antibodies might precipitate a state of withdrawal (LeSage et al 2006), 
although again there is no indication from clinical trials thus far that this is the 
case (Hatsukami et al 2005). However, this issue could potentially pose a 
significant problem, as anti-nicotine vaccines do not address the feelings of 
craving and other withdrawal symptoms experienced as a result of nicotine 
abstinence.
- 2 3 2 -
Chapter 5 -  Conclusions and future perspective
NRT is currently one of the main treatment options for nicotine dependence 
(see Chapter 1). The presence of anti-nicotine antibodies in the blood of 
vaccinated individuals would render all forms of NRT ineffective by binding the 
nicotine administered therapeutically and preventing it from entering the brain 
(Le Houezec 2005).
Whilst neither immunotherapy strategy targets non-nicotine components of 
tobacco or sensory and environmental stimuli, which may contribute to nicotine 
dependence, vaccination against cotinine could have several advantages over 
anti-nicotine vaccines:
Anti-cotinine vaccination would not block the effects of nicotine and is therefore 
unlikely to lead to compensatory increases in the number of cigarettes smoked. 
In fact, it could be used in a "reduce-to-quit” approach to smoking cessation, as 
removing cotinine-mediated antagonism of nicotine's actions should lead to a 
reduction in the number of cigarettes required to achieve a desired effect. 
Furthermore, this would have the added bonus of reducing a smoker's exposure 
to other harmful tobacco constituents.
Due to its mechanism of action, the vaccination against cotinine is expected to 
increase the efficacy of NRT, rather than preventing the use of such a mainstay 
of smoking cessation pharmacotherapy. In an abstinent smoker using NRT, 
anti-cotinine antibodies are therefore expected to reduce the severity of any 
withdrawal symptoms, which may be experienced.
5.5.3 Possible ethical concerns
There are several possible scenarios in which anti-nicotine immunotherapy 
might be used: in current smokers to assist with a quit attempt, in ex-smokers to 
help maintain abstinence, and finally, in never smokers to prevent the 
development of nicotine dependence (Le Houezec 2005).
Use of vaccination as a therapeutic approach in the treatment of nicotine 
dependence is likely to be relatively uncontroversial (Hasman & Holm 2004). 
Patients are likely to be adults or adolescents who have been smoking for 
several years and are motivated to quit, but have perhaps been unable to do so 
in the past, or abstinent smokers experiencing difficulties in remaining abstinent.
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However, there is a danger of discrimination against such individuals, by 
insurance companies for example (Hall 2005), since nicotine-specific antibodies 
resulting from vaccination would be detectable as a persistent sign of previous 
addiction, even if the individual had been abstinent for years. The use of 
passive immunisation would avoid this problem, antibodies administered would 
be present for a much shorter period of time (weeks rather than months) than 
after active immunisation (Kosten & Owens 2005); however, the cost of passive 
immunisation is currently prohibitively high (Kosten & Owens 2005, LeSage et 
al 2006).
Prophylactic immunotherapy is much more controversial. This would involve the 
vaccination of vulnerable individuals, who may have never taken nicotine, in 
order to prevent them from becoming dependent. Children and young adults are 
thought to be particularly susceptible to the effects of nicotine and are likely to 
have an increased risk of developing nicotine dependence (DiFranza et al
2002). If vaccination resulted in a lack of effect of nicotine, adolescents might be 
less likely to experiment in the first place, and the likelihood of becoming 
dependent as a result of experimentation with smoking might be reduced 
(Hasman & Holm 2004).
Parents might seek to have their children vaccinated against nicotine in early 
adolescence, before they start experimenting with tobacco (Kosten & Owens 
2005, Hasman & Holm 2004, Hall 2005). However, providing adequate 
protection at the right point in time could prove to be extremely difficult, since 
the protection afforded by the current generation of anti-nicotine vaccines is not 
very long-lasting (without regular booster immunisations), and it is impossible to 
predict when an adolescent is likely to smoke their first cigarette (Kosten & 
Owens 2005).
Experimentation with drugs during adolescence may reflect a form of defiant 
behaviour, rather than pharmacological dependence, and reducing the effects 
of nicotine might therefore not deter the use of the drug or might promote 
alternative undesirable activities, such as a switch to other drugs of abuse 
(Kosten & Owens 2005). There is also a risk that adolescent smokers might be 
prompted to test vaccine efficacy by increasing nicotine intake, or that they may
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turn to other drugs of abuse if the reinforcing effects of nicotine were blocked by 
vaccination (Kosten & Owens 2005, Hall 2005).
As minors, children would not legally be able to consent to vaccination (Hall 
2005). Some have suggested that parents should be able to make such a 
decision on their behalf, as is already the case for a number of other childhood 
vaccinations (Hall 2005); however, it is difficult to compare anti-nicotine 
vaccines with vaccines against measles or whooping cough, for example, as 
nicotine dependence is not infectious (Hasman & Holm 2004). Whilst nicotine 
dependence might be regarded as a disease, tobacco use could be classified 
as a lifestyle choice, similar to consumption of alcohol or excessive quantities of 
fatty foods, or lack of exercise, which can also result in an increase in 
morbidity/mortality (Hasman & Holm 2004). On the other hand, there are known 
links between smoking and various diseases, such as lung cancer, 
emphysema, and coronary disease (Hasmand & Holm 2004).
It has been argued that parental powers are limited by the child's right to an 
open future (Hasman & Holm 2004). Anti-nicotine vaccination is potentially 
irreversible and would therefore limit the future options of a child. Although 
smoking is often considered a noxious habit, it can also have a number of social 
functions in addition to its neurobehavioural effects. For some smokers the habit 
can provide essential pauses in a hectic daily life, whereas for others it can play 
an important part in social interactions. Vaccination against nicotine would not 
only block the neurochemical effects of the drug, but would also prevent the 
child from choosing to exploit the social functions of smoking (Hasman & Holm 
2004).
Furthermore, there is likely to be a cost implication for prophylactic 
immunotherapy, as higher regulatory and safety standards would be required if 
anti-nicotine vaccines were to be used on healthy individuals (Hall 2005).
The anti-cotinine vaccine has the significant advantage over anti-nicotine 
vaccines that it is designed purely as an immunotherapy, for the treatment of 
nicotine dependence. It reduces cotinine-mediated antagonism of nicotine's 
actions by means of anti-cotinine antibodies, and could therefore be used either 
in a "reduce to quit" approach to smoking cessation, or in combination with NRT 
to enhance the efficacy of such products. Due to its mode of action it has no
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utility as a vaccine to prevent the development of nicotine dependence, and the 
issues and problems relating to prophylactic immunotherapy therefore do not 
apply to this vaccine.
5.6 Conclusions
The case for an anti-cotinine vaccine as an immunotherapy is compelling; the 
data presented in this thesis support the hypothesis set out in Chapter 1, and 
there were no signs of adverse effects as a result of vaccination against 
cotinine. However, the efficacy of this strategy remains to be fully tested in 
animals generating higher titres of cotinine-specific antibodies than could be 
achieved here.
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